chri
meier
christian
ducho
hen
j
jessen
jan
balzarini
cyclos
pronucleotid
system
design
intracellular
deliveri
therapeut
activ
nucleosid
monophosph
recent
cyclos
nucleotid
bear
esterasecleav
side
chain
describ
lockin
modifi
deriv
design
intracellular
trap
prodrug
due
carboxyesteras
activ
contrast
ester
releas
moder
polar
cyclos
alcohol
compound
design
releas
highli
polar
cyclos
carboxyl
poor
substrat
carboxyesteras
henc
differ
way
achiev
intracellular
releas
carboxyl
develop
therefor
synthes
cyclos
deriv
bear
amor
pomprotect
carboxyl
moieti
side
chain
see
figur
two
differ
synthet
pathway
yield
target
nucleotid
develop
amand
pommodifi
cyclos
deriv
releas
desir
carboxyl
deriv
cem
cell
extract
within
minut
display
satisfi
hydrolyt
stabil
enzymefre
phosphat
buffer
sever
hour
halflif
addit
investig
carri
concern
stabil
prodrug
differ
ph
valu
cell
cultur
medium
furthermor
pommodifi
cyclos
deriv
fluoresc
nucleosid
analogu
synthes
model
studi
membran
penetr
synthes
hydrolysi
studi
well
antihiv
vitro
evalu
novel
lockin
modifi
cyclos
nucleotid
present
seri
eight
new
phosphon
nucleosid
lthreos
sugar
moieti
two
new
compound
identifi
pmdta
pmdtt
show
potent
activ
ec
gml
pmdta
gml
pmdtt
cell
cytox
observ
highest
concentr
test
gml
kinet
incorpor
pmdta
dna
use
diphosph
pmdta
substrat
revers
transcriptas
catalyst
similar
kinet
observ
datp
diphosph
pmdta
poor
substrat
dna
polymeras
incorpor
pmdta
fit
well
activ
pocket
site
revers
transcriptas
robert
w
buckheit
jr
traci
l
hartman
karen
watson
imquest
bioscienc
inc
frederick
md
usa
previous
report
antihiv
activ
highli
potent
inhibitor
inhibit
replic
two
mechan
act
nonnucleosid
rt
inhibitor
entri
inhibitor
recogn
conform
target
form
upon
associ
viru
target
cell
inhibit
subnanomolar
concentr
subnanomolar
micromolar
concentr
compar
evalu
congen
result
definit
highli
activ
inhibitor
therapeut
indic
rang
million
addit
studi
perform
defin
antivir
properti
molecul
order
defin
optim
clinic
candid
develop
rank
order
molecul
inhibitori
bioassay
measur
activ
viru
attach
revers
transcript
defin
four
molecul
highli
inhibitori
virus
rt
possess
mutat
rt
evalu
seri
perform
defin
rel
oral
bioavail
candid
compound
mice
dose
equival
amount
materi
solubil
colloid
suspens
defin
compound
would
expect
achiev
highest
plasma
concentr
evalu
focus
rel
abil
activ
test
molecul
prevent
emerg
resist
viru
strain
concentr
compound
requir
steril
viru
infect
cultur
defin
final
highli
sensit
compar
resist
select
assay
perform
quantit
compar
kinet
resist
viru
emerg
ident
select
condit
foldresist
viru
obtain
passag
well
resist
engend
mutat
rt
env
defin
complet
preclin
character
molecul
present
along
result
initi
pharmacokinet
profil
mice
assess
use
nitrotyrosin
stain
viru
product
assess
elisa
western
blot
viru
titrat
electron
microscopi
treatment
sod
mimet
compound
gene
express
mm
determin
microarray
analysi
apoptosi
two
human
neuron
cell
line
sknsh
evalu
fac
analysi
nitrotyrosin
overproduct
hivinfect
mm
dramat
decreas
presenc
um
microarray
analysi
mm
show
sod
solubl
gene
upregul
matur
strongli
inhibit
acut
chronic
infect
mm
um
result
confirm
electron
microscopi
show
strongli
reduct
particl
infect
mm
treat
consequ
infect
reduc
log
compar
control
drug
treatment
treatment
show
reduct
replic
acut
chronic
infect
mm
inhibit
releas
sup
compar
control
respect
moreov
treatment
um
sknsh
incub
supernat
mm
strongli
antagon
apoptosi
relat
superoxid
anion
gener
result
support
role
superoxid
anion
product
replic
mm
relat
neurodegener
suggest
sod
mimet
compound
may
counteract
replic
hivrel
neural
damag
combin
antiretrovir
treatment
juli
qi
hang
yu
li
yanli
yang
stan
tsing
jim
barnett
nick
cammack
joseph
martin
klau
klumpp
roch
palo
alto
llc
palo
alto
ca
usa
hiv
rnase
h
activ
essenti
synthesi
viral
dna
hiv
revers
transcriptas
hivrt
differ
interact
enzymat
activ
hivrt
substrat
recess
dna
end
dmode
compar
substrat
recess
rna
end
rmode
describ
previous
mutat
alloster
nonnucleosid
revers
transcriptas
inhibitor
nnrti
bind
site
also
influenc
rnase
h
activ
hivrt
fluoresc
rnase
h
assay
develop
allow
rapid
compar
enzym
activ
measur
activ
site
concentr
determin
hiv
rnase
h
use
hivrt
wildtyp
mutant
protein
substrat
depend
mode
bind
rnase
h
activ
also
assess
hivrt
wildtyp
singl
mutant
doubl
mutant
enzym
show
similar
rnase
h
specif
activ
mean
activ
site
concentr
measur
rmode
appar
activ
site
concentr
reduc
rel
rmode
measur
dmode
suggest
hivrt
may
bind
substrat
recess
dna
two
differ
conform
refer
compound
recent
identifi
nhydroxyimid
seri
rnase
h
inhibitor
show
similar
inhibitori
potenc
either
substrat
consist
bind
interact
rnase
h
activ
site
nonact
site
bind
compound
could
also
interfer
hiv
rnase
h
activ
nnrti
capravirin
found
partial
inhibit
hiv
rnase
h
activ
hivrt
rmode
mode
potenc
inhibit
significantli
reduc
variant
hivrt
enzym
consist
bind
capravirin
alloster
nnrti
bind
site
hivrt
merced
imma
clotet
cristina
tintori
fabrizio
manetti
bonaventura
clotet
maurizio
botta
retrovirolog
laboratori
irsicaixa
hospit
universitari
german
tria
pujol
badalona
spain
dep
farmaco
chimico
tecnologico
degli
studi
di
siena
via
aldo
moro
siena
itali
present
model
dock
molecul
appli
show
accord
vitro
experi
molecular
model
simul
perform
build
structur
start
xray
crystallograph
coordin
core
loop
comput
ad
appropri
mutat
includ
model
obtain
three
sequenc
turn
submit
structur
optim
molecular
dynam
simul
three
differ
model
base
amino
acid
sequenc
three
strain
one
wild
type
laboratori
adapt
strain
second
strain
resist
third
resist
compound
interfer
viru
bind
lymphoid
cell
line
resist
virus
show
mutat
molecular
dock
calcul
appli
explor
bind
mode
neg
charg
molecul
evalu
bind
conform
onto
structur
compound
suppos
bind
differ
affin
result
physicochem
properti
theoret
complex
three
structur
agreement
vitro
data
first
inhibitor
preferenti
bound
level
loop
agreement
fact
found
loop
moreov
decreas
posit
charg
loop
caus
deep
chang
stereoelectron
properti
protein
surfac
justifi
mark
drop
affin
toward
mainli
due
miss
profit
electrostat
interact
hydrogen
bond
contact
fact
electrostat
contribut
bind
reduc
complex
respect
chung
k
chu
vika
yadav
kl
rapp
mervi
detorio
raymond
f
schinazi
nucleosid
integr
part
combin
therapi
use
mani
hivinfect
individu
potenc
rel
safeti
develop
nucleosideresist
mutant
seriou
problem
manag
infect
sinc
dapd
amdoxovir
found
activ
aztand
mutant
sever
nucleosid
dioxolan
moieti
synthes
laboratori
antihiv
activ
drug
sensit
drugresist
mutant
determin
molecular
mechan
studi
molecular
model
among
seri
dioxolan
nucleosid
thymin
dot
show
signific
promis
antihiv
activ
without
cytotox
ic
g
human
pbm
cell
varieti
clinic
relev
nucleosideresist
mutant
shown
found
molecular
model
studi
dioxolan
moieti
play
signific
role
stabil
bind
mutant
hivrt
nucleosid
triphosph
dot
markedli
effect
mani
clinic
relev
drug
resist
mutant
includ
contain
tam
hivrt
thu
addit
biolog
studi
warrant
determin
full
potenti
dot
clinic
candid
reduc
suscept
lopinavir
due
mutat
proteas
kirsten
stray
andrew
mulato
holli
macarthur
stephani
leavitt
christoph
baer
xiaohong
liu
christian
callebaut
gongxin
martin
mcdermott
toma
cihlar
gilead
scienc
foster
citi
ca
usa
background
lopinavir
lpv
combin
low
dose
ritonavir
frequent
prescrib
hiv
proteas
inhibitor
pi
rare
emerg
vivo
primari
resist
lpv
resist
aris
either
vitro
vivo
select
mutat
proteas
pr
typic
includ
multipl
pr
mutat
often
necessari
highlevel
resist
lpv
report
character
novel
combin
pr
mutat
select
vitro
lpv
method
iiib
passag
cell
presenc
lpv
select
virus
character
genotyp
phenotyp
recombin
virus
pr
mutat
gener
provir
dna
clone
enzym
kinet
isotherm
titrat
calorimetri
itc
use
assess
interact
pi
wt
mutant
pr
exposur
iiib
strain
lpv
month
select
mutat
pr
viru
less
suscept
lpv
wt
show
similar
resist
sever
pi
contrast
parallel
select
strain
result
mutat
pr
select
viru
show
resist
lpv
resist
amprenavir
apv
remain
suscept
saquinavir
sqv
recombin
viru
replic
extrem
ineffici
preclud
phenotyp
character
recombin
remain
fit
suscept
lpv
contrast
viru
show
reduc
suscept
lpv
apv
hypersensit
sqv
enzym
exhibit
lower
specif
activ
elev
ic
lpv
apv
rel
wt
enzym
howev
differ
sqv
ic
found
wt
mutant
pr
data
itc
indic
affect
enthalp
h
entrop
contribut
bind
lpv
pr
result
reduct
bind
affin
conclus
novel
combin
pr
mutat
select
lpv
vitro
residu
local
pr
activ
site
howev
result
indic
consid
primari
lpv
resist
mutat
like
compensatori
effect
sequenti
antihbv
therapi
may
lead
select
complex
mutant
analyz
genet
phenotyp
evolut
viral
quasispeci
patient
receiv
success
lamivudin
addon
adefovir
adv
follow
adv
hepat
b
immunoglobulin
hbig
liver
transplant
sampl
bp
region
polymeras
gene
encompass
rt
domain
overlap
gene
amplifi
pcr
sequenc
baselin
hbv
genom
carri
wildtyp
wt
rt
gene
harbor
mutat
within
gene
associ
vaccin
escap
follow
viral
breakthrough
monotherapi
complex
mixtur
hbv
strain
mutant
prevail
addit
adv
ongo
treatment
viral
load
drop
patient
underw
liver
transplant
receiv
hbig
viral
load
rose
mutat
emerg
combin
mutat
hbv
genom
harbor
gene
mutat
escap
hbig
sampl
hbv
strain
mutat
prevail
mutat
disappear
get
insight
combin
mutat
construct
hbv
mutant
sitedirect
mutagenesi
hbv
replicationcompet
plasmid
hepatoma
cell
line
transfect
compar
replic
fit
strain
wt
hbv
suscept
panel
nucleo
ide
analog
phenotyp
analysi
tripl
mutant
hepatoma
cell
line
indic
replic
weakli
genom
exhibit
resist
pyrimidin
analog
includ
combin
adv
mutant
sensit
vitro
tenofovir
entecavir
conclus
genet
phenotyp
analysi
show
evolut
viral
quasispeci
toward
select
mutant
escap
multipl
select
pressur
clearli
indic
sequenti
therapi
may
select
multipl
drug
resist
mutant
de
novo
combin
therapi
evalu
prevent
delay
viral
drug
resist
antonin
hol
petra
dolkov
institut
organ
chemistri
biochemistri
academi
scienc
praha
czech
republ
new
gener
acycl
nucleosid
phosphon
anp
base
replac
purin
heterocycl
bear
chain
phosphon
residu
posit
wherein
substitu
contain
phosphonomethyl
ether
group
link
oxygen
atom
posit
phosphonomethoxi
propyl
seri
substitu
contain
chiral
center
antivir
activ
enantiospecif
parallel
correspond
anp
complet
purin
ring
also
r
propyl
deriv
exhibit
high
activ
hbv
poxvirus
effort
elucid
effect
chiral
phosphonatebear
sidechain
biolog
activ
seri
synthes
enantiom
latter
mention
compound
well
guanin
congen
multistep
procedur
optic
activ
respect
dichloro
deriv
also
use
prepar
novel
type
chiral
anp
contain
posit
two
ident
opposit
enantiom
differ
chiral
phosphonatebear
substitu
detail
synthesi
chiropt
properti
biolog
activ
discuss
antivir
activ
tfv
measur
cell
transient
stablytransfect
hbv
suscept
lamr
advr
hbv
tfvpp
tfv
analyz
enzymat
cell
cultur
assay
respect
intracellular
phosphoryl
halflif
tfvpp
afvpp
measur
cell
primari
human
hepatocyt
mass
spectroscopi
result
tfvpp
competit
inhibitor
ki
hbv
polymeras
regard
datp
valu
tfv
rang
transient
stablytransfect
cell
tfv
addit
antihbv
activ
afv
ftc
cellbas
combin
assay
tfv
demonstr
higher
afvpp
cell
tfvpp
afvpp
display
halflif
h
primari
human
hepatocyt
conclus
tenofovir
alon
combin
adefovir
ftc
demonstr
potent
antihbv
activ
tenofovir
activ
major
pattern
lamr
hbv
increas
advr
hbv
vitro
clinic
efficaci
tdf
patient
advr
hbv
unknown
tenofovir
achiev
higher
intracellular
diphosph
concentr
adefovir
cell
halflif
tenofovir
diphosph
h
primari
hepatocyt
angelin
bartholomeusz
stephen
locarnini
anna
ayr
geoff
thompson
david
chalmer
michael
kuiper
backgroundaim
resist
adv
origin
found
domain
hbv
polymeras
mutat
b
domain
also
associ
adv
resist
detect
class
hbv
polymeras
mutat
patient
adv
therapi
aim
studi
analys
mechan
adv
resist
crosssensit
profil
use
molecular
model
togeth
vitro
function
analysi
newli
describ
mutat
method
hbv
polymeras
gene
amplifi
pcr
sequenc
patient
fail
adv
therapi
three
dimension
model
hbv
polymeras
develop
base
hiv
revers
transcriptas
crystal
structur
vitro
phenotyp
analysi
specif
hbv
mutat
perform
use
transient
transfect
infecti
clone
use
standard
techniqu
result
new
cluster
adv
resist
mutat
outsid
activ
site
detect
patient
fail
adv
therapi
mutat
locat
cd
interdomain
molecular
model
cd
interdomain
reveal
directli
interact
nucleotid
bind
pocket
dna
may
involv
conform
interact
within
polymeras
use
seqhepb
databas
mutat
also
detect
patient
lmv
treatment
vitro
antivir
test
show
mutat
associ
adv
resist
also
increas
lamivudin
resist
conclus
identifi
new
class
adv
resist
mutat
outsid
activ
site
polymeras
new
class
mutat
potenti
multidrug
resist
mutat
molecular
model
associ
vitro
test
assist
determin
signific
mutat
may
aid
choic
next
therapeut
agent
abstract
mark
n
prichard
carol
b
hartlin
william
j
britt
earl
r
kern
univers
alabama
school
medicin
depart
pediatr
birmingham
al
usa
maribavir
good
antivir
activ
human
cytomegaloviru
replic
vitro
clinic
trial
treatment
infect
viru
inhibit
protein
kinas
activ
thought
import
mechan
action
drug
one
characterist
infect
cell
treat
inhibitor
format
larg
nuclear
inclus
appear
late
infect
structur
also
observ
cell
infect
recombin
viru
express
kinas
hypothes
viral
protein
aggreg
inappropri
absenc
kinas
activ
investig
natur
structur
help
understand
mechan
action
maribavir
well
function
kinas
nuclear
inclus
purifi
near
homogen
constitu
protein
identifi
malditof
mass
spectrometri
analysi
demonstr
aggreg
form
princip
tegument
protein
well
virion
protein
immunoblot
experi
confirm
result
identifi
number
addit
viral
protein
present
purifi
tegument
aggreg
interestingli
format
structur
appear
depend
sinc
occur
drug
treat
cell
infect
recombin
viru
express
protein
neg
viru
also
unexpectedli
exhibit
signific
resist
antivir
effect
inhibitor
suggest
tegument
protein
involv
mechan
action
drug
suggest
tegument
aggreg
form
consequ
reduc
kinas
activ
process
depend
data
consist
model
inhibit
kinas
maribavir
result
aberr
function
tegument
phosphoprotein
nucleu
robert
jordan
guang
yang
sylvi
laquerr
linda
baron
daniel
c
pevear
thoma
r
bailey
susan
rippin
marc
collett
erik
de
clercq
johan
neyt
kevin
f
jone
tove
bolken
rm
buller
erin
touchett
kem
waller
denni
e
hrubi
recent
concern
use
variola
smallpox
viru
biolog
weapon
prompt
new
interest
develop
small
molecul
therapeut
target
variola
viru
replic
small
molecul
compound
mw
potent
ec
select
cc
activ
monkeypox
camelpox
cowpox
ectromelia
mousepox
variola
virus
also
activ
cidofovirresist
strain
cowpox
viru
drug
resist
variant
isol
drug
resist
phenotyp
map
singl
amino
acid
chang
within
vaccinia
viru
gene
gene
encod
major
envelop
protein
requir
product
extracellular
envelop
viru
eev
viru
yield
assay
reduc
format
eev
intracellular
matur
viru
imv
vivo
deliv
oral
mgkg
bid
protect
ancr
mice
lethal
infect
follow
intranas
inocul
ld
ectromelia
viru
infecti
viru
titer
day
postinfect
liver
spleen
lung
anim
limit
detect
pfuml
respect
protect
balbc
mice
lethal
infect
follow
intranas
inocul
ld
vaccinia
viru
mice
surviv
infect
acquir
protect
immun
resist
subsequ
challeng
lethal
dose
ld
vaccinia
viru
administ
oral
inhibit
vaccinia
virusinduc
tail
lesion
nmri
mice
inocul
via
tail
vein
immunocompromis
nunu
nmri
mice
deliv
oral
topic
inhibit
progress
vaccinia
viru
infect
taken
togeth
result
indic
valid
antivir
target
demonstr
deliv
oral
use
treat
orthopoxviru
infect
rapid
degrad
mice
monkey
potent
hcmv
inhibitor
benzimidazol
bdcrb
compar
structur
lanalog
maribavir
attribut
select
glycosid
bond
cleavag
enzym
respons
select
bdcrb
degrad
howev
identifi
report
identif
two
enzym
dna
glycosylas
nmethylpurin
dna
glycosylas
mpg
catalyz
nglycosid
bond
cleavag
bdcrb
maribavir
explor
substrat
specif
reveal
anoth
nucleosid
substrat
homolog
bdcrb
knowledg
first
demonstr
free
nucleosid
substrat
mpg
whose
endogen
function
excis
damag
base
dna
via
nglycosid
bond
cleavag
elucid
uniqu
catalyt
mechan
dock
simul
perform
use
nativ
crystal
coordin
result
simul
suggest
nucleosid
nglycosid
bond
cleavag
involv
proton
imidazol
cy
subsequ
nucleophil
attack
ly
although
nucleophil
attack
ly
previous
report
catalysi
dna
substrat
cy
consid
directli
involv
mechan
minimum
requir
catalysi
free
nucleosid
therefor
rel
basic
imidazol
nitrogen
locat
opposit
glycosid
bond
pk
roughli
greater
requir
may
explain
select
metabol
bdcrb
compar
maribavir
vivo
find
suggest
dna
repair
enzym
pose
previous
unidentifi
obstacl
effect
deliveri
antivir
anticanc
nucleosid
drug
acknowledg
research
support
nih
grant
train
grant
pll
david
r
white
daniel
choo
greg
stroup
mark
r
schleiss
cincinnati
children
hospit
depart
otolaryngolog
pediatr
univers
minnesota
school
medicin
depart
pediatr
divis
infecti
diseas
object
studi
evalu
util
therapi
cyclic
cogen
anticmv
agent
cidofovir
chpmpc
efficaci
cmvinduc
hear
loss
guinea
pig
model
thirtysix
guinea
pig
randomli
divid
four
group
n
first
group
underw
auditori
brainstem
respons
abr
test
click
stimuli
intervent
second
group
underw
abr
test
follow
sham
surgeri
consist
unilater
round
window
inject
l
steril
viral
media
day
third
group
fourth
group
underw
abr
test
follow
round
window
inject
pfu
guinea
pig
cytomegaloviru
gpcmv
day
group
receiv
antivir
treatment
intraperiton
inject
cidofovir
mgkg
two
divid
dose
day
postinocul
anim
challeng
gpcmv
seroconvert
although
antibodi
titer
significantli
lower
treat
anim
system
viral
load
monitor
realtim
pcr
assay
one
anim
untreat
group
develop
highgrad
dnaemia
none
cidofovir
treatment
group
anim
abr
perform
day
four
nine
day
five
nine
day
anim
receiv
gpcmv
cidofovir
treatment
demonstr
hear
loss
least
db
contrast
none
anim
untreat
sham
surgeri
cidofovirtr
group
hear
loss
db
differ
statist
signific
day
p
onetail
fisher
exact
test
day
p
onetail
fisher
exact
test
histolog
evalu
hearingimpair
anim
reveal
inflammatori
infiltr
predomin
mononuclear
cell
particularli
scala
tympani
conclud
cidofovir
effect
antivir
intervent
cytomegalovirusinduc
hear
loss
guinea
pig
insight
support
experiment
evalu
pathogenesi
treatment
gpcmv
labyrinth
antivir
therapi
hcmvassoci
deaf
infant
david
bernstein
fernando
j
bravo
rhonda
cardin
cincinnati
children
hospit
medic
center
divis
infecti
diseas
cincinnati
oh
usa
congenit
cmv
infect
occur
birth
unit
state
common
caus
hear
loss
mental
retard
previous
shown
cyclic
hpmpc
chpmpc
safe
effect
immunocompromis
model
guinea
pig
cmv
gpcmv
infect
given
singl
dose
antivir
re
studi
evalu
effect
chpmpc
treatment
gpcmv
infect
dam
infect
outcom
dam
pup
pregnant
hartley
guinea
pig
infect
virul
gpcmv
pfu
secondthird
trimest
guinea
pig
receiv
either
chpmpc
mgkg
ip
placebo
first
experi
anim
n
follow
deliveri
number
liveborn
stillborn
pup
evalu
tissu
harvest
liveborn
stillborn
pup
evalu
cell
cultur
gpcmv
infect
placebo
group
pup
liveborn
wherea
liveborn
chpmpc
treat
anim
p
placenta
chpmpc
treat
anim
similarli
treatment
reduc
viral
load
fetal
liver
spleen
thu
antivir
therapi
decreas
mortal
congenit
cmv
infect
magnitud
viral
replic
dam
fetu
prevent
infect
pup
first
evid
antivir
therapi
modifi
outcom
congenit
cmv
infect
acknowledg
fund
nih
ai
littl
evidencebas
literatur
regard
long
term
manag
patient
sinc
advent
haart
mani
patient
diagnos
aid
immun
recoveri
led
increas
life
expect
therefor
understand
diagnosi
treatment
monitor
diseas
critic
decreas
morbid
aid
patient
respons
haart
report
case
woman
aid
diagnos
porn
clinic
exam
real
time
pcr
amplif
vzv
aqueou
humor
diseas
occur
initi
right
eye
rapidli
becam
bilater
although
right
eye
unsalvag
vision
left
eye
maintain
month
durat
describ
extend
clinic
cours
patient
use
intravitr
inject
left
eye
haart
quantit
pcr
tempor
correl
obtain
success
outcom
tandem
approach
ophthalmolog
medicin
key
element
longterm
manag
porn
infer
case
recurr
occur
patient
despit
continu
intraven
antivir
respond
aggress
intravitr
inject
dual
antivir
support
use
intravitr
inject
main
mode
therapi
highlight
inadequaci
system
antivir
alon
manag
diseas
second
porn
remiss
appear
occur
count
improv
emphas
import
immun
recoveri
control
diseas
progress
suggest
may
threshold
antivir
may
ultim
withdrawn
use
quantit
pcr
appear
use
tool
monitor
longterm
progress
porn
may
serv
use
clinic
surrog
marker
influenza
highli
infecti
acut
respiratori
diseas
character
recurr
annual
epidem
period
major
worldwid
pandem
outbreak
caus
highli
divers
mutabl
influenza
virus
b
ifv
ifv
b
ongo
human
infect
highli
pathogen
avian
strain
set
alarm
pandem
influenza
vaccin
requir
annual
updat
suppli
unreli
would
inadequ
pandem
neuraminidas
inhibitor
oseltamivir
effect
antivir
chemic
compound
recent
link
surprisingli
high
frequenc
drug
resist
virus
children
provid
urgent
need
altern
treatment
modal
influenza
gener
recombin
fusion
protein
refer
work
elimin
receptor
human
anim
influenza
virus
also
builtin
featur
enabl
long
drug
retent
time
airway
surfac
low
immunogen
human
distinct
convent
vaccin
potenti
confer
broadspectrum
protect
subtyp
strain
influenza
virus
without
need
annual
updat
produc
inexpens
bacteria
appli
topic
inhal
prevent
treat
influenza
present
data
demonstr
potent
protect
effect
spectrum
human
anim
influenza
virus
vitro
well
vivo
data
ferret
studi
acknowledg
work
support
part
nih
grant
contract
virolog
branch
nation
institut
allergi
infecti
diseas
influenza
viru
infect
pose
seriou
threat
public
health
economi
inhibitor
viral
neuraminidas
nai
zanamivir
inhal
oseltamivir
oral
approv
clinic
use
influenza
na
destroy
sialicacid
bear
receptor
bind
viral
hemagglutinin
ha
nai
exert
antivir
effect
inhibit
na
enzymat
function
prevent
releas
progeni
virion
cell
cultur
mutat
ha
confer
resist
class
drug
allow
viral
releas
reduc
affin
ha
receptor
associ
depend
na
activ
inhibit
na
activ
accompani
sialyl
nglycan
attach
newli
synthes
ha
molecul
consequ
investig
effect
individu
nglycan
attach
vicin
ha
receptorbind
site
oseltamivirsuscept
influenza
virus
use
sitedirect
mutagenesi
revers
genet
techniqu
gener
seri
ha
glycosylationsit
mutant
virus
assess
drugsuscept
standard
mtt
assay
mdck
cell
cultur
glycosyl
accompani
increas
viru
suscept
oseltamivir
wherea
glycan
reduc
glycan
tip
ha
reduc
drugsuscept
greatli
domin
role
glycan
regardless
ha
amino
acid
backbon
also
support
success
rescu
recombin
mutant
complet
lack
na
activ
due
delet
na
gene
nonetheless
despit
compensatori
role
ha
glycosyl
vitro
na
activitylack
mutant
sever
attenu
test
ferret
model
influenza
viru
infect
base
signific
reduct
nasal
wash
viral
titer
log
ml
cell
count
threefold
protein
concentr
compar
wildtyp
viru
result
demonstr
influenza
viru
depend
na
function
much
greater
vivo
cell
cultur
thu
reinforc
util
na
target
antivir
design
develop
highthroughput
cellbas
assay
address
critic
need
antivir
drug
treatment
sever
acut
respiratori
syndromeassoci
coronaviru
sarscov
assay
inhibit
sarscov
induc
cytopath
effect
cpe
vero
cell
assess
use
celltiterglo
luminesc
cell
viabil
assay
promega
reagent
measur
amount
atp
present
cell
signal
directli
proport
number
metabol
activ
cell
valid
studi
execut
establish
optim
cell
densiti
viral
concentr
dmso
concentr
compound
solubil
incub
time
virusinduc
cpe
control
drug
concentr
compound
exhibit
cpe
inhibit
greater
consid
hit
calpain
iv
chosen
drug
control
perform
consist
reproduc
data
variabl
thu
assay
qualiti
assess
calcul
estim
z
factor
test
librari
independ
prestwick
microsourc
two
differ
fdaapprov
divers
set
compound
screen
triplic
concentr
ugml
ugml
hit
rate
librari
determin
develop
assay
identifi
sever
compound
effect
inhibit
induc
cpe
sarscov
vitro
provid
candid
evalu
coronavirus
evolv
rapidli
associ
sever
diseas
bird
mammal
includ
human
peptideconjug
antisens
morpholino
oligom
ppmo
use
inhibit
product
infecti
sar
coronaviru
strain
probe
function
conserv
viral
rna
motif
secondari
structur
ppmo
reduc
virusassoci
cytopatholog
spread
consequ
decreas
viral
growth
ppmo
activ
administ
time
prior
peak
viral
synthesi
exert
sustain
antivir
effect
present
cultur
medium
ppmo
show
low
nonspecif
activ
nontarget
rna
unrel
arenaviru
randomsequ
control
ppmo
also
show
low
activ
sar
coronaviru
two
ppmo
target
viral
transcriptionassoci
sequenc
region
effect
sar
coronaviru
develop
point
mutat
bind
site
effect
antivir
ppmo
result
develop
attenu
ppmoresist
viru
clone
also
report
complementari
result
use
ppmo
relat
coronaviru
murin
hepat
viru
result
suggest
pmo
compound
power
therapeut
investig
potenti
toward
coronaviru
infect
justin
g
juland
peiyong
shi
quinton
winger
craig
w
day
aaron
l
olsen
robert
w
sidwel
john
morrey
placenta
often
serv
protect
barrier
viral
infect
fetu
object
determin
role
placenta
fetal
west
nile
viru
wnv
infect
subcutan
challeng
timedpregn
mice
cell
cultur
infecti
dose
wnv
day
postcoitu
dpc
result
fetal
infect
infecti
viru
detect
day
matern
challeng
viral
challeng
dpc
result
low
fetal
infect
rate
fetal
infect
respect
murin
placent
barrier
matern
fetal
blood
function
around
dpc
correl
reduct
inhibit
fetal
wnv
infect
observ
placenta
suscept
viral
infect
rel
high
titer
regardless
gestat
timepoint
matern
infect
placenta
detect
wnv
titer
earli
day
matern
viral
challeng
murin
trophoblast
stem
ts
cell
use
vitro
model
placent
cell
maintain
prolif
state
media
contain
fibroblast
growth
upon
remov
ts
cell
termin
differenti
giant
cell
gc
ts
cell
differenti
gc
challeng
wnv
construct
express
green
fluoresc
protein
gfpwnv
gfp
fluoresc
observ
day
postvir
challeng
ts
cell
gc
suscept
wnv
infect
fluoresc
observ
gfpwnvinfect
ts
cell
allow
differenti
viral
infect
gfp
fluoresc
observ
differenti
gc
result
suggest
format
function
placenta
includ
differenti
syncytiotrophoblast
cell
prevent
fetal
infect
across
mous
placenta
antemortem
marker
benchmark
patholog
event
adequ
identifi
west
nile
viru
wnv
enceph
biolog
sampl
reason
avail
antemortem
clinic
analysi
human
serum
cerebrospin
fluid
csf
among
protein
csf
may
marker
cn
diseas
seen
multipl
sclerosi
cjd
ferritin
marker
nonspecif
acut
neurolog
episod
cerebrospin
fluid
collect
hamster
antemortem
analysi
minim
invas
procedur
advers
affect
anim
current
studi
use
proteom
approach
identifi
protein
express
wnvinfect
hamster
csf
collect
wnv
infect
noninfect
hamster
label
differ
fluorochrom
superimpos
use
dige
mani
separ
spot
identifi
differenti
express
infect
anim
one
major
spot
infect
anim
pick
identifi
mass
spectrophotomet
analysi
put
apolipoprotein
e
apo
modul
cholesterol
phospholipid
homeostasi
select
subcellular
membran
compart
brain
cell
genet
variant
apo
also
marker
alzheim
diseas
provid
proofofprincipl
hamster
model
use
studi
wnv
diseas
marker
csf
addit
protein
associ
wnv
infect
identifi
role
character
evalu
abil
indic
clinic
outcom
diseas
acknowledg
support
contract
virolog
branch
niaid
nih
differenti
bind
two
human
monoclon
antibodi
hcv
quasispeci
popul
liver
transplant
patient
ari
zauberman
ofer
nussbaum
dorit
landstein
shai
shahar
tal
waisman
rachel
eren
ehud
ilan
shlomo
dagan
xtl
biopharmaceut
ltd
rehovot
israel
background
hepat
c
viru
hcv
relat
cirrhosi
lead
indic
liver
transplant
current
avail
therapi
prevent
reinfect
liver
graft
occur
shortli
transplant
almost
patient
neutral
antibodi
could
consid
passiv
immunotherapi
prevent
reinfect
liver
transplant
patient
high
mutat
rate
hcv
genom
caus
genet
heterogen
lead
evolut
quasispeci
complex
popul
genet
distinct
close
relat
viral
variant
given
host
follow
liver
transplant
chang
quasispeci
composit
occur
singl
monoclon
antibodi
mab
recogn
variant
heterogen
quasispeci
popul
object
propos
use
mixtur
two
differ
human
mab
bind
distinct
epitop
envelop
protein
hcv
obtain
broad
reactiv
prevent
reinfect
liver
transplant
patient
method
quasispeci
analysi
perform
sera
five
liver
transplant
patient
sequenc
analyz
compar
prior
day
post
transplant
addit
test
abil
two
neutral
human
mab
hcvab
hcvab
immunoprecipit
viral
particl
sera
sampl
taken
prior
post
transplant
result
chang
detect
bind
characterist
mab
hcv
particl
reinfect
liver
graft
immunoprecipit
viral
particl
sequenc
analyz
sequenc
align
indic
evolv
quasispeci
liver
transplant
bind
differ
mab
sequenc
analysi
indic
quasispeci
popul
patient
vari
post
transplant
variat
observ
entir
amino
acid
sequenc
conclus
analysi
impli
one
mab
may
need
bind
wide
rang
viral
quasispeci
antibodi
direct
differ
epitop
may
potenti
broad
reactiv
evolv
quasispeci
pieter
leyssen
jan
balzarini
erik
de
clercq
johan
neyt
ku
leuven
rega
institut
medic
research
laboratori
virolog
experiment
chemotherapi
minderbroedersstraat
leuven
belgium
yet
debat
extent
deplet
intracellular
gtp
pool
contribut
antivir
activ
ribavirin
therefor
inhibitori
effect
ribavirin
ii
analogu
eicar
iii
mycophenol
acid
mpa
compound
sole
inhibit
cellular
inosin
monophosph
dehydrogenas
activ
evalu
replic
flaviviru
yellow
fever
yfv
vaccin
strain
human
parainfluenza
type
paramyxoviru
vero
cell
mpa
prove
ribavirin
least
potent
ec
yfv
ribavirin
eicar
mpa
gml
respect
ec
gml
respect
mpa
prove
also
potent
reduc
intracellular
gtp
pool
ec
vero
cell
gml
ribavirin
eicar
mpa
linear
correl
observ
broad
concentr
rang
antivir
activ
ribavirin
eicar
mpa
effect
gtp
pool
deplet
yfv
r
ribavirin
eicar
mpa
r
ribavirin
eicar
mpa
ec
valu
antivir
activ
ribavirin
eicar
mpa
plot
respect
ec
valu
gtp
pool
deplet
linear
correl
obtain
yfv
r
r
similar
correl
also
calcul
gtp
deplet
ec
inhibit
replic
three
flavivirus
dengu
viru
type
modoc
viru
montana
myoti
leukoenceph
viru
vero
cell
similarli
strong
correl
observ
inhibit
respiratori
syncyti
viru
replic
hela
cell
ec
gml
ribavirin
mpa
gtp
pool
deplet
ec
gml
respect
data
provid
compel
evid
predomin
mechan
action
ribavirin
vitro
flaviand
paramyxovirus
base
inhibit
cellular
inosin
monophosph
dehydrogenas
cyclosporin
csa
recent
shown
inhibit
vitro
replic
hcv
watashi
et
al
hepatolog
nakagawa
et
al
biochem
biophi
re
commun
report
potent
antihcv
activ
nonimmunosuppress
cyclosporin
analogu
antivir
activ
assess
monitor
effect
hcv
genotyp
subgenom
replicon
replic
either
determin
luciferas
activ
cell
hcv
replicon
contain
firefli
luciferas
gene
ii
q
quantit
rtpcr
viral
rna
isol
cell
effect
concentr
inhibit
viral
replic
cell
gml
csa
gml
luciferas
activ
monitor
concentr
reduc
growth
exponenti
prolifer
cell
gml
gml
csa
thu
result
select
index
compar
csa
superior
antihcv
activ
corrobor
qrtpcr
inhibit
subgenom
replicon
replic
gml
gml
respect
csa
data
support
find
watashi
see
supra
antihcv
activ
csa
independ
immunosuppress
function
csa
inhibitori
effect
replic
member
famili
flavivirida
ie
bovin
viral
diarrhea
viru
genu
pestiviru
mdbk
cell
yellow
fever
viru
genu
flaviviru
vero
cell
cell
exhibit
also
potent
antihiv
activ
current
evalu
phase
clinic
trial
may
interest
candid
treatment
chronic
hcv
infect
includ
hiv
infect
patient
coinfect
hcv
morphogenesi
hcv
belong
step
viral
cycl
yet
target
antivir
strategi
use
bovin
viral
diarrhea
viru
pestiviru
relat
hcv
model
previous
shown
iminosugar
inhibitor
alpha
glucosidas
could
inhibit
viral
morphogenesi
cellulo
via
perturb
nglycosyl
pathway
fold
envelop
glycoprotein
due
heavi
nglycosyl
hcv
glycoprotein
anticip
inhibitor
would
also
affect
hcv
morphogenesi
lack
effici
reliabl
cultur
system
abl
produc
secret
hcv
virion
use
two
complementari
approach
studi
effect
hcv
morphogenesi
secret
entri
first
use
baculovirus
carri
hcv
structur
gene
produc
viru
like
particl
vlp
cell
order
studi
effect
fold
assembl
hcv
glycoprotein
vlp
product
bindinginternalis
properti
shown
presenc
synthesis
retain
er
contain
unprocess
triglycosyl
nglycan
ii
impair
interact
calnexin
iii
least
partial
misfold
moreov
observ
vlp
produc
presenc
modifi
bind
internalis
properti
hepatoma
cell
second
use
infecti
hcv
pseudotyp
retrovir
particl
hcvpp
harbour
unmodifi
measur
demonstr
effect
viral
secret
entri
use
model
found
product
secret
hcvpp
impair
presenc
inhibitor
alpha
glucosidas
ii
hcvpp
contain
misfold
misassembl
viral
glycoprotein
iii
hcvpp
entri
target
cell
impair
treatment
two
approach
allow
us
demonstr
antivir
effect
hcv
structur
glycoprotein
fold
assembl
morphogenesi
viral
secret
viral
infect
resist
reversetranscriptas
rt
inhibitori
ddn
indic
hiv
acquir
abil
discrimin
ddn
physiolog
dn
incorpor
ddn
grow
provir
dna
andor
elimin
alreadi
incorpor
ddn
provir
dna
terminu
take
mechan
account
base
follow
rational
design
deoxynucleosid
sdn
one
could
highli
activ
variou
hiv
delay
allow
emerg
resist
hiv
sdn
much
like
dn
function
group
dn
therefor
could
difficult
hiv
discrimin
quaternar
carbon
make
oh
unreact
neopentyl
type
secondari
alcohol
therefor
dna
biosynthesi
would
stop
sdn
thu
sdn
could
chaintermin
rt
reaction
synthes
variou
kind
sdn
highli
activ
wide
spectrum
hiv
toxic
recent
design
synthes
turn
potent
eg
ec
iiib
nm
nm
mdr
nm
si
acut
mous
toxic
mgkg
seen
role
oh
biolog
activ
sliddiqui
et
al
discuss
present
sliddiqui
contact
hiv
produc
cell
primari
cell
may
induc
uptak
hiv
particl
target
cell
absenc
membran
fusion
product
hiv
replic
hiv
uptak
cell
depend
cellular
contact
mediat
bind
independ
express
appropri
hiv
coreceptor
later
step
hiv
viral
cycl
also
requir
thu
antihiv
agent
target
hiv
fusion
revers
transcriptas
block
transfer
hiv
particl
intracellular
compart
later
releas
infecti
viral
particl
recombin
protein
complet
inhibit
uptak
hiv
particl
cell
persist
infect
cell
express
resist
hiv
envelop
glycoprotein
consequ
subsequ
releas
viru
particl
endocyt
vesicl
infect
report
cell
also
prevent
polyanion
agent
dextran
sulfat
prevent
intracellular
uptak
virion
cell
also
increas
hiv
uptak
dose
depend
manner
suggest
function
differ
specif
agent
nonspecif
hiv
bind
inhibitor
novel
mechan
hiv
transmiss
convert
cell
lack
appropri
coreceptor
hiv
carrier
could
favor
spread
hiv
compart
antiretrovir
drug
could
reach
studi
target
agent
coreceptor
independ
viru
transmiss
provid
new
tool
understand
relev
novel
mechan
synthet
cyclosporin
csa
analog
select
absenc
immunosuppress
capac
high
affin
bind
cyclophilin
cypa
lack
immunosuppress
activ
compar
csa
demonstr
vitro
vivo
select
inhibit
replic
laboratori
strain
lymphocyt
cell
line
pbmc
potent
activ
test
clinic
isol
differ
subclad
demonstr
pbmc
also
potent
inhibitor
clinic
isol
multipl
resist
revers
transcriptas
proteas
inhibitor
drug
combin
studi
synergist
addit
inhibitori
effect
clinic
use
drug
found
vivo
activ
evalu
scidhu
thyliv
mous
model
mice
infect
viru
strain
treat
oncedaili
oral
gavag
reduc
viral
load
dose
depend
protect
thymocyt
virusmedi
deplet
compet
gag
cypa
bind
inhibit
incorpor
cypa
viru
particl
cypa
known
essenti
earli
step
replic
plausibl
mechan
counteract
effect
innat
primat
restrict
factor
support
clinic
isol
identifi
natur
resist
depend
cypa
infect
sequenc
comparison
motif
identifi
cypa
bind
region
capsid
protein
confer
resist
safeti
pharmacokinet
toxicolog
investig
rat
monkey
man
good
oral
bioavail
long
halflif
low
toxic
profil
found
proof
concept
studi
human
start
recent
acknowledg
fund
nih
contract
jan
balzarini
kristel
van
laethem
sigrid
hats
kurt
vermeir
erik
de
clercq
willi
peuman
el
van
damm
annemiek
vandamm
dominiqu
schol
sever
sugarbind
protein
select
mannos
plant
lectin
deriv
hyppeastrum
hybrid
hha
galanthu
nivali
gna
cyanovirin
mannosespecif
lectin
bluegreen
alga
nostoc
ellipsosporum
plant
lectin
deriv
urtica
dioica
uda
specif
nacetylglucosamin
shown
potent
inhibitor
hiv
replic
cell
cultur
prevent
transmiss
viru
persist
hivinfect
tcell
uninfect
tlymphocyt
prevent
entri
hiv
target
cell
therefor
may
qualifi
potenti
microbicid
drug
iiib
expos
escal
hha
gna
uda
concentr
cem
cell
cultur
viru
strain
could
isol
sever
stage
select
process
strain
show
decreas
suscept
mannoseand
nacetylglucosaminespecif
plant
lectin
amino
acid
chang
envelop
glycoprotein
observ
major
amino
acid
chang
occur
nglycosyl
site
residu
part
nglycosyl
motif
degre
drug
resist
close
correl
increas
number
mutat
glycosyl
site
sever
hiv
entri
inhibitor
retain
full
sensit
plant
lectinresist
viru
strain
virul
sever
mutant
viru
strain
alter
viru
strain
highest
degre
drug
resist
contain
mutat
least
total
glycosyl
site
resist
profil
mutat
glycosyl
site
mannoseand
nacetylglucosaminebind
protein
entir
differ
antihiv
drug
includ
viral
entri
inhibitor
antagonist
bicyclam
viru
adsorpt
inhibitor
dextran
sulfat
viruscel
fusion
inhibitor
enfuvirtid
acknowledg
financi
support
european
commiss
empro
grate
acknowledg
infect
target
cell
human
immunodefici
viru
hiv
mainli
depend
presenc
surfac
molecul
serv
primari
viru
receptor
therefor
drug
target
receptor
thu
inhibit
viral
entri
may
promis
agent
treatment
aid
report
resist
profil
hiv
receptor
downregul
cada
novel
potent
antihiv
agent
prototyp
compound
cyclotriazadisulfonamid
cada
inhibit
hiv
infect
tcell
line
phastimul
pbmc
monocytesmacrophag
antihiv
activ
markedli
enhanc
pretreat
cell
cada
h
cada
show
synergi
evalu
combin
variou
known
hiv
inhibitor
revers
transcriptas
inhibitor
proteas
inhibitor
viru
entri
inhibitor
flow
cytometr
analysi
reveal
signific
decreas
cell
surfac
intracellular
express
receptor
cadatr
cell
moreov
antivir
activ
cada
correl
abil
downmodul
receptor
interestingli
cada
affect
express
least
surfac
molecul
examin
includ
hiv
coreceptor
expos
escal
concentr
cada
strain
isol
subcultiv
show
decreas
sensit
compound
cadaresist
viru
strain
investig
sensitivityresist
profil
varieti
hiv
inhibitor
show
signific
reduct
sixfold
sensit
monoclon
antibodi
compar
wildtyp
counterpart
determin
amino
acid
chang
viral
envelop
reveal
sever
mutat
envelop
glycoprotein
interestingli
two
amino
acid
chang
occur
domain
subject
mutagenesi
experi
antisens
phosphorodiamid
morpholnio
oligom
pmo
design
inhibit
ebola
zair
express
np
l
gene
product
report
plasmid
contain
portion
viral
sequenc
flank
translat
start
site
l
fuse
luciferas
construct
vitro
translat
rna
report
construct
identifi
effect
antisens
sequenc
ic
approxim
nm
noncompetit
inhibitor
translat
singl
dose
pharmacokinet
studi
indic
administ
either
iv
subcutan
rout
effect
distribut
tissu
includ
liver
kidney
spleen
tissu
accumul
oligom
concentr
greater
nm
h
analys
plasma
tissu
sampl
indic
degrad
clear
primarili
urin
unchang
oligom
surviv
efficaci
observ
mous
adapt
ebola
zair
dose
ug
either
ip
sq
rout
administr
greatest
antivir
efficaci
observ
follow
administr
pmo
target
efficaci
target
l
intermedi
nomin
efficaci
observ
target
np
vivo
surviv
efficaci
dose
oligom
sequenc
depend
studi
indic
continu
evalu
pmo
prophylaxi
treatment
ebola
infect
reason
among
high
threat
categori
virus
four
new
world
arenavirus
machupo
guanarito
virus
capabl
caus
sever
often
fatal
hemorrhag
fever
diseas
human
arenavirusspecif
antivir
drug
current
approv
use
human
avail
antivir
drug
direct
virus
would
provid
strong
deterr
use
biowarfar
agent
antivir
drug
could
readili
stockpil
rapidli
deploy
event
arenaviru
outbreak
sinc
antivir
drug
easili
administ
oral
pill
liquid
exert
antivir
effect
within
hour
administr
serv
effect
treat
diseas
patient
protect
suspect
expos
pathogen
postexposur
prophylaxi
assist
time
contain
outbreak
work
categori
arenavirus
requir
biosafeti
contain
use
relat
new
world
arenaviru
tacarib
viru
develop
high
throughput
screen
ht
assay
viru
replic
tacarib
viru
ident
viru
amino
acid
level
four
viral
protein
approxim
small
molecul
compound
screen
use
tacarib
virusinduc
cytopath
effect
cpe
assay
compound
identifi
screen
show
antivir
activ
specif
tacarib
viru
also
categori
new
world
arenavirus
drug
resist
variant
isol
suggest
compound
target
viral
gene
product
act
cellular
toxic
mechan
lead
compound
chosen
drug
develop
vitro
antivir
potenc
select
mechan
action
well
anim
pharmacokinet
efficaci
present
inhibitor
repres
import
step
toward
develop
small
molecul
antivir
drug
new
world
arenavirus
infect
grow
number
arenavirus
lead
frequent
fatal
hemorrhag
fever
due
sever
diseas
potenti
intent
releas
identifi
effect
treatment
infecti
diseas
arenavir
origin
consider
prioriti
biodefens
mission
past
treatment
arenavir
infect
type
interferon
yield
favor
result
present
evid
interferon
infergen
tm
nonnatur
bioengin
consensu
interferon
contain
frequent
occur
amino
acid
among
nonallel
interferonalpha
subtyp
activ
pichind
tacarib
arenavirus
cell
cultur
hamster
model
pichind
viru
pcv
infect
interferon
treatment
significantli
protect
anim
death
prolong
surviv
eventu
die
reduc
viru
titer
limit
liver
damag
characterist
pcvinduc
diseas
treatment
still
effect
initi
late
day
postviru
challeng
demonstr
potenti
applic
therapeut
agent
despit
observ
benefici
activ
interferon
pcv
hamster
model
effort
stimul
protect
immun
known
interferoninduc
ampligen
poli
poli
c
u
offer
limit
protect
data
first
report
demonstr
efficaci
treatment
acut
arenavir
diseas
interferonbas
drug
suggest
increas
potenc
biooptim
interferon
molecul
may
essenti
observ
antivir
effect
acknowledg
support
contract
virolog
branch
nation
institut
allergi
infecti
diseas
nation
institut
health
present
human
papillomaviru
hpv
genotyp
describ
show
cutan
mucos
tropism
strong
associ
infect
specif
genit
virus
ie
type
develop
cervic
cancer
vitro
studi
shown
note
cidofovir
cdv
mechan
cell
death
follow
treatment
pmeg
appear
induct
apoptosi
accumul
cell
sphase
cell
cycl
describ
effect
pmeg
cdv
growth
cervic
carcinoma
siha
posit
hela
posit
xenograft
athymicnud
mice
sixweek
old
mice
inject
subcutan
siha
hela
cell
tumor
establish
mice
inject
l
pb
placebo
solut
mgml
cdv
mgml
mgml
pmeg
mgml
arac
cytarabin
tumor
site
five
time
per
week
total
five
week
tumor
size
record
weekli
group
mice
five
anim
per
group
five
week
treatment
signific
reduct
tumor
size
observ
pmegand
cdvtreat
group
compar
either
untreat
placebotr
anim
without
sign
toxic
tumor
size
increas
respect
untreat
placebotr
siha
xenograft
compar
cdvtreat
mgml
pmeg
mgml
pmegtreat
mice
respect
similarli
strike
decreas
tumor
growth
note
pmegand
cdvtreat
hela
xenograft
tumor
size
increas
control
placebo
cdv
mgml
pmegand
mgml
pmegtreat
group
respect
contrast
treatment
arac
reduc
tumor
growth
tumor
size
increas
respect
siha
hela
xenograft
mice
treat
solut
mgml
arac
conclus
shown
athymicnud
mice
cdv
pmeg
inhibit
growth
human
cervic
carcinoma
xenograft
harbor
integr
multitarget
entranc
door
block
aminoglycosidearginin
conjug
aac
weizmann
institut
scienc
organ
chemistri
rehovot
israel
multistep
natur
entri
provid
multisit
target
entranc
door
cell
use
one
drug
target
multipl
site
andor
step
viral
life
cycl
obviou
advantag
clinic
use
aac
repres
new
class
compound
may
serv
lead
compound
develop
multitarget
entri
inhibitor
litovchick
et
al
litovchick
et
al
borkow
et
al
borkow
et
al
lapidot
et
al
press
serv
antagonist
fusion
inhibitor
potent
aac
hexaarginin
neomycin
b
compet
aac
interact
select
without
affect
natur
activ
contrast
coreceptor
inhibitor
resist
viral
isol
contain
mutat
envelop
subunit
mutat
associ
chang
nonpolar
polar
amino
acid
residu
appar
import
antivir
activ
mutat
isol
found
amino
acid
residu
differ
describ
viral
isol
resist
inhibitor
interact
taken
togeth
competit
aac
monoclon
antibodi
ii
competit
aac
bind
iii
isol
sensit
wt
viru
natur
ligand
strongli
suggest
aac
obstruct
replic
interf
fusion
step
fusion
step
depend
conform
chang
follow
interact
well
conform
chang
induc
interact
also
inhibit
death
human
neuroblastoma
cell
vitro
catani
et
al
plausibl
mechan
neuroprotect
via
blockad
interact
taken
togeth
data
support
notion
differ
aac
exert
antivir
activ
via
differ
mechan
depart
medicin
san
diego
va
healthcar
system
univers
california
san
diego
la
jolla
ca
usa
phosphonomethoxi
propyl
adenin
hpmpa
effect
broad
spectrum
antivir
mani
dna
virus
includ
herp
simplex
viru
human
cytomegaloviru
human
adenoviru
variou
orthopoxvirus
howev
hpmpa
report
essenti
inact
retrovirus
report
previous
long
chain
alkoxyalkyl
ester
nucleosid
phosphon
cidofovir
show
significantli
increas
antivir
activ
doubl
strand
dna
virus
prepar
alkoxyalkyl
ester
hpmpa
r
hpmpa
report
activ
cell
infect
lai
use
reduct
assay
compar
increas
antivir
effect
hpmpa
r
hpmpa
synthes
two
enantiom
prepar
lipid
ester
hexadecyloxypropylhpmpa
hdphpmpa
octadecyloxyethylhpmpa
odehpmpa
oleyloxyethylhpmpa
olehpmpa
oleyloxypropylhpmpa
olphpmpa
unmodifi
hpmpa
r
hpmpa
essenti
inact
report
previous
ec
valu
howev
alkoxyalkyl
ester
enantiom
highli
activ
exhibit
submicromolar
ec
although
alkoxyalkyl
ester
r
enantiom
hpmpa
consider
less
activ
still
exhibit
substanti
increas
antivir
activ
compar
unmodifi
r
hpmpa
alkoxyalkyl
ester
hpmpa
oral
activ
orthopoxvirus
mice
worthi
evalu
possibl
therapi
infect
man
xin
yan
hua
shen
lipe
wang
hongjian
jiang
xinqi
wu
jun
wang
dan
hu
delia
wolf
zhaoxiong
yang
ming
dao
peihua
ni
chengsheng
zhang
background
casebas
studi
shown
extern
qi
qi
extern
qi
water
qi
water
yan
xin
life
scienc
technolog
yxlst
exhibit
signific
effect
reduc
viral
load
improv
immun
function
aid
patient
observ
side
effect
explor
potenti
applic
qi
qi
water
yxlst
new
therapeut
agent
infect
examin
effect
qi
qi
water
replic
underli
molecular
mechan
method
human
pbmc
infect
hivada
virus
respect
cultur
presenc
absenc
qi
qi
water
latent
infect
cell
pma
treat
cell
cultur
presenc
absenc
qi
qi
water
product
cell
cultur
supernat
measur
revers
transcriptas
rt
assay
test
possibl
effect
qi
qi
water
ltr
activ
jurkat
cell
cotransfect
phivltrluc
pcmvtat
plasmid
cultur
presenc
absenc
qi
qi
water
cell
lysat
prepar
luciferas
assay
h
transfect
result
qi
qi
water
yxlst
potent
inhibit
viral
replic
pbmc
dramat
suppress
product
pma
treat
cell
moreov
qi
qi
water
potent
inhibit
tatmedi
ltr
activ
jurkat
cell
howev
signific
cytotox
cell
treat
either
qi
qi
water
conclus
data
suggest
extern
qi
qi
water
yxlst
may
potenti
becom
novel
therapeut
agent
infect
xin
wang
kazunobu
yamataka
mika
okamoto
satoru
ikeda
masanori
baba
divis
antivir
chemotherapi
center
chronic
viral
diseas
graduat
school
medic
dental
scienc
kagoshima
univers
kagoshima
japan
japan
tobacco
inc
osaka
japan
search
effect
transcript
inhibitor
evalu
compound
inhibitori
effect
long
termin
repeat
ltr
driven
report
gene
express
identifi
novel
naphthalen
deriv
compound
could
suppress
product
provir
dnaintegr
latent
chronic
infect
cell
lower
concentr
effect
concentr
ec
express
latent
infect
cell
constitut
viral
product
chronic
infect
cell
respect
affect
viabil
prolifer
cell
concentr
cytotox
concentr
cell
select
suppress
mrna
synthesi
cell
dosedepend
fashion
determin
quantit
rtpcr
analysi
viral
mrna
synthesi
achiev
even
howev
acut
infect
cell
cultur
peripher
blood
mononuclear
cell
pbmc
antivir
activ
found
diminish
result
suggest
inhibit
replic
suppress
viral
gene
express
especi
transcript
level
carlo
fatima
rodriguezbarrio
federico
gago
erik
de
clercq
jan
balzarini
camarasa
sonsol
velazquez
revers
transcriptas
rt
repres
one
main
target
develop
chemotherapi
hiv
activ
form
enzym
heterodim
form
two
subunit
dimer
rt
prerequisit
enzymat
activ
therefor
interfer
process
could
constitut
addit
interest
strategi
convent
rt
inhibit
tsao
deriv
peculiar
nnrti
famili
discov
group
first
exampl
small
nonpeptid
molecul
interfer
dimer
process
upon
bind
loop
region
subunit
two
residu
loop
seem
particularli
import
enzym
stabil
therebi
enzym
activ
highli
conserv
key
interact
residu
tsao
deriv
enzym
present
design
synthesi
biolog
evalu
tripeptid
deriv
may
mimick
key
interact
subunit
ntermin
residu
asn
residu
chosen
ctermin
residu
amino
acid
aromat
natur
phe
tyr
interact
stack
subunit
use
central
residu
dpro
flexibl
residu
gli
ala
introduc
design
peptid
prepar
differ
nctermin
cap
group
order
increas
stabil
lipophyl
compound
synthes
evalu
inhibitori
effect
replic
cellcultur
preliminari
result
show
deriv
endow
moder
activ
micromolar
rang
studi
suggest
asn
dpro
residu
import
structur
compon
observ
antivir
activ
revers
transcriptas
rt
viru
critic
target
antivir
chemotherapi
essenti
rule
replic
process
nucleosid
inhibitor
first
class
antivir
compound
shown
efficaci
rt
unfortun
antihiv
chemotherapi
limit
appear
drugresist
virus
mutat
map
viral
pol
gene
encod
rt
abund
multidrugresist
mdr
virus
one
major
problem
mani
treat
patient
therapi
ineffect
new
gener
drug
urgent
need
therapeut
research
activ
ongo
design
synthes
new
analogu
activ
mdr
virus
show
better
antivir
efficaci
better
pharmacolog
properti
found
new
analogu
show
excel
properti
resist
multiresist
suppress
alphaboranophosph
figur
enzymat
studi
realiz
sever
alphaborano
deriv
sever
rt
shown
better
efficaci
phosphoryl
cellular
kinas
ndpk
compound
unmodifi
analogu
better
inhibit
rt
unmodifi
analogu
due
increas
effici
incorpor
dna
discrimin
compar
natur
nucleotid
decreas
complet
suppress
resist
recent
alphaboranonucleotid
analogu
found
increas
catalyt
rate
phosphodiest
bond
format
independ
substitut
rt
nucleotid
analogu
use
time
first
exampl
rt
resist
suppress
found
nucleotid
analogu
follow
work
synthes
two
new
origin
seri
boranonucleotid
ludov
bannwarth
sandrin
ongeri
nicol
boggetto
merabet
bruno
collinet
same
sicsic
reboudravaux
institut
jacqu
monod
umr
cnrsuniv
pari
et
place
jussieu
pari
cedex
franc
bioci
umrcnr
de
pharmaci
univ
pari
rue
jb
ch
tenaymalabri
cedex
franc
cross
resist
current
antiproteas
serious
compromis
effici
aid
treatment
remark
antiparallel
form
interdigit
nand
ctermin
strand
proteas
monom
contribut
stabil
forc
dimer
found
rel
free
mutat
target
highli
conserv
dimer
interfac
demonstr
proteas
dimer
disrupt
loss
activ
lipopeptid
k
id
nm
dumond
et
al
guanidiniumbas
molecul
k
id
nm
brecciaet
al
constrain
molecular
tong
k
id
nm
merabet
et
al
latter
molecul
two
peptid
strand
crosslink
rigid
naphthalen
quinolin
spacer
figur
order
creat
proteolysi
resist
inhibitor
one
peptid
strand
replac
pseudopeptid
activ
sever
molecul
recombin
proteas
display
mutat
found
resist
variant
also
analyz
result
indic
antidim
strategi
use
lowmolecularweight
molecul
may
provid
novel
therapeut
approach
breccia
p
boggetto
n
perezfernandez
r
van
gool
takahashi
pol
gene
hiv
encod
three
key
viral
enzym
essenti
replic
viru
discoveri
develop
clinic
use
inhibitor
two
enzym
hiv
revers
transcriptas
hiv
proteas
treatment
aid
last
two
decad
remark
howev
third
enzym
pol
gene
hiv
integras
receiv
much
less
attent
drug
clinic
use
hivaid
mechan
action
inhibit
hiv
integras
biochem
mechan
integr
hiv
dna
host
cell
genom
occur
specif
order
sequenc
dna
tailor
coupl
strand
transfer
integr
reaction
number
compound
consider
structur
divers
report
recent
year
inhibitor
integras
among
nucleasest
dinucleotid
report
us
nonnucleosid
compound
bear
acid
function
respect
latter
class
almost
compound
investig
appear
show
select
inhibit
step
design
synthes
diketo
structur
heterocycl
scaffold
potent
inhibitor
strand
transfer
step
integras
present
discuss
approach
design
compound
methodolog
use
synthesi
detail
structur
conform
inhibitori
data
involv
integras
recent
report
effici
stereoselect
synthesi
new
bicycl
nucleosid
use
common
cyclic
enamin
start
materi
compound
easili
prepar
reaction
otosyl
tsaot
basic
nonnucleophil
condit
addit
reaction
ethanol
gave
tricycl
nucleosid
result
nucleophil
attack
alcohol
carbon
atom
compound
test
vitro
inhibitori
effect
hiv
replic
compound
found
exhibit
highli
specif
activ
inact
retro
virus
establish
structuralact
relationship
requir
activ
differ
type
modif
carri
prototyp
compound
modif
includ
replac
ethoxi
group
posit
hydrogen
thio
alkoxi
sidechain
differ
length
flexibl
also
studi
effect
termin
function
alkoxi
side
chain
role
tbdm
group
posit
best
anti
activ
achiev
compound
bear
flexibl
alkoxi
sidechain
medium
length
contain
tbdm
group
posit
tricycl
nucleosid
herein
describ
repres
entir
new
class
nnrti
bonach
mc
chamorro
c
cordeiro
camarasa
mj
jimeno
ml
j
org
chem
press
noah
h
duffi
thoma
w
bell
sreenivasa
anugu
kaka
dey
qi
jin
meinrado
f
samala
andrej
sodoma
kurt
vermeir
erik
de
clercq
dominiqu
schol
depart
chemistri
univers
nevada
reno
nv
usa
rega
institut
medic
research
ku
leuven
leuven
belgium
cada
specif
downmodul
receptor
surfac
lymphocyt
monocytesmacrophag
princip
host
cell
util
hiv
replic
structur
modif
cada
made
increas
potenc
reduc
cytotox
report
quantit
structureact
relationship
qsar
studi
base
compar
molecular
field
analysi
comfa
deriv
cada
specif
partialleast
squar
pl
analysi
perform
inhibitori
concentr
ic
downmodul
cada
analogu
gener
comput
model
correl
import
structur
featur
potenc
exampl
increas
steric
bulk
tail
z
region
cada
indic
mesh
figur
top
right
top
left
correl
higher
downmodul
activ
also
report
synthesi
cada
compound
includ
sidearm
tail
z
head
group
x
analogu
figur
center
sidearm
variat
includ
benzenesulfonyl
group
bear
electron
donat
electron
withdraw
substitu
tail
consist
variou
aromat
aliphat
group
head
group
includ
polar
substitu
good
leav
group
altern
synthet
rout
cada
analogu
involv
tbd
intermedi
also
report
current
studi
aim
refin
qsar
well
determin
molecular
target
cada
produc
modest
increas
error
frequenc
genom
rna
virus
class
mutagen
agent
may
drive
viru
popul
error
catastroph
area
infect
viabil
highli
reduc
order
limit
crossresist
well
addit
toxic
group
interest
studi
compound
inhibit
prolifer
origin
mechan
part
current
work
prepar
analogu
ribavirin
triphosph
deriv
base
chosen
propos
enabl
base
pair
four
natur
occur
nucleobas
simpl
bond
rotat
mutagen
activ
compound
examin
cell
cultur
elong
sever
primertempl
complex
rt
presenc
triphosph
evalu
vitro
chemic
synthesi
titl
compound
deriv
describ
result
biolog
studi
concern
abil
these
compound
creat
mismatch
lethal
error
revers
transcript
discuss
order
explor
physiolog
correl
nnrti
bind
pocket
rnase
h
activ
site
want
verifi
whether
effect
gener
nnrti
irrespect
chemic
structur
interact
nnrti
bind
pocket
whether
differ
nnrti
could
affect
rnase
h
activ
compoundspecif
pattern
therefor
assess
effect
polymeraseindepend
rnase
h
activ
shown
nevirapin
efavirenz
nnrti
potenti
microbicid
activ
current
develop
inhibit
rt
associ
rnadepend
dna
polymeras
activ
noncompetit
result
show
three
nnrti
activ
polymeraseindepend
rnase
h
activ
howev
potenc
stimul
vari
accord
nnrti
studi
particular
increas
rnase
h
activ
obtain
efavirenz
nevirapin
steadyst
kinet
studi
show
presenc
nnrti
vari
k
valu
rnase
h
reaction
homopolymer
rna
dna
hybrid
substrat
wherea
determin
twofold
increas
k
cat
valu
hydrolysi
reaction
heteropolymer
hybrid
substrat
use
reaction
result
show
nnrti
alter
cleavag
specif
rnase
h
determin
compoundspecif
substrat
cleavag
pattern
result
confirm
two
rt
activ
site
structur
correl
indic
alloster
interact
nnrti
rt
determin
inhibitorspecif
effect
rt
rnase
h
associ
activ
centro
de
molecular
severo
ochoa
csicuam
madrid
spain
revers
transcriptas
rt
play
key
role
viru
life
cycl
enzym
respons
convers
viral
genom
rna
doublestrand
dna
integr
host
cell
genom
lack
proofread
activ
highli
error
prone
therefor
contribut
high
degre
genet
variabl
hiv
highli
conserv
form
togeth
pocket
accommod
ribos
moieti
incom
dntp
amino
acid
substitut
posit
known
deleteri
rt
function
ie
influenc
fidel
dna
synthesi
ie
addit
chang
posit
confer
resist
dideoxynucleosid
analogu
use
treatment
hiv
infect
ie
obtain
seri
mutant
rt
substitut
posit
order
defin
role
ddntp
resist
well
nucleotid
recognit
fidel
dna
synthesi
found
increas
volum
sidechain
posit
deleteri
effect
dna
polymeras
activ
thu
mutant
show
reduc
primer
extens
effici
comparison
wildtyp
rt
mutant
show
decreas
suscept
azttp
dna
polymer
assay
poli
ra
oligo
dt
howev
enzym
show
similar
azttp
versu
dttp
select
assay
carri
heteropolymer
templateprim
furthermor
show
similar
select
valu
rntp
versu
dntp
incorpor
differ
found
fidel
dna
synthesi
measur
misinsert
mispair
extens
fidel
assay
use
laczbas
genet
assay
loss
interact
methyl
group
ribos
moieti
incom
dntp
emerg
major
determin
predict
resist
zalcitabin
didanosin
display
mikhail
dobrikov
barbara
ramsay
shaw
depart
chemistri
pm
gross
chemic
laboratori
duke
univers
durham
nc
usa
dideoxynucleosid
ddn
wide
use
clinic
treatment
aid
metabol
activ
correspond
dideoxynucleosid
triphosph
ddntp
inhibit
viral
dna
synthesi
howev
emerg
revers
transcriptasedepend
drug
resist
limit
effect
treatment
ddn
enzymat
studi
show
better
substrat
cellular
ndp
kinas
parent
ddndp
better
inhibitor
viral
revers
transcriptas
resist
atpdepend
remov
viral
dna
parent
ddntp
order
obtain
structureact
relationship
discrimin
modifi
ddntp
dntp
bacteri
dna
polymeras
viral
revers
transcriptas
examin
steadyst
presteadyst
kinet
incorpor
analogu
two
ddntpresist
enzym
murin
moloney
leukemia
viru
revers
transcriptas
mmlv
rt
taq
dna
polymeras
presteadyst
condit
substitut
ddctp
increas
effici
incorpor
isom
mmlv
rt
slightli
decreas
effici
taq
polymeras
contrast
modif
decreas
effici
incorpor
mmlv
rt
taq
dna
polymeras
respect
modif
alter
rate
constant
k
pol
valu
effect
affin
constant
k
valu
base
data
propos
chemic
mechan
explain
differenti
influenc
substitut
drug
resist
mmlv
rt
taq
dna
polymeras
select
suppress
drugresist
viral
rt
ddctp
analogu
suggest
approach
design
new
antivir
agent
julia
blanco
imma
clotet
bonaventura
clotet
jose
assay
hiv
envelop
env
function
base
measur
postfus
event
howev
prior
induc
complet
fusion
env
requir
bind
subunit
coreceptor
mediat
membran
hemifus
use
flow
cytometri
simultan
quantifi
prefus
event
associ
env
function
cocultur
bal
chronic
infect
cell
line
unstimul
primari
cell
h
primari
cell
chosen
sensit
cell
surfac
express
envinduc
cell
death
inabl
replic
hiv
cellular
contact
mediat
suffici
induc
transfer
hiv
particl
infect
target
cell
measur
stain
hiv
antigen
coreceptor
express
necessari
allow
target
cell
death
celltocel
fusion
death
singl
target
cell
associ
hemifus
measur
chang
cell
morpholog
cellto
cell
fusion
evalu
calcul
absolut
number
singl
cell
disappear
cultur
morpholog
measur
cell
death
valid
comparison
standard
techniqu
stain
show
high
correl
r
p
measur
lost
cell
correl
microscop
evalu
syncytium
format
r
p
analysi
sever
inhibitor
reveal
particular
inhibitori
profil
drug
act
differ
step
hiv
env
function
anti
hiv
env
compound
test
block
celltocel
fusion
howev
drug
target
bind
block
hiv
transfer
cell
death
inhibitor
block
cell
death
increas
hiv
transfer
coreceptor
inhibitor
act
engag
select
block
cell
death
induc
appropri
env
fail
inhibit
transfer
hiv
particl
infect
uninfect
cell
combin
use
hiv
envelop
multiparametr
analysi
provid
rapid
method
simultan
evalu
bind
hemifusionfus
event
mediat
analysi
may
use
screen
anti
hiv
envelop
drug
rapidli
identifi
mode
action
activ
compound
eduardo
paul
jordi
senserrich
bonaventura
clotet
retrovirolog
laboratori
irsicaixa
hospit
german
tria
pujol
badalona
spain
shown
hiv
infect
lead
activ
cascad
event
lead
cell
death
express
activ
associ
faster
hiv
diseas
progress
probabl
induc
cell
death
also
cooper
effect
control
viral
gene
transcript
viral
regulatori
protein
activ
also
associ
hiv
envelopedepend
death
hivinduc
syncytia
gener
neg
lymphoid
cell
line
stabl
express
short
hairpin
rna
shrna
target
gene
infect
cell
express
shrna
target
hiv
rev
strain
significantli
reduc
compar
control
cell
convers
interfer
express
shrna
target
rev
alter
cell
viabil
prolifer
effect
silenc
hiv
replic
confirm
singl
round
replic
experi
infect
luciferaseexpress
hiv
chimera
syncytium
format
cocultur
persist
infect
cell
cell
significantli
alter
compar
cocultur
control
cell
pseudotyp
hiv
express
vsv
envelop
vsvenvhiv
use
assess
role
hiv
entri
block
viru
replic
contrari
hiv
express
hiv
envelop
hivenvhiv
vsvenvhiv
infect
could
block
inhibitor
hiv
entri
could
block
shrna
target
rev
similarli
replic
hivenvhiv
vsvenvhiv
block
suggest
play
role
postentri
event
viru
replic
conclus
result
suggest
express
significantli
alter
hiv
replic
lymphoid
cell
role
appear
independ
hivenvelop
hiv
entri
process
recent
clinic
data
indic
regimen
contain
drug
inhibit
ribonucleotid
reductas
rr
hydroxyurea
hu
effect
therapeut
option
hivinfect
patient
immun
activ
respons
alter
immun
patholog
present
aid
therefor
compound
inhibit
immun
activ
consid
novel
approach
treat
hivinfect
compound
hu
consid
member
new
famili
antivir
compound
refer
virostat
function
inhibit
immun
activ
addit
viral
replic
studi
compar
antivir
immun
activ
effect
hu
two
novel
polyphenol
inhibitor
rr
rri
trimidox
didox
acid
presenc
absenc
didanosin
ddi
lp
mulv
retroviru
model
murin
aid
evalu
treat
viral
infect
anim
follow
paramet
splenomegali
hypergammaglobulinemia
activ
bsplenocyt
loss
splenic
architectur
viral
def
express
femor
cellular
hematopoiet
progenitor
stem
cell
combin
rr
inhibitor
ddi
extrem
effect
dx
tx
hu
inhibit
retrovirusinduc
diseas
includ
viral
replic
toxic
result
show
tx
dx
combin
ddi
well
toler
howev
hu
ddi
associ
myelosuppress
inhibitor
rr
combin
ddi
provid
signific
protect
retrovir
diseas
murin
aid
tx
dx
effect
less
myelosuppress
hu
test
ddi
model
hiroshi
takaku
jacob
barnor
kazuya
yamaguchi
naoko
miyanokurosaki
depart
life
environment
scienc
chiba
institut
technolog
chiba
japan
high
technolog
research
center
chiba
institut
technolog
chiba
japan
noguchi
memori
institut
medic
research
depart
virolog
accra
ghana
rna
interfer
rnai
silenc
gene
express
short
interf
mer
doublestrand
rna
segment
guid
cognat
mrna
degrad
sequencespecif
fashion
rnarna
interact
howev
group
report
shrna
direct
viral
nef
vif
gene
induc
escap
variant
order
overcom
problem
one
use
dual
antigen
avoid
evolut
escap
variant
herebi
report
employ
two
mechanist
strategi
vector
system
result
novel
construct
simultan
express
decoy
tar
shrna
singl
molecul
latter
cleav
endogen
dicer
cell
separ
compon
decoy
tar
rna
competit
interact
tat
protein
rnaprotein
interact
downregul
level
gene
express
ltr
promot
achiev
sustain
suppress
escap
mutant
end
shrna
link
end
decoy
tar
rna
uu
signal
cleavag
warrant
tar
rna
act
complement
factor
proteinrna
interact
sequenc
analysi
reveal
mutat
vifgen
vifshrnatarrna
control
vifshrna
alon
hand
strongli
enhanc
synergist
inhibit
efficaci
replic
suppress
shrnarel
escap
mutant
phenomenon
longterm
cultur
assay
multipl
antigen
could
lead
effect
gene
therapi
strategi
avoid
rnaimedi
escap
variant
traci
l
hartman
robert
w
buckheit
jr
imquest
bioscienc
inc
frederick
usa
rapid
select
drugresist
viru
strain
hivinfect
patient
antivir
therapi
primari
reason
treatment
failur
nucleosid
nonnucleosid
rt
inhibitor
although
resist
would
appear
detriment
outcom
antivir
therapi
may
possibl
select
resist
virus
reduc
replic
capac
andor
fit
resistanceengend
mutat
may
yield
benefici
therapeut
effect
select
mutat
caus
reduct
rate
andor
extent
viru
replic
reduc
viru
replic
may
effect
prolong
interv
initi
hiv
infect
aid
allow
immun
system
effect
deal
viru
allow
effect
therapeut
intervent
hiv
inhibitori
agent
laboratori
develop
assay
allow
us
evalu
rel
rate
resist
select
antivir
compound
compar
wildtyp
resist
viru
strain
regard
replic
kinet
capac
rel
fit
well
identifi
potenti
contribut
compensatori
chang
viru
result
enhanc
replic
low
fit
virus
assay
employ
viru
specif
amino
acid
chang
introduc
revers
transcriptas
proteas
site
direct
mutagenesi
use
competit
viral
replic
assay
shown
viru
contain
point
mutat
confer
resist
nucleosid
nonnucleosid
rt
inhibitor
proteas
inhibitor
may
exhibit
reduc
increas
rate
extent
viru
replic
may
exhibit
chang
replic
rel
growth
potenti
mutant
viru
also
compar
wildtyp
viru
absenc
presenc
drug
select
pressur
assay
compar
rel
replic
capac
cemss
cell
fresh
human
primari
mononuclear
cell
result
demonstr
druginduc
singl
multipl
mutat
revers
transcriptas
proteas
posit
neg
effect
abil
hiv
replic
human
cell
evalu
mutat
alon
combin
may
prove
valuabl
design
therapeut
strategi
hivinfect
patient
cyanovirinn
cvn
kda
protein
potent
antihiv
activ
cvn
origin
discov
purifi
extract
cyanobacterium
bluegreen
alga
nostoc
ellipsosporum
report
cvn
extrem
resist
method
use
physicochem
degrad
cvn
withstand
treatment
denatur
deterg
organ
solvent
extrem
temperatur
without
signific
loss
antivir
activ
low
nanomolar
concentr
cvn
inhibit
replic
clinic
hiv
strain
evalu
laboratori
strain
siv
fiv
moreov
cvn
activ
subtyp
cvn
bind
irrevers
hiv
surfac
envelop
glycoprotein
specif
interact
high
mannos
group
bind
block
interact
receptor
variou
target
cell
lead
inhibit
attach
fusion
viru
particl
target
cell
express
recombin
cvn
inclus
bodi
cytoplasm
e
coli
result
monomer
cvn
bind
nanomolar
affin
retain
potent
antihiv
activ
cellbas
assay
evalu
antivir
activ
varieti
excipi
alon
combin
recombin
cvn
well
vitro
activ
formul
drug
product
specif
recombin
cvn
formul
hydroxyethylcellulos
hec
copolym
test
depoproveratr
chines
rhesu
macaqu
anim
treat
cvn
hec
infect
note
week
postinfect
measur
plasma
viral
rna
result
suggest
cvn
formul
gel
effect
vagin
microbicid
addit
hec
placebo
gel
analyz
vitro
vivo
effect
safeti
efficaci
demonstr
appropri
physic
properti
stabil
vagin
gel
formul
safeti
use
clinic
studi
investig
microbicid
final
uniqu
properti
cvn
potent
inactiv
hiv
make
protein
relev
develop
vagin
antihiv
microbicid
advanc
preclin
develop
underway
miguel
steven
oriana
tabarrini
violetta
cecchetti
erik
de
clercq
arnaldo
fravolini
christoph
pannecouqu
quinolon
deriv
shown
inhibit
human
immunodefici
viru
hiv
replic
transcript
level
recent
publish
seri
new
endow
stronger
antihiv
activ
compar
formerli
report
fluoro
quinolon
deriv
tabarrini
et
al
j
med
chem
compound
complet
suppress
tumor
necrosi
factor
alpha
phorbol
pma
induc
express
latent
cell
line
subtox
concentr
addit
express
also
mrna
product
cell
line
markedli
inhibit
dosedepend
manner
concentr
rang
compound
abl
inhibit
releas
pmainduc
cell
induct
product
observ
cell
cytotox
concentr
deriv
inhibitori
tatmedi
transactiv
ltr
promotor
also
found
interfer
celldepend
way
transactiv
process
mediat
cmvie
human
promotor
find
suggest
mechan
action
deriv
attribut
specif
inhibit
hiv
replic
inhibitori
effect
deriv
transcript
transactiv
process
may
explain
broadspectrum
antivir
activ
antihcmv
activ
wide
therapeut
spectrum
remark
low
cytotox
may
provid
interest
perspect
antivir
activ
quinolon
despit
exist
effici
vaccin
chronic
hepat
b
viru
infect
continu
major
public
health
problem
worldwid
current
treatment
chronic
hepat
b
reli
mainli
use
interferon
alpha
nucleosid
analog
lamivudin
adefovir
dipivoxil
howev
limit
respons
relaps
upon
withdraw
treatment
emerg
viral
resist
still
major
shortcom
treatment
therefor
discoveri
safe
effect
antivir
drug
continu
present
consider
challeng
chlorophyllin
mixtur
sodiumcopp
salt
chlorophyl
deriv
found
effect
anticarcinogen
experiment
model
clinic
trial
data
suggest
chlorophyllin
may
serv
chemoprevent
agent
aflatoxininduc
hepatocellular
carcinoma
besid
lack
known
toxic
prompt
us
evalu
potenti
chlorophyllin
antivir
present
studi
use
primari
duck
hepatocyt
cultur
postnat
infect
duck
hepat
b
viru
dhbv
hbvproduc
cell
line
hep
studi
vitro
antivir
activ
chlorophyllin
duck
hepat
b
viru
dhbv
hepat
b
viru
hbv
respect
result
reveal
chlorophyllin
induc
reduct
extracellular
dhbv
dna
level
ic
valu
inhibitori
concentr
gml
addit
chlorophyllin
also
found
strongli
inhibit
secret
hepat
b
surfac
antigen
hbsag
hepat
b
e
antigen
hbeag
hep
cell
ic
gml
gml
respect
data
indic
chlorophyllin
potent
antihepadnavir
agent
worth
studi
efficaci
vivo
anim
model
howev
sequenc
variat
whv
isol
gener
necessit
use
blottingbas
detect
method
overcom
problem
creat
realtim
taqman
pcr
assay
whv
use
degener
primer
inosin
residu
employ
locat
known
sequenc
heterogen
taqman
assay
dynam
rang
genom
equival
ge
whv
dna
per
reaction
assay
robust
reproduc
ge
whv
dna
per
reaction
rang
intraassay
coeffici
variat
interassay
cv
assay
valid
clone
analyz
seri
six
natur
occur
viru
variant
contain
sequenc
heterogen
taqman
primer
sequenc
region
show
presenc
sequenc
variat
prevent
pcr
amplif
target
regular
primer
sequenc
use
degener
primer
sequenc
abl
effici
amplifi
test
sequenc
equal
well
high
level
hepat
b
surfac
antigen
hbsag
bear
noninfecti
particl
serum
infect
individu
thought
play
role
suppress
hepat
b
viru
hbv
specif
immun
respons
current
hbv
therapeut
directli
reduc
viral
antigenemia
group
pursu
strategi
compound
reduc
hbsag
secret
either
complement
exist
therapi
serv
research
tool
highthroughput
screen
ht
small
molecul
librari
druglik
compound
undertaken
discov
novel
inhibitor
hbsag
secret
use
stabli
hbvtransfect
human
hepatocyt
deriv
cell
line
develop
htscompat
elisa
protocol
detect
hbsag
cultur
media
earli
decemb
approxim
compound
screen
yield
primari
hit
rate
determin
toxic
remain
hit
closelyrel
seri
pyridin
emerg
ec
measur
rang
measur
molecular
weight
rang
da
clog
p
rang
nascent
structureact
relationship
suggest
central
moieti
molecul
essenti
activ
aromat
side
group
contribut
potenc
seri
current
investig
sar
determin
mechan
action
secret
hepat
b
viru
hbv
larg
l
middl
envelop
glycoprotein
requir
proper
protein
fold
prevent
inhibitor
endoplasm
reticular
er
alpha
glucosidas
use
competit
inhibitor
er
glucosidas
shown
amount
glycosyl
unglycosyl
form
hbv
l
protein
reduc
dramat
tissu
cultur
produc
hbv
envelop
glycoprotein
contrast
glucosidas
inhibitor
affect
secret
stabil
hbv
protein
proteasom
degrad
pathway
mediat
reduct
l
glycoprotein
sinc
lactacystin
epoxomicin
two
inhibitor
proteasom
prevent
degrad
importantli
specif
degrad
occur
day
remov
glucosidas
inhibitor
cultur
suggest
prolong
antivir
affect
sinc
detect
proteasom
degrad
l
cell
function
glucosidas
implic
nearli
ident
sensit
glycosyl
unglycosyl
form
l
protein
cell
glucosidas
inhibit
surpris
implic
possibl
immunotherapi
discuss
view
recent
discoveri
promis
antivir
activ
ringexpand
fat
nucleobas
nucleosid
contain
imidazo
ring
system
synthes
biolog
screen
number
heterocycl
nucleosid
deriv
analogu
part
extend
structureact
relationship
studi
number
compound
show
potent
activ
hepat
b
hbv
andor
hepat
c
hcv
viru
synthesi
biolog
screen
result
compound
present
dutartr
boretto
jeanclaud
guillemot
bruno
canard
sever
nucleotid
analogu
describ
inhibitor
essenti
viral
rna
depend
rna
polymeras
hepat
c
viru
howev
precis
mode
action
remain
poorli
defin
molecular
level
much
like
differ
step
de
novo
initi
viral
rna
synthesi
show
elong
de
novo
rna
synthesi
made
least
two
distinct
kinet
phase
creation
first
phosphodiest
bond
effici
nucleotid
incorpor
event
use
differ
rna
templat
abl
separ
biochem
character
differ
step
rna
replic
name
initi
elong
experiment
procedur
allow
identif
precis
mode
action
nucleotid
analog
molecular
level
first
exampl
studi
omethyl
gtp
inhibitor
rna
synthesi
nucleotid
competitor
gtp
rna
synthesi
omethyl
gtp
abl
act
chain
termin
inhibit
rna
synthesi
rel
gtp
find
analogu
strongli
discrimin
initi
step
compar
elong
step
interestingli
discrimin
omethyl
gtp
initi
suppress
variant
delet
subdomain
critic
initi
flap
encompass
aa
show
select
alter
transit
initi
elong
result
demonstr
conform
chang
occur
initi
elong
depend
alloster
gtpbind
site
relax
nucleotid
select
rna
elong
may
repres
probabl
target
modifi
nucleotid
analogu
permiss
inhibit
initi
worldwid
million
peopl
infect
hepat
c
viru
hcv
result
least
case
liver
cancer
annual
despit
magnitud
problem
treatment
option
remain
limit
develop
replic
compet
subgenom
replicon
rna
huge
impetu
antivir
drug
develop
howev
major
replicon
use
antivir
drug
discoveri
effort
genotyp
genotyp
one
import
clinic
worldwid
number
genotyp
contribut
significantli
diseas
burden
sinc
signific
differ
genotyp
suscept
current
treatment
regimen
seek
improv
util
antivir
screen
program
employ
replicon
genotyp
addit
genotyp
report
result
studi
nucleosid
analog
cmecytidin
compound
previous
found
activ
hcv
subgenom
replicon
stuyver
et
al
j
virol
evalu
compound
use
secret
alkalin
phosphatas
express
replicon
multipl
genotyp
cmecytidin
show
excel
activ
genotyp
reduc
seap
product
ec
valu
ugml
rang
activ
confirm
direct
quantif
effect
treatment
viral
rna
abund
rtpcr
studi
design
examin
effect
combin
treatment
show
clear
addit
activ
cmecytidin
interferon
alpha
studi
explor
therapeut
interact
class
compound
underway
huil
chiou
chiajun
wu
school
medic
technolog
chung
medic
univers
institut
biochemistri
chung
medic
univers
chronic
hepat
c
infect
import
health
topic
taiwan
sinc
effect
vaccin
avail
protect
therefor
earli
effect
treatment
becom
practic
way
block
diseas
progress
cirrhosi
hepatocellular
carcinoma
current
treatment
hcv
combin
therapi
interferon
ribavirin
often
costli
timeconsum
low
effici
numer
predict
factor
includ
viral
host
factor
studi
predict
effici
previou
studi
genet
polymorph
certain
cytokin
prove
involv
regul
cytokin
product
addit
inappropri
product
certain
cytokin
appear
contribut
viral
persist
affect
antivir
therapi
respons
hepat
c
infect
studi
serum
level
genet
polymorph
sever
cytokin
hepat
c
patient
healthi
control
analyz
elisa
pcrrflp
respect
furthermor
associ
paramet
hepat
c
chronic
infect
well
therapi
respons
statist
analyz
analyz
snp
cytokin
includ
result
show
serum
level
certain
cytokin
includ
chronic
hcv
patient
higher
health
control
howev
correl
cytokin
serum
level
treatment
respons
distribut
allel
statist
differ
patient
healthi
control
p
signific
differ
health
control
patient
genotyp
allel
distribut
addit
signific
correl
snp
cytokin
gene
longterm
respons
antivir
therapi
furthermor
found
signific
correl
snp
cytokin
gene
serum
level
ehud
ilan
rachel
eren
dorit
landstein
riva
kovjazin
ziva
galili
tal
waisman
sigal
aviel
dov
terkieltaub
judi
gopher
ari
zauberman
zhenyong
keck
steven
foung
shlomo
dagan
xtl
biopharmaceut
ltd
rehovot
israel
depart
patholog
stanford
univers
school
medicin
stanford
ca
usa
background
urgent
need
develop
effect
therapi
prevent
reinfect
hepat
c
viru
hcv
associ
liver
transplant
patient
hcv
reinfect
postliv
transplant
could
prevent
passiv
immunotherapi
combin
sever
monoclon
antibodi
direct
differ
epitop
may
advantag
highli
mutat
viru
hcv
object
develop
human
monoclon
antibodi
hmab
envelop
protein
hcv
test
abil
neutral
viru
prevent
human
liver
infect
use
uniqu
vitro
vivo
system
method
panel
hmab
two
antibodi
hcvab
xtl
hcvab
xtl
recogn
differ
epitop
select
assess
bind
characterist
viral
neutral
potenti
test
hcv
cell
cultur
system
well
mous
anim
model
hcv
infect
hcv
trimera
model
result
hmab
character
vitro
biochem
function
hmab
affin
constant
rang
abl
immunoprecipit
hcv
particl
infect
patient
sera
divers
genotyp
stain
hcv
infect
human
liver
tissu
abil
prevent
infect
liver
cell
demonstr
vitro
cellbas
assay
system
hcv
infect
human
hepatoma
cell
line
infect
hcv
high
titer
sera
viral
replic
demonstr
presenc
strand
hcvrna
infect
cell
ad
hmab
infecti
sera
prevent
infect
cell
line
vivo
hmab
capabl
inhibit
hcv
infect
human
liver
fragment
hcv
trimera
model
measur
reduct
mean
viral
load
percentag
hcvrna
posit
mice
conclus
demonstr
neutral
activ
two
hmab
hcv
hcvab
xtl
hcvab
xtl
indic
potenti
prevent
reinfect
liver
transplant
patient
victor
e
buckwold
jiayi
wei
juli
russel
aysegul
nalca
jay
well
william
lang
peter
langeck
infecti
diseas
research
depart
southern
research
institut
frederick
md
usa
intarcia
therapeut
inc
emeryvil
ca
usa
human
omega
interferon
ifn
type
ifn
shown
welltoler
man
induc
reduct
hepat
c
viru
hcv
rna
level
dosedepend
genotyp
effect
test
dose
genotyp
seri
human
clinic
trial
provid
overview
preclin
evalu
human
ifnproduc
cho
cell
evalu
clinic
ifnwa
associ
biolog
relev
advers
effect
seri
safeti
pharmacolog
experi
ame
mutagen
test
micronucleu
test
intraarteri
intraven
paraven
subcutan
local
toler
studi
conduct
rabbit
rat
acut
subacut
subchron
reproduct
toxic
studi
perform
cynomolgu
monkey
rat
unremark
toxic
profil
similar
human
except
acut
singledos
toxicolog
studi
toxic
studi
also
show
evid
format
antiifnantibodi
time
anim
antibodi
found
neutral
ifnantivir
activ
vitro
dosedepend
manner
averag
pharmacokinet
paramet
follow
singl
dose
ifnin
rabbit
rat
monkey
determin
antivir
activ
human
assess
seri
vitro
inhibit
cytopath
effect
assay
use
bovin
viral
diarrhea
viru
bvdv
yellow
fever
viru
west
nile
viru
ifnwa
potent
test
ifn
virus
drugdrug
combin
analysi
perform
use
ifnand
ribavirin
bvdv
commonlyemploy
surrog
model
hcv
replic
statist
signific
synergi
antivir
effect
two
drug
found
well
signific
antagon
cytotox
effect
ribavirin
ifn
clinic
trial
examin
effect
ifnbi
daili
subcutan
inject
ribavirin
initi
celgosivir
castanospermin
current
clinic
trial
treatment
chronic
hepat
c
infect
celgosivir
target
host
essenti
replic
flavivirida
includ
hepat
c
viru
hcv
bovin
viral
diarrhea
viru
bvdv
cytopath
protect
assay
mdbk
madindarbi
bovin
kidney
cell
infect
bvdv
use
determin
therapeut
effect
celgosivir
combin
ribavirin
synergist
level
antivir
effect
calcul
synergist
volum
deriv
confid
interv
celgosivir
combin
ribavirin
use
macsynergi
ii
softwar
model
ribavirin
demonstr
synerg
combin
averag
synergist
volum
celgosivir
combin
ribavirin
demonstr
synergist
antivir
effect
averag
volum
respect
synergist
interact
celgosivir
ribavirin
suggest
celgosivir
potenti
efficaci
ribavirin
hcv
infect
celgosivir
novel
antivir
agent
current
clinic
develop
treatment
chronic
hepat
c
viru
hcv
infect
celgosivir
castanospermin
activ
metabolit
castanospermin
potent
inhibitor
enzym
alter
process
viral
glycoprotein
oral
administ
celgosivir
welltoler
human
produc
mainli
side
effect
flatul
mild
moder
diarrhea
purpos
present
studi
determin
effect
antidiarrho
drug
loperamid
hydrochlorid
pharmacokinet
pk
oral
administ
celgosivir
effect
diarrhea
also
investig
male
cd
rat
oral
administ
loperamid
mgkg
follow
oral
dose
celgosivir
mgkg
dosag
loperamid
celgosivir
base
human
dose
adjust
total
bodi
surfac
area
anoth
group
rat
fast
overnight
administ
castor
oil
mlkg
induc
diarrhea
anim
immedi
given
access
food
follow
dose
celgosivir
one
hour
later
blood
sampl
collect
h
celgosivir
pk
investig
follow
plasma
concentr
primari
metabolit
castanospermin
use
lcm
oral
administr
mgkg
dose
celgosivir
normal
rat
yield
mean
c
max
max
auc
valu
gml
h
ghml
respect
compar
result
obtain
celgosivir
loperamidetr
anim
indic
antidiarrho
agent
signific
effect
pk
celgosivir
cmax
auc
valu
diarrhoeainduc
rat
reduc
respect
compar
normal
rat
differ
cmax
determin
statist
signific
conclus
concomit
administr
loperamid
effect
pk
celgosivir
normal
rat
could
consid
viabl
treatment
option
reduc
gastrointestin
effect
may
associ
celgosivir
treatment
sinc
inducedinduc
rat
show
reduct
castanospermin
cmax
auc
treatment
loperamid
might
prevent
lower
system
drug
exposur
patient
experienc
diarrhea
hepat
c
dengu
positivesens
rna
virus
hepat
c
viru
major
etiolog
agent
posttransfus
hepat
worldwid
estim
world
popul
infect
hcv
accord
world
health
organ
infect
hcv
regularli
result
chronic
hepat
lead
liver
cirrhosi
hepatocellular
carcinoma
liver
failur
dengu
current
import
viral
diseas
transmit
mosquito
afflict
human
worldwid
clinic
symptom
rang
mild
fever
sever
hemorrhag
diseas
date
specif
antivir
treatment
exist
vaccin
avail
either
infect
thu
urgent
need
new
therapi
aim
project
design
establish
enzymat
assay
use
screen
potenti
inhibitor
helicas
hcv
dengu
virus
well
helicaseproteas
complex
dengu
viru
helicas
interest
target
drug
design
firstli
vital
function
viral
cell
cycl
secondli
fact
human
cell
lack
helicas
capabl
unwind
posit
sens
doubl
strand
rna
gene
hcv
helicas
dengu
viru
helicas
dengu
viru
domain
helicas
proteas
incorpor
pet
system
express
vector
vector
carri
gene
transform
e
coli
cell
gene
express
strain
determin
helicas
produc
cell
without
need
induct
confirm
express
test
variabl
concentr
induc
mm
iptg
found
protein
present
express
system
howev
one
induc
mm
show
max
yield
induct
cell
suspens
harvest
sdspage
histag
western
blot
confirm
exist
variou
protein
protein
isol
base
tag
three
protein
protein
test
function
use
specif
enzymat
assay
background
influenza
mass
acut
infect
influenza
virus
also
caus
global
epidem
diseas
known
pandem
rate
morbid
mortal
influenzarel
complic
increas
dramat
elabor
method
mean
prevent
therapi
extrem
import
actual
task
adaptogen
vitamin
biogen
stimul
may
increas
resist
organ
infect
goal
research
studi
antivir
activ
biolog
activ
food
supplement
biotrit
c
experiment
influenza
infect
model
method
mice
experiment
control
group
infect
intranas
highli
pathogen
mice
influenza
viru
strain
experi
carri
use
six
mice
viru
dilut
within
rang
death
anim
monitor
record
day
day
model
infect
ld
calcul
kerber
method
modifi
ashmarin
result
biotrit
c
biolog
activ
food
supplement
made
pulver
green
sprout
wheat
also
contain
vitamin
c
elabor
produc
institut
stomatolog
collabor
odessa
biotechnolog
compani
biotrit
c
daili
dose
mg
per
mous
shown
protect
action
experiment
influenza
mice
anim
experiment
group
take
biotrit
c
week
infect
continu
take
end
experi
supplement
decreas
consider
death
rate
infect
anim
start
day
mice
got
experiment
infect
influenza
infect
differ
control
experiment
group
day
till
day
mice
got
infect
result
present
studi
show
evid
antiinfluenza
efficaci
biotrit
c
therefor
believ
inclus
biolog
activ
food
supplement
diet
healthi
peopl
epidem
period
patient
influenza
infect
advis
mous
model
extens
use
evalu
potenti
influenza
viru
inhibitor
viral
strain
employ
fairli
old
howev
repres
current
circul
virus
natur
develop
two
new
lethal
infect
model
mice
use
mouseadapt
influenza
anew
influenza
virus
viru
infect
use
studi
effect
oral
treatment
oseltamivir
ribavirin
use
alon
combin
oral
treatment
regimen
twice
day
day
start
h
infect
initi
studi
influenza
ribavirin
activ
mg
kg
day
protect
mice
death
reduc
lung
consolid
oseltamivir
similarli
effect
mg
kg
day
treatment
initi
viru
challeng
delay
treatment
oseltamivir
even
day
caus
ineffect
ribavirin
prevent
mortal
treatment
delay
day
infect
combin
two
drug
ribavirin
mg
kg
day
oseltamivir
mg
kg
day
better
ribavirin
alon
ribavirin
oseltamivir
show
similar
doserel
antivir
activ
influenza
b
viru
infect
mice
oseltamivir
ribavirin
increas
surviv
significantli
treatment
start
day
infect
ribavirin
activ
surviv
compar
surviv
start
treatment
day
infect
vari
dose
drug
use
combin
ribavirin
mg
kg
day
oseltamivir
mg
kg
day
certain
drug
dosag
combin
superior
either
compound
use
alon
assess
decreas
mortal
lung
viru
titer
lung
score
lung
weight
activ
two
drug
virus
differ
publish
result
older
virus
bhong
oseltamivir
less
effect
ribavirin
activ
report
previous
acknowledg
support
contract
virolog
branch
niaid
nih
present
studi
design
investig
aspect
effect
rimantadin
oxid
stress
alveolocyt
isol
influenza
viru
infect
mice
establish
supplement
mice
rimantadin
protect
alveolocyt
lipid
peroxid
induct
mice
experiment
infect
influenza
viru
two
product
lipid
peroxid
cell
suspens
determin
malondialdehyd
hplc
analysi
lipofuscinelik
product
spectrofluorimetr
analysi
level
natur
antioxid
vitamin
e
glutathion
detect
hplc
spectrofluorimetri
respect
result
show
influenza
viru
infect
accompani
signific
increas
endogen
lipid
peroxid
product
decreas
natur
antioxid
vitamin
e
gluthation
mous
alveolocyt
found
rimantadin
treatment
led
decreas
lipid
peroxid
product
well
increas
content
endogen
vitamin
e
glutathion
influenza
viru
infect
mice
order
elucid
mechan
effect
experi
carri
model
system
capabl
rimantadin
scaveng
superoxid
radic
scaveng
properti
studi
system
xanthinexanthin
oxidas
gener
superoxid
amount
superoxid
measur
spectrophotometr
nbttest
chemiluminesc
potenc
rimantadin
interact
hydroxyl
radic
studi
system
iron
iondepend
hydroxyl
radic
format
detect
luminoldepend
chemiluminesc
antioxid
properti
rimantadin
investig
measur
induc
lipid
peroxid
system
egg
liposom
suspens
result
obtain
show
rimantadin
exert
superoxid
hydroxyl
radic
scaveng
properti
antioxidantlik
effect
observ
vivo
result
direct
action
process
lipid
peroxid
andor
interact
antioxid
enzym
find
model
system
prove
antioxid
effect
drug
process
lipid
peroxid
appar
observ
antioxidantlik
effect
rimantadin
vivo
connect
directli
free
radic
process
infect
organ
research
investig
influenc
molecular
structur
macrocycl
pyridinophan
analog
antiinfluenza
activ
hierarch
technolog
qsar
model
base
simplex
represent
molecular
structur
sirm
essenc
technolog
qsar
problem
solv
sequenti
seri
improv
model
descript
molecular
structur
sirm
approach
molecul
repres
system
differ
simplex
descriptor
tetratom
fragment
level
detail
increas
consecut
grossformula
ensembl
conform
represent
molecular
structur
take
account
differ
atom
characterist
exampl
charg
lipophil
etc
principl
featur
offer
approach
antiinfluenza
activ
express
lgtid
reflect
suppress
viral
replic
experiment
sampl
control
train
set
possess
essenti
structur
varieti
differ
mcp
acycl
analogu
wellknown
antivir
agent
deiteforin
remantadin
ribavirin
ambenum
variou
class
organ
compound
repres
popular
qsar
approach
comfa
hasl
appli
set
main
reason
onevalu
optim
align
heterogen
structur
calcul
molecular
field
paramet
imposs
limit
exist
simplex
represent
molecular
structur
statist
characterist
qsar
partial
least
squar
model
satisfactori
r
cvr
molecular
fragment
increas
decreas
antivir
activ
defin
demonstr
inform
use
design
direct
synthesi
novel
antivir
agent
sever
compound
predict
high
antiinfluenza
antiherpet
activ
alreadi
synthes
activ
confirm
experiment
julia
serkedjieva
iskra
ivanova
influenza
viru
infect
trigger
reduct
proteas
activ
mice
lung
h
pi
mark
increas
h
day
pi
proteas
inhibit
lung
reduc
h
slight
rise
observ
h
day
pi
nasal
inocul
polyphenolrich
extract
obtain
geranium
sanguineum
l
pc
dose
mgkg
h
infect
brought
activ
normal
level
pctreatment
virusinfect
mice
led
signific
decreas
mortal
rate
protect
index
distinct
prolong
mst
day
lung
lesion
visibl
amelior
shown
macroscop
microscop
examin
lung
weight
score
indic
reduc
lung
viru
titr
also
decreas
tcid
ml
intact
mice
pc
caus
slight
reduct
proteas
antipoteas
activ
h
inocul
later
differ
control
mice
observ
vitro
pc
inhibit
activ
trypsin
pepsin
proteinas
k
catepsin
dosedepend
manner
activ
toward
subtilizin
chimotrypsin
antivir
drug
arbidol
monohydr
wide
use
prophylaxi
therapi
influenza
b
russia
studi
effect
arbidol
viral
replic
show
arbidol
inhibit
viral
reproduct
antigen
subtyp
human
influenza
b
virus
avian
influenza
virus
possess
rimantadineresist
strain
influenza
virus
arbidol
demonstr
broadspectrum
antivir
activ
respiratori
virus
inhibit
rsv
adenoviru
type
viral
replic
cell
cultur
arbidol
previous
shown
inhibit
earli
stage
influenza
viru
replic
studi
arbidol
effect
upon
replic
panel
reassort
weybridg
strain
show
greater
sensit
weybridg
viru
arbidol
determin
ha
gene
correl
sensit
arbidol
gene
arbidolresist
mutant
obtain
pass
virus
mdck
cell
presenc
increas
drug
concentr
mutant
select
resist
arbidol
promot
membran
fusion
higher
ph
wildtyp
viru
arbidol
inhibit
haemolysi
induc
wildtyp
viru
inhibit
haemolysi
induc
arbidolresist
mutant
determin
molecular
basic
arbidolresist
ha
gene
wildtyp
arbidolresist
mutant
sequenc
mutant
amino
acid
substitut
subunit
differ
posit
studi
effect
arbidol
conform
ha
use
conform
antibodi
show
arbidol
caus
conform
chang
structur
ha
wildtyp
viru
arbidolresist
mutant
data
indic
target
arbidol
ha
arbidol
increas
stabil
low
phinduc
chang
consequ
inhibit
membran
fusion
viru
infect
barrogen
protein
endem
gut
protozoan
eimeria
spp
potent
stimul
releas
dendrit
cell
upregul
demonstr
antitumor
properti
mice
man
materi
studi
efficaci
influenza
viru
infect
mice
util
vari
treatment
schedul
intraperiton
ip
intranas
treatment
rout
barrogen
administ
ip
h
postand
day
postviru
exposur
util
dosag
g
per
inject
consid
highli
effect
seen
prevent
death
lessen
arteri
oxygen
satur
sao
declin
inhibit
lung
viru
titer
latter
occur
rel
late
day
viru
exposur
treatment
administ
combin
ip
less
efficaci
use
ip
treatment
similar
therapi
influenza
viru
infect
mice
indic
barrogen
also
inhibit
infect
although
lesser
extent
probabl
overwhelm
viral
challeng
toxic
seen
toxic
control
mice
use
dosag
high
g
per
inject
studi
other
cancer
trial
mice
vitro
indic
combin
treatment
barrogen
granul
macrophagecoloni
stimul
factor
gmcsf
result
cure
studi
prompt
similar
studi
mice
infect
influenza
viru
gmcsf
use
ip
dosag
ng
per
inject
barrogen
dose
g
per
inject
combin
higher
gmcsf
dose
barrogen
result
increas
number
survivor
prolong
mean
day
death
compar
barrogen
use
alon
gmcsf
use
alon
consid
inhibitori
viru
infect
data
suggest
immunostimul
barrogen
potenti
treatment
influenza
viru
infect
acknowledg
support
part
barro
research
institut
contract
virolog
branch
niaid
nih
qing
ge
david
stein
andrew
kroeker
herman
eisen
patrick
iversen
jianzhu
chen
influenza
remain
major
worldwid
human
health
problem
current
therapeut
consider
sideeffect
gener
drugresist
viru
phophorodiamid
morpholino
oligom
pmo
nucleas
resist
antisens
compound
act
steric
block
target
rna
sequenc
sever
pmo
design
hybrid
variou
region
influenza
rna
evalu
abil
inhibit
influenza
viru
product
vero
cell
cultur
pmo
conjug
short
argininerich
peptid
order
facilit
cell
uptak
vero
cell
incub
pmo
compound
inocul
influenza
viru
viral
titer
determin
hemagglutinin
assay
andor
plaqueassay
day
later
survey
eight
antisens
sequenc
reveal
compound
target
aug
translat
start
site
np
segment
mrna
terminu
respect
vrna
highli
effect
reduc
titer
influenza
viru
order
magnitud
dosedepend
sequencespecif
manner
period
day
combin
pmo
exhibit
synergist
antivir
effect
effect
antiinfluenza
compound
alter
titer
nonhomolog
influenza
b
viru
grown
vero
cell
data
indic
evalu
sever
pmo
test
studi
potenti
influenza
therapeut
warrant
background
aethonium
decametoxin
bisquarternari
ammoniumbas
approv
ukrain
effect
antisept
cation
surfact
action
demonstr
broad
antibacteri
antimycot
activ
spectrum
aim
research
studi
antivir
activ
aethonium
decametoxin
method
vitro
antivir
activ
aethonium
decametoxin
studi
model
influenza
viru
strain
ahong
ndv
strain
la
sota
replic
tissu
cultur
day
chicken
embryo
choryoallanto
membran
cam
antiinfluenza
efficaci
intranas
appli
prepar
test
mice
infect
viru
action
aethonium
decametoxin
dna
replic
virus
research
basi
studi
prepar
influenc
polymeras
chain
reaction
pcr
activ
express
via
minim
concentr
mm
prepar
inhibit
polymeras
chain
reaction
complet
result
determin
aethonium
dose
mkgml
decametoxin
dose
mkgml
inhibit
reproduct
influenza
b
virus
ndv
prepar
dose
shown
virucid
action
decreas
cam
cell
abil
support
virus
replic
prophylact
therapeut
applic
prepar
consider
decreas
mortal
anim
infect
influenza
viru
aethonium
complet
inhibit
dna
replic
hsv
cmv
papilloma
virus
dose
mm
decametoxin
complet
inhibit
polymeras
chain
reaction
infecti
agent
dose
hsv
mm
cmv
mm
papilloma
virus
mm
result
present
studi
show
evid
antivir
efficaci
bisquarternari
ammoniumbas
aethonium
decametoxin
usag
treatment
viral
infect
prevent
bacteri
complic
thank
wellknown
antisept
action
depart
zoolog
tel
aviv
univers
tel
aviv
israel
influenza
one
preval
signific
viral
infect
despit
avail
formalininactiv
trival
vaccin
influenza
still
associ
signific
morbid
mortal
worldwid
recent
estim
put
cost
influenza
epidem
economi
unit
state
alon
billion
dollar
per
year
fact
sheet
march
aim
research
investig
cinnamon
extract
ce
fraction
novel
sourc
antivir
inhibitor
explor
commerci
potenti
abil
ce
neutral
influenza
viru
test
vitro
human
erythrocyt
vivo
mice
dose
gml
crude
extract
suffici
achiev
total
neutral
hau
viru
within
one
minut
ce
long
shelflif
least
year
refriger
room
temperatur
still
retain
antivir
activ
dialysi
bag
cutoff
kd
heat
variou
temperatur
c
antivir
activ
also
stabl
wide
rang
ph
even
heat
c
extrem
ph
partial
impair
antivir
activ
ce
also
prove
abil
inhibit
viru
vivo
ce
mix
viru
prior
infect
mice
administr
h
viral
infect
mice
develop
diseas
lose
weight
die
conclus
ce
exhibit
effect
antivir
activ
influenza
viru
vitro
vivo
cinnamon
use
human
diet
thousand
year
therefor
obstacl
introduc
isol
antivir
fraction
human
anim
use
influenza
infect
possess
special
place
among
viral
infect
widespread
infecti
deceas
influenza
epidem
hurt
human
health
great
degre
one
import
purpos
pharmaceut
scienc
develop
prophylaxi
treatment
one
effect
antiinfluenza
drug
rimantadin
oral
administr
often
lead
side
effect
nausea
dizzi
abdomin
pain
etc
reduc
effect
approach
use
transderm
drug
deliveri
method
administr
provid
mani
advantag
prolong
drug
action
maintain
concentr
therapeut
rang
reduc
firstpass
liver
metabol
aim
work
compar
evalu
antiinfluenza
rimantadin
efficaci
oral
transderm
administr
rimantadin
administ
either
oral
prophylaxi
day
infect
viru
administr
dose
mgmous
transderm
applic
matrix
sm
contain
mgsm
shave
back
mice
h
infect
permeabl
enhanc
experiment
infect
mice
carri
intranas
administr
highli
pathogen
influenza
viru
strain
dilut
rang
anim
mortal
record
day
infect
ld
estim
shown
transderm
rimantadin
administr
effect
prophylaxi
therapi
ld
differ
compar
oral
administr
also
found
transderm
rimantadin
effect
dose
mgsm
though
dose
higher
mgsm
caus
higher
protect
action
creat
model
sever
acut
respiratori
syndrom
sar
macaca
rhesu
coronaviru
cov
detect
differ
sampl
come
six
macaca
rhesus
differ
day
viru
isol
immunofluresc
assay
patholog
inspect
revers
transcript
polymeras
chain
reaction
rtpcr
result
show
sar
cov
isol
sampl
furthermor
sar
cov
rna
could
detect
blood
second
fifth
day
secreta
nosethroat
seventh
ninth
day
fece
third
day
fece
urin
fifth
day
infect
tabl
microscop
found
group
infect
sar
cov
pulmonari
alveolu
interv
broaden
mani
lymphocyt
monocyt
infiltr
fig
much
exud
chamber
pulmonari
alveolu
even
form
hyalin
membran
final
organ
pneumonia
could
found
sever
pulmonari
alveolu
also
observ
great
necrosi
foci
liver
compani
inflammatori
cell
infiltr
may
success
creat
model
sar
macaca
rhesu
show
anim
model
use
evalu
antisar
cov
drug
vaccin
dale
l
barnard
sever
acut
respiratori
syndrom
sar
respiratori
ill
caus
sarscov
lifethreaten
highli
contagi
febril
respiratori
ill
initi
describ
earli
treatment
diseas
support
approv
univers
recommend
therapi
sar
therefor
compound
found
activ
vitro
sever
immunomodul
evalu
efficaci
murin
sarscov
replic
model
partial
anesthet
balbc
mice
g
inocul
intranas
ccid
viru
normal
h
prior
viru
exposur
mice
pretreat
intraperiton
ip
compound
use
one
concentr
drug
infect
mice
treat
ip
compound
per
day
bid
total
day
mice
sacrif
either
day
day
maximum
lung
titer
untreat
mice
day
day
complet
viral
clearanc
lung
untreat
mice
net
bodi
weight
gainsloss
calcul
lung
weigh
score
lung
consolid
andor
surfac
inflamm
lung
viru
titer
done
cytopath
effect
cpe
assay
experi
cytokin
array
done
serum
lung
sampl
follow
compound
reduc
viral
titer
log
log
calpain
inhibitor
vi
ip
mg
kg
day
per
day
nelfinavir
ip
mg
kg
day
bid
contrast
ribavirin
mg
kg
day
bid
ip
promot
viru
infect
viru
log
still
present
day
howev
ribavirin
mg
kg
day
bid
ip
enhanc
viru
titer
day
although
viru
clear
day
placebotr
anim
mycophenol
acid
eicar
also
seem
increas
viru
titer
day
data
suggest
compound
modestli
inhibit
viral
replic
lung
balbc
mice
contrast
ribavirin
appear
prolong
viral
infect
balbc
mice
compound
seem
increas
viru
titer
support
contract
virolog
branch
niaid
nih
shiro
shigeta
shuichi
mori
tatsuo
suzutani
norio
yamamoto
naoki
yamamoto
toshihiro
yamas
fukushima
medic
univers
fukushima
japan
tokyo
medic
dental
univers
tokyo
japan
tokyo
institut
technolog
sever
acut
respiratori
distress
syndrom
sar
emerg
late
guandong
china
spread
world
wide
juli
almost
patient
thought
correspond
probabl
case
cost
live
person
although
success
antivir
chemotherapi
sar
establish
sever
antisar
cov
agent
report
vitro
examin
abat
sar
outbreak
world
research
sar
cov
replic
mechan
viru
bind
cell
fusion
viru
infect
uninfect
cell
membran
process
essenti
viral
protein
etc
disclos
polyoxometal
pom
neg
charg
inorgan
compound
core
transit
metal
w
v
ti
mo
surround
oxygen
atom
v
ti
substitut
polyoxotungst
shown
broadspectrum
antirna
viru
activ
vitro
rna
virus
includ
sever
human
respiratori
diseas
virus
influenza
b
rsv
parainfluenza
etc
examin
compound
antivir
activ
sever
coronavirus
cov
caus
porcin
bovin
felin
diseas
sar
compound
show
common
anticov
activ
cov
examin
inhibit
viru
replic
occur
earli
stage
viru
infect
thought
inhibit
adsorpt
fusion
viru
particl
cell
pom
promis
compound
develop
broad
spectrum
antirespiratori
infecti
diseas
drug
genera
rhinoand
enterovirus
famili
picornavirus
consist
larg
number
serotyp
wherea
rhinovirus
estim
caus
approxim
onethird
upper
respiratori
tract
viral
infect
enterovirus
may
caus
sever
acut
chronic
diseas
like
asept
mening
enceph
handfootmouth
diseas
myocard
well
specif
antivir
treatment
infect
avail
promis
compound
discov
inhibitor
viral
adsorpt
andor
penetr
studi
synthes
seri
biaryl
deriv
pleconaril
order
evalu
structur
featur
requir
antirhinoviru
antienteroviru
activ
deriv
test
cytotox
activ
pleconarilresist
coxsackieviru
nanci
pleconarilsensit
rhinoviru
cytopath
effect
cpe
inhibitori
assay
hela
cell
pleconaril
includ
control
compound
biaryl
analogu
demonstr
moder
antivir
effect
nanci
seri
compound
inhibit
replic
good
even
better
pleconaril
result
studi
structureact
relationship
reveal
compound
contain
small
substitu
like
f
ch
ch
benzen
ring
show
activ
antivir
activ
reduc
lost
substitut
well
butadien
activ
compound
small
electron
acceptor
group
atom
paraposit
phenyl
ring
deriv
substitu
metaposit
two
substitu
paraand
metaposit
compar
less
activ
contrast
novel
synthesis
analogu
fulli
inact
univers
georgia
depart
pharmaceut
biomed
scienc
athen
ga
usa
interest
discoveri
molecul
antivir
activ
rna
virus
led
us
design
ribonucleosid
surrog
base
intent
use
inhibit
inosin
monophosph
dehydrogenas
impdh
probe
antivir
drug
discoveri
impdh
catalyz
convers
imp
xmp
util
coenzym
nad
hydrid
acceptor
impdh
key
ratedetermin
enzym
de
novo
guanin
nucleotid
biosynthesi
consid
signific
target
enzym
discoveri
therapeut
agent
includ
antivir
agent
molecular
design
inhibitor
impdh
base
mechan
substrat
action
impdh
involv
coval
interact
sulfhydryl
group
posit
imp
thu
modif
posit
purin
nucleosid
involv
michael
acceptor
import
consider
design
impdh
inhibitor
synthet
work
requir
chemoenzymat
approach
specif
function
posit
purin
nucleosid
final
deprotect
step
util
adenosin
deaminas
serv
excel
reagent
clean
remov
mask
group
detail
synthesi
present
impdh
inhibit
studi
carri
spectrophotometr
monitor
format
nadh
antivir
data
obtain
collabor
studi
present
correl
antivir
activ
impdh
inhibit
discuss
lidiya
n
nosach
nataliya
dyachenko
valentina
l
zhavnovataya
olga
yu
povnitsa
ludmila
shipulina
institut
microbiolog
virolog
nation
academi
scienc
ukrain
kyiv
ukrain
npo
vilar
moskow
russia
activ
helepin
alpizarin
hyporamin
adenovirus
ad
type
studi
cell
cultur
hyporamin
show
antiadenoviru
activ
case
presenc
compound
adsorbt
ad
cell
hyporamin
concentr
gml
decreas
number
infect
cell
intra
nuclear
inclus
control
infect
cell
hyporamin
gml
select
index
si
case
infect
cell
gml
hyporamin
antivir
effect
absent
cell
treat
adsorpt
viru
antiviru
effect
hyporamin
connect
virucid
compound
reduc
viru
titer
incub
h
hyporamin
caus
chang
morpholog
ad
treat
particl
interact
antibodi
hexonemajor
protein
capsid
studi
ad
adsorbt
label
presenc
hyporamin
shown
effect
viru
attach
antivir
effect
hyporamin
probabl
take
place
stage
penetr
ad
cell
stage
uncoat
impot
peculiar
antiadenoviru
action
hyporamin
block
adenoviru
reproduct
first
stage
interact
viru
cell
synthesi
viru
macromolecul
public
health
signific
hemorrhag
fever
enceph
caus
flavivirus
enorm
global
year
million
peopl
infect
dv
alon
part
program
discov
develop
new
compound
treatment
flavivirus
bioterror
concern
evalu
use
imino
sugar
west
nile
viru
wnv
wnv
replicon
live
viru
infect
system
util
initi
screen
anoth
member
flavivirida
bovin
viral
diarrhea
viru
bvdv
analysi
appropri
wnv
model
sinc
imino
sugar
affect
common
host
pathway
use
system
identifi
sever
inhibitor
wnv
distinct
mechan
action
wnv
activ
compound
mechan
action
compound
discuss
addit
start
highthroughput
effort
discov
novel
small
molecul
compound
inhibit
west
nile
viru
rna
replic
cell
base
replicon
assay
preliminari
hit
demonstr
great
potenti
approach
ravi
k
ujjinamatada
yankanagouda
agasimundin
peter
borowski
ramachandra
hosman
depart
chemistri
biochemistri
univers
maryland
umbc
baltimor
md
usa
abteilung
fur
virologi
bernhardnochtinstitut
fur
tropenmedizin
hamburg
germani
attempt
synthesi
ringexpand
guanosin
contain
imidazo
diazepin
ring
system
condens
deoxyderythropentofuranosyl
guanidin
result
format
unexpect
product
deoxyderythropentofuranosyl
structur
well
pathway
format
corrobor
isol
intermedi
follow
convers
product
nucleosid
show
promis
vitro
antihelicas
activ
west
nile
viru
ic
gml
ravi
k
ujjinamatada
ramachandra
hosman
depart
chemistri
biochemistri
univers
maryland
umbc
baltimor
md
usa
corollari
effort
synthesi
analogu
novel
imidazol
nucleosid
recent
exhibit
excel
vitro
activ
west
nile
viru
effici
gener
method
develop
select
convers
ester
group
correspond
carboxamid
carboxyl
acid
vinylog
esteraldehyd
attach
aromat
heterocycl
ring
method
use
excess
guanidin
mediat
observ
convers
also
protect
aldehyd
function
diaminodihydrostriazin
moieti
tent
mechan
convers
present
carboxaldehyd
group
regener
hydrolysi
triazin
moieti
provid
either
vinylog
amidealdehyd
acidaldehyd
final
product
dimitrio
p
vlachaki
steven
p
oldfield
andrea
brancal
medicin
chemistri
welsh
school
pharmaci
cardiff
univers
wale
uk
hepat
c
dengu
positivesens
rna
virus
hcv
major
etiolog
agent
posttransfus
hepat
worldwid
accord
world
health
organ
world
popul
suffer
hcv
infec
fig
superimposit
hcv
dengu
polymeras
conserv
residu
activ
site
either
protein
spacefil
render
red
hcv
templst
polymeras
magenta
dengu
polymeras
model
green
oligonucleotid
ssrna
tion
hcv
infect
lead
chronic
hepat
may
caus
liver
cirrhosi
may
lead
hepatocellular
carcinoma
liver
failur
dengu
viru
caus
mild
fever
sever
haemorrhag
diseas
dengu
viru
current
consid
import
human
affect
mosquitotransmit
diseas
worldwid
effect
cure
mean
effici
vaccin
either
diseas
make
need
develop
new
drug
therapi
much
urgent
aim
project
design
structur
polymeras
protein
primarili
dengu
viru
consequ
west
nile
viru
japanes
enceph
viru
yellow
fever
viru
hcv
polymeras
xray
use
templat
homolog
ident
approxim
low
homolog
ident
percentag
overcom
perform
ligandsupport
homolog
model
techniqu
conserv
residu
anchor
approach
implement
model
viabil
four
modelpolymeras
evalu
silico
score
function
fact
rna
bind
motif
atp
bind
motif
conserv
model
hcv
templat
superimposit
hcv
modelpolymeras
show
seven
residu
activ
site
involv
rnabind
motif
conserv
yield
overal
rmsd
fig
oluwafemi
olawuyi
adeyemi
falegan
tor
high
rate
spread
std
among
nigerian
youth
descript
self
develop
valid
reliabl
questionnair
r
use
collect
data
need
studi
percentag
use
analyz
data
popul
studi
made
resid
undergraduategradu
student
male
hostel
obafemi
awolowo
univers
ileif
osun
state
nigeria
sampl
size
select
simpl
random
sampl
techniqu
demograph
data
follow
respond
year
old
year
rel
risk
rr
calcul
ie
rr
indic
factor
risk
factor
confidenti
interv
ci
rr
signific
level
rr
ci
upper
limit
rr
ci
use
valid
instrument
lesson
learn
tabl
reveal
respons
std
knowledg
averag
knowledg
diseas
expect
higher
educ
student
tabl
show
nigeria
student
engag
one
riski
sexual
behaviour
conclus
clearli
seen
low
level
knowledg
engag
riski
sexual
behaviour
obviou
risk
factor
high
rate
std
among
nigerian
youth
also
develop
countri
activ
specif
proteas
essenti
mani
fundament
cellular
viral
process
viral
polyprotein
process
indispens
replic
matur
mani
virus
consequ
sitespecif
proteolysi
attract
target
develop
antivir
therapi
base
potent
select
viral
inhibitor
gener
therapi
base
inhibit
sitespecif
proteolysi
clearli
illustr
develop
effect
inhibitor
human
immunodefici
viru
type
hepat
c
viru
hcv
demonstr
bacteriophag
lambda
base
genet
screen
use
isol
character
sitespecif
proteas
previous
adapt
system
studi
hcv
proteas
genet
screen
system
base
bacteriophag
lambda
cicro
regulatori
circuit
encod
repressor
ci
specif
cleav
initi
lysogenictolyt
switch
inher
difficulti
safeti
requir
ex
vivo
propag
sever
acut
respiratori
syndrom
sar
coronaviru
cov
scov
prompt
us
explor
genet
system
simpl
altern
approach
character
scov
proteas
activ
specif
target
scov
proteas
savlqsgfrk
insert
lambda
phage
ci
repressor
target
specif
scov
repressor
evalu
coexpress
repressor
chemic
synthes
scov
proteas
gene
construct
upon
infect
escherichia
coli
cell
contain
two
plasmid
encod
ci
scov
proteas
construct
lambda
phage
replic
effici
cell
express
scov
proteas
therefor
simpl
highli
specif
assay
use
monitor
activ
proteas
differ
mechan
action
potenti
use
screen
specif
inhibitor
victor
e
kuzmin
anatoli
g
artemenko
evgen
n
drug
design
develop
new
antivir
agent
perman
actual
task
use
modern
comput
technolog
could
allow
solv
problem
effect
hierarch
system
qsar
model
base
simplex
represent
molecular
structur
sirm
develop
essenc
system
qsar
problem
solv
sequenti
seri
improv
model
descript
molecular
structur
thu
subsequ
stage
hierarch
system
qsar
problem
solv
ab
ovo
inform
obtain
previou
step
use
actual
deal
system
solut
defin
exactli
sirm
approach
molecul
repres
system
differ
simplex
descriptor
tetratom
fragment
fix
composit
structur
chiral
symmetri
level
simplex
descriptor
detail
increas
consecut
represent
molecular
structur
take
account
differ
atom
characterist
exampl
charg
lipophil
etc
principl
featur
offer
approach
enabl
determin
easili
fragment
structur
promot
interf
given
biolog
activ
realiz
molecular
design
compound
given
level
activ
possibl
base
sirm
principl
featur
offer
strategi
hierarchi
model
also
hierarchi
purpos
taken
account
evid
one
model
solv
problem
relat
influenc
structur
set
studi
molecul
examin
properti
herebi
solv
everi
concret
task
necessari
develop
set
differ
qsar
model
suitabl
prognosi
studi
properti
interpret
obtain
relat
third
molecular
design
model
togeth
complex
work
problem
creation
new
perspect
compound
matter
given
set
properti
import
featur
approach
gener
result
obtain
differ
independ
model
alway
relev
thu
propos
strategi
allow
solv
problem
deal
virtual
screen
model
function
biolog
target
advanc
hypothes
mechan
action
last
design
new
compound
complex
use
properti
effici
method
demonstr
seri
macrocycl
pyridinophan
analog
wellknown
antivir
agent
group
devot
understand
fundament
mechan
viral
replic
emerg
new
virus
last
year
exampl
sar
highlight
urg
discov
new
bioactiv
molecul
viral
target
need
speed
discoveri
potenti
inhibitor
therapeut
agent
prompt
us
develop
mediumthroughput
screen
program
howev
techniqu
easili
appli
hazard
contagi
virus
problem
overcom
design
assay
direct
toward
isol
essenti
viral
enzym
polymeras
expertis
variou
field
rang
enzymolog
molecular
model
includ
molecular
structur
biolog
organ
chemistri
enabl
us
envis
level
overal
project
good
confid
differ
step
project
includ
target
enzym
design
reliabl
assay
target
enzym
miniatur
automat
plate
format
constitut
diversifi
chemic
compound
librari
storag
analysi
data
gather
identif
specif
hit
optim
obtain
lead
compound
potenti
activ
drug
problem
encount
propos
solut
includ
develop
new
comput
softwar
manag
data
present
togeth
interest
result
oleksandr
p
fedchuk
andriy
fedchuk
alla
fedchuk
pavlo
fedchuk
luminesc
microscopi
approv
use
wide
standard
mean
viruscel
interact
efficaci
monitor
necessari
take
million
frame
cover
regularli
size
substrat
seri
imag
instead
fractal
microscopi
propos
fulli
autom
imag
process
full
cover
substrat
plate
area
mm
parallel
imag
use
data
obtain
laboratori
trial
acyclovir
antiherpet
mean
herp
simplex
viru
hsv
strain
appli
substrat
without
preliminari
action
eaminocapro
acid
eaca
shown
best
antiherpet
result
achiev
combin
use
acyclovir
eaca
minim
cur
dose
acyclovir
minim
two
time
diffract
pattern
obtain
optic
fourier
transform
microscop
object
use
filter
stabil
diod
laser
fractogram
obtain
data
regular
photographi
digit
photographi
direct
input
imag
electron
version
time
hsv
multipl
establish
use
regular
luminesc
microscopi
equal
h
result
fractal
microscop
allow
us
monitor
influenc
eaca
presenc
valu
cell
toxic
limit
regist
fractogram
statist
reliabl
differ
valu
variou
stage
viruscel
interact
eclips
dna
duplic
viru
releas
fractal
approach
use
herebi
made
possibl
evalu
minim
size
fractal
cluster
structur
element
size
submicron
valu
structur
microscop
object
system
circl
differ
diamet
restor
use
invers
fourier
transform
diffract
pattern
follow
imag
process
comparison
made
present
studi
shown
fractal
microscop
power
laboratori
tool
drug
design
clinic
practic
much
better
possibl
regular
microscopi
present
work
support
part
stcu
grant
author
deepli
indebt
foundat
andriy
fedchuk
oleksandr
p
fedchuk
alla
fractal
microscop
propos
dynam
system
viruscel
interact
studi
base
diffract
bright
spot
diffract
pattern
dp
form
laser
ray
diffract
transpar
point
system
fractal
dimens
dp
equal
object
studi
chang
fractal
dimens
system
herp
simplex
viru
hsv
strain
interact
cell
cultur
antiherpet
mean
investig
acyclovir
taken
concentr
modifi
cell
rigid
use
eaminocapro
acid
eaca
effect
proteolysi
inhibitor
depict
cell
stabil
use
exchang
data
fractal
regular
luminesc
microscopi
indic
hsv
radiu
cell
nuclear
inclus
number
diminish
result
acyclovir
treatment
minim
element
size
minim
time
h
begin
infecti
start
time
correspond
stage
virion
engulf
releas
found
stabl
spheric
cell
structur
r
c
constant
k
c
stage
engulf
surfac
area
cell
diminish
v
v
surfac
virion
cell
volum
increas
volum
virion
v
v
r
v
take
account
mass
conserv
law
assum
surfac
tension
coeffici
constant
less
possibl
surfac
given
volum
correspond
stabl
structur
releas
stage
character
also
correspond
cell
surfac
volum
decreas
propos
mathemat
analysi
fractal
properti
cell
stabil
paramet
show
us
fractal
microscop
could
detect
real
time
chang
occur
cell
viruscel
interact
author
grate
partial
support
stcu
grant
hope
serv
fractal
microscop
wider
applic
problem
viruscel
interact
studi
mariepierr
egloff
bruno
coutard
campanacci
barbara
philipp
lieutaud
sacha
grisel
karen
dall
fabienn
tocqu
nicola
juli
violain
lantez
christian
cambillau
bruno
canard
architectur
et
fonction
de
biologiqu
umr
cnr
aixmarseil
ii
ch
joseph
aiguier
marseil
cedex
franc
drug
discoveri
increasingli
depend
avail
threedimension
structur
target
protein
inde
structur
enabl
model
perform
silico
drug
screen
well
sar
easier
improv
chemic
scaffold
structur
basi
rather
blind
approach
binari
complex
use
reveal
actual
interact
compound
interest
protein
final
screen
chemic
also
perform
within
protein
crystal
laboratori
coordin
vizier
compar
structur
genom
viral
enzym
involv
replic
european
project
whose
goal
lay
solid
foundat
ration
screen
drug
wide
rang
rnabas
virus
belong
three
genet
differ
class
name
doublestrand
singl
strand
rna
virus
posit
neg
polar
dsrna
ssrna
respect
class
virus
employ
wide
differ
replic
mechan
driven
poorli
character
replic
machineri
although
virusspecif
latter
conserv
essenti
viral
compon
thu
attract
target
antivir
therapi
vizier
project
perform
largescal
rna
viru
genom
sequenc
predict
potenti
enzymat
activ
subdomain
genom
sequenc
robotmedi
htp
process
select
target
xray
analysi
integr
accumul
knowledg
effort
screen
inhibitori
antivir
compound
vizier
aim
identif
lead
molecul
inhibit
replic
enzym
enter
broad
field
clinic
drug
develop
offer
cooper
made
pharmaceut
biotechnolog
industri
drug
develop
contractu
basi
although
preliminari
stage
progress
report
present
clinic
relev
emerg
pathogen
flaviviru
coronaviru
famili
past
decad
increas
number
research
group
focus
attent
mononucleotid
prodrug
studi
name
pronucleotid
entiti
design
give
rise
intracellular
deliveri
mononucleotid
later
metabol
correspond
triphosph
analogu
order
exert
antivir
activ
prove
new
seri
mononucleotid
analogu
act
effect
pronucleotid
decomposit
pathway
studi
cell
extract
thu
develop
valid
simpl
rapid
method
highperform
liquid
chromatographi
simultan
quantif
zidovudin
azt
monophosph
aztmp
without
pretreat
biolog
sampl
could
directli
inject
analyt
system
use
ionpair
agent
azt
aztmp
intern
standard
trap
clean
precolumn
protein
quickli
elut
thereaft
precolumn
connect
reversephas
analyt
column
analyt
separ
detect
use
uv
detect
nm
method
valid
rang
gml
azt
aztmp
extract
recoveri
analyt
cell
extract
higher
method
current
use
studi
decomposit
pathway
azt
prodrug
cell
extract
among
cytomegalovirus
cmv
small
anim
guinea
pig
cmv
gpcmv
interest
antivir
research
due
similar
diseas
pathogenesi
human
cytomegaloviru
hcmv
includ
transplacent
transmiss
unfortun
gpcmv
resist
commonli
use
hcmv
antivir
ganciclovir
gcv
render
vivo
studi
agent
problemat
anim
model
use
gpcmv
genom
clone
infecti
bacteri
artifici
chromosom
e
coli
use
induc
recombin
system
engin
seri
mutant
gpcmv
includ
viru
delet
gpcmv
homolog
virus
replac
nativ
gene
hcmv
town
strain
gene
studi
demonstr
delet
viru
retain
replic
compet
sever
attenu
vitro
replic
two
chimer
virus
replac
gene
hcmv
contrast
replic
effici
cell
cultur
evalu
gcv
suscept
profil
wildtyp
mutant
gpcmv
reveal
replac
hcmv
result
substanti
improv
suscept
chimer
viru
inhibitori
effect
gcv
plaqu
reduct
assay
reveal
ic
wildtyp
bacderiv
gpcmv
gcv
approxim
contrast
two
independ
deriv
chimer
gpcmv
express
hcmv
gcvsuscept
demonstr
ic
northern
blot
use
hcmv
probe
perform
probe
hybrid
rna
purifi
reconstitut
chimer
virus
wildtyp
bac
viru
studi
demonstr
use
employ
recombin
system
e
coli
gener
bacderiv
chimer
gpcmv
express
hcmv
gene
improv
gcv
suscept
profil
recombin
gpcmv
facilit
test
gcv
potenti
antivir
target
uniqu
use
small
anim
model
human
herp
virus
caus
varieti
clinic
signific
diseas
cold
sore
genit
herp
vzv
chicken
pox
shingl
hcmv
retin
pneumon
current
treatment
diseas
use
nucleosid
acyclovir
ganciclovir
cidofovir
phosphat
pfa
substrat
analogu
toxic
associ
pfa
ganciclovir
togeth
emerg
mutant
resist
acyclovir
need
new
class
antiherp
compound
novel
mechan
action
cours
search
novel
small
molecul
heterocycl
base
templat
antivir
screen
program
panel
virus
cell
cultur
initi
test
discov
entir
new
class
nonnucleosid
inhibitor
gener
formula
ii
show
mark
activ
hcmv
vzv
infect
inact
varieti
dna
rna
virus
structureact
relationship
investig
sar
initi
focus
substitu
sulton
moieti
studi
show
import
two
aromat
ring
activ
substitut
phenyl
ring
length
linker
signific
influenc
activ
compound
synthesi
biolog
evalu
preliminari
sar
studi
new
famili
compound
describ
cytomegaloviru
cmv
infect
still
contribut
significantli
increas
morbid
mortal
immunocompromis
individu
ganciclovir
gcv
success
reduc
cmv
viral
titr
howev
mutat
gene
point
mutat
viral
dna
polymeras
result
increas
emerg
resist
strain
reinvigor
search
altern
antivir
therapi
studi
investig
efficaci
novel
virostat
inhibit
enzym
ribonucleotid
reductas
rr
play
critic
role
de
novo
synthesi
deoxyribonucleotid
didox
dx
acid
trimidox
tx
secondgener
ribonucleotid
reductas
inhibitor
polyphenol
hydroxam
acid
amidox
side
chain
inhibit
rr
enzym
previous
shown
effect
compound
inhibit
maid
induc
perturb
mice
present
studi
plaqu
reduct
assay
use
determin
effect
antivir
drug
vari
concentr
ic
incub
period
result
obtain
show
dx
tx
inhibit
viral
plaqu
format
dose
depend
manner
b
signific
differ
plaqu
reduct
pre
posttreat
compar
post
infect
treatment
alon
c
antivir
activ
gcv
tx
dx
correspond
ic
respect
work
current
way
examin
antivir
effect
toxic
profil
drug
gcv
resist
strain
cmv
previous
describ
seri
methylenecyclopropan
purin
consist
firstgener
hydroxymethyl
compound
qiu
et
al
j
med
chem
secondgener
bishydroxymethyl
compound
zhou
et
al
j
med
chem
potent
select
activ
hcmv
town
strain
hcmv
select
separ
resist
firstgener
adenin
synadenol
guanin
synguanol
analog
approxim
resist
plaqu
yield
reduct
assay
sever
firstgener
purin
analog
similar
resist
observ
secondgener
guanin
analog
cyclopropavir
ic
plaqu
reduct
assay
respect
wildtyp
wt
synguanolresist
viru
likewis
hcmv
larg
delet
prichard
et
al
j
virol
resist
first
secondgener
compound
ic
wt
del
respect
synguanol
cyclopropavir
contrast
hcmv
delet
komazin
u
mich
phd
dissert
sensit
compound
hcmv
strain
select
resist
first
gener
compound
synadenol
sequenc
two
mutat
identifi
hcmv
either
relat
mutat
alon
sensit
synadenol
synguanol
baldanti
et
al
antivir
re
hypothes
two
mutat
requir
resist
firstand
secondgener
analog
hypothesi
test
construct
three
strain
hcmv
hcmv
bac
one
mutat
conclud
function
requir
activ
hcmv
like
two
mutat
requir
resist
methylenecyclopropan
purin
studi
support
grant
nih
fund
univers
michigan
tsugiya
murayama
nobuo
yamaguchi
yoshito
eizuru
divis
persist
oncogen
virus
ccvd
graduat
school
medic
dental
scienc
kagoshima
univers
kagoshima
japan
depart
serolog
kanazawa
medic
univers
uchinada
ishikawa
japan
human
cytomegaloviru
hcmv
ubiquit
herpesviru
infect
normal
adult
depend
geograph
locat
hcmv
infect
individu
earli
life
establish
thereaft
lifelong
latent
infect
howev
latent
infect
hcmv
frequent
activ
immunocompromis
individu
patient
aid
organ
bone
marrow
transplant
therebi
caus
sever
morbid
eventu
mortal
symptomat
hcmv
infect
success
treat
ganciclovir
gcv
appear
gcvresist
viru
current
problem
treatment
immunocompromis
patient
hcmv
infect
new
altern
efficaci
antihcmv
agent
need
develop
sever
kampo
japanes
herbal
medicin
km
wide
use
japan
china
effect
medic
disord
human
bodi
order
clarifi
interact
hcmv
km
examin
effect
km
hcmv
replic
human
embryon
fibroblast
hel
cell
method
monolay
hel
cell
infect
gcvresist
sensit
strain
hcmv
treat
km
produc
infecti
virion
dna
level
hcmv
measur
plaqu
assay
dot
blot
hybrid
respect
result
conclus
treatment
km
inhibit
cytopath
effect
hcmv
infect
cell
replic
concomit
decreas
dna
level
meanwhil
km
virocid
effect
cellfre
hcmv
also
found
antiifnb
antibodi
recov
kminduc
decreas
hcmv
replic
result
suggest
km
potenti
valu
sourc
new
power
compound
gcvresist
hcmv
pan
kee
bae
ju
ryung
nam
hae
soo
kim
myungjin
lee
kwon
chung
chongkyo
lee
intens
studi
thymidin
kinas
tk
perform
mani
aspect
viral
tk
express
cell
fusion
protein
fluoresc
protein
genetransfect
found
mainli
nucleu
viral
tk
virusinfect
cell
consid
locat
mainli
cytoplasm
perform
intracellular
local
vtk
virusinfect
cell
use
immunofluoresc
confoc
microscopi
cell
fix
import
factor
caus
differ
local
profil
regardless
viral
strain
cell
type
vtk
observ
mainli
nucleu
detect
nucleu
vero
cell
h
pi
end
viral
growth
onestep
growth
experi
apart
viru
amplif
imag
local
vtk
could
good
tool
confirm
cell
suscept
viru
check
homogen
cell
popul
intens
studi
herp
simplex
viru
type
thymidin
kinas
tk
perform
mani
aspect
intracellular
local
viral
tk
use
immunofluoresc
confoc
microscopi
power
tool
confirm
whether
viru
enter
host
cell
tk
polypeptid
detect
nucleu
vero
cell
h
pi
end
viral
growth
onestep
growth
experi
compar
efficaci
variou
antivir
agent
differ
mode
action
inhibitor
dna
synthesi
inhibitor
viru
bind
andor
fusion
onestep
condit
experi
dna
replic
inhibitor
acyclovir
ganciclovir
penciclovir
phosphonoform
acid
could
inhibit
express
tk
gene
entri
inhibitor
dextran
sulfat
pentosan
polysulf
aurintricarboxyl
acid
could
inhibit
method
might
use
confirm
whether
new
antiherpet
agent
inhibit
earli
phase
viru
replic
cycl
also
homogen
cell
popul
suscept
entri
inhibitor
dominiqu
devillebonn
laurenc
sarah
galloismontbrun
michel
veron
sylvi
pochet
human
umpcmp
kinas
structur
recent
known
xray
crystalographi
free
monomer
protein
segurapena
et
al
natur
bind
site
still
discuss
hsu
et
al
competit
experi
use
fluoresc
probe
mantatp
mabacdp
rudolph
et
al
studi
specif
sever
triphosph
donor
monophosph
acceptor
nucleosid
well
bisubstr
analog
exampl
cidofovir
cytidin
phosphon
present
antiherp
antivariola
properti
shown
bind
acceptor
site
well
cmp
dcmp
rel
affin
acceptor
compar
enzymat
reactiv
devillebonn
et
al
hou
wei
yang
z
qiu
li
j
jing
cheng
li
xiao
hong
yang
j
jiang
rheum
officinal
medicin
plant
grown
west
south
china
report
previous
rheum
palmatum
prepar
rhizom
chines
rhubarb
rheum
officinal
demonstr
good
activ
herpesviru
determin
extent
antiherp
simplex
viru
hsv
activ
present
number
plant
extract
emodin
extract
extract
rheum
officinal
quantiti
emodin
achiev
extract
verifi
emodin
monom
high
perform
liquid
chromatographi
hplc
antihsv
effect
investig
observ
cytopath
effect
cpe
adopt
mtt
colorimetr
assay
viabl
cell
rate
detect
hsvdna
polymeras
chain
reaction
pcr
test
viral
titer
found
emodin
antivir
abil
directli
kill
adsorpt
block
group
antibiolog
synthesi
median
inhibitori
concentr
ic
emodin
gml
respect
treatment
index
ti
rel
figur
regard
median
toxic
concentr
gml
enhanc
dose
degre
cpe
viral
titer
titer
hsvdna
cultur
media
decreas
correspondingli
wherea
viral
inhibit
rate
increas
result
show
emodin
may
inhibit
hsv
biolog
synthesi
directli
inactiv
virus
block
adsorpt
suscept
cell
vitro
anatoli
g
artemenko
victor
e
kuzmin
evgen
n
diseas
caus
herp
simplex
viru
hsv
wide
distribut
prophylaxi
treatment
infect
signific
problem
health
care
drug
design
develop
new
medicin
direct
hsv
perman
actual
task
system
effect
drug
choic
base
total
screen
noneffect
use
modern
comput
technolog
could
allow
solv
problem
effect
hierarch
technolog
qsar
model
base
simplex
represent
molecular
structur
sirm
use
seri
macrocycl
pyridinophan
analog
wellknown
antiherpet
agent
compound
abil
inhibit
herpet
reproduct
estim
reduct
percentag
infect
cell
treat
cell
cultur
comparison
statist
characterist
partial
least
squar
model
satisfactori
r
cvr
molecular
fragment
promot
interf
antivir
activ
defin
use
inform
structur
c
h
n
high
antiherpet
activ
design
synthes
us
test
vitro
thu
develop
hierarch
approach
effect
instrument
design
direct
synthesi
novel
effect
antiherpet
agent
elabor
effect
antiherpet
agent
computerassist
hierarch
system
perman
research
interest
basic
compound
antiherpet
follow
eaminocapro
acid
eaca
paraaminomethylbenzo
acid
ambenum
eaca
analogssodium
salt
acetylaminocapro
acid
aceminum
well
newli
synthes
compound
contain
eaca
sodium
termin
fragment
pyridin
bridg
amino
gexan
acid
compound
design
use
qsarmethod
studi
antiherpet
activ
herp
simpl
viru
strainu
strain
bh
titrat
presenc
prepar
present
cultiv
cultur
chicken
embryon
fibroblast
antiherpet
action
prepar
toward
studi
use
cytomorpholog
method
cell
cultur
rate
hsvlike
viral
reproduct
inhibit
evalu
decreas
percentag
cell
specif
viral
intranuclear
inclus
regist
eaca
taken
concentr
mkgml
ambenum
taken
concentr
mkgml
hinder
hsv
reproduct
statist
reliabl
cultur
chicken
fibroblast
ambenum
also
hinder
hsv
mdck
cell
cultur
effect
dose
exce
toxic
one
time
aceminum
taken
concentr
hinder
reproduct
chicken
fibroblast
cell
cultur
log
correspondingli
aceminum
taken
concentr
decreas
number
intranuclear
viru
specif
inclus
cell
cultur
prepar
taken
concentr
decreas
number
intranuclear
inclus
cell
cultur
concentr
eaca
effect
author
deepli
indebt
stcu
foundat
financi
support
present
research
grant
iryna
g
bartsykovska
alla
fedchuk
cosmet
dental
clinic
laboratori
odessa
ukrain
ii
mechnikov
ukrainian
research
antiplagu
institut
odessa
ukrain
acut
herpet
stomat
ah
regist
frequent
earli
childhood
begin
age
month
year
older
shown
everi
tenth
child
diseas
transform
chronic
form
recur
herpet
stomat
rh
studi
laboratori
clinic
efficaci
use
leukocyt
interferon
li
protein
low
molecular
mass
antivir
properti
myramistin
benzyldimethyl
ammoniumchloridemonohydr
cation
surfac
activ
compound
antisept
action
specif
herpet
antibodi
detect
healthi
children
regist
patient
saliva
use
method
fluoresc
antibodi
made
cytolog
analysi
materi
taken
patient
mouth
caviti
presenc
degen
epitheli
cell
simplast
multinuclear
cell
prepar
shown
experiment
first
group
ah
patient
contain
children
treat
li
unitsml
applic
subsequ
gargl
mouth
caviti
four
five
time
daili
second
group
children
person
treat
local
applic
myramistin
greas
hyperemi
surfac
accompani
wash
mouth
caviti
water
solut
myramistin
mkgml
well
applic
prepar
inner
surfac
patient
mouth
caviti
third
group
ah
patient
person
treat
combin
therapi
li
myramistin
effect
prove
combin
therapi
use
li
myramistin
patient
group
demonstr
repetit
erupt
test
taken
surfac
mouth
caviti
shown
activ
regener
epitheli
cell
full
form
structur
well
fagocyt
activ
averag
longitud
ah
patient
treatment
shorten
result
combin
li
myramistin
therapi
use
day
analysi
result
obtain
show
maxim
therapeut
effect
achiev
use
medicin
variou
mechan
antivir
action
svetlana
zagorodnya
nadezhda
v
nesterova
nataliya
dyachenko
galina
v
baranova
institut
microbiolog
virolog
nation
academi
scienc
ukrain
kyiv
ukrain
virus
affect
infect
cell
differ
way
along
deep
altern
metabol
process
redirect
synthesi
virion
compon
infect
lead
chang
function
state
regulatori
process
cell
purpos
activ
analysi
influenc
antitumor
drug
name
commerci
doxorubicin
ebew
austria
vepesid
etoposid
titolar
italiana
process
apoptosi
lymphoma
cell
infect
epsteinbarr
viru
studi
apoptosi
cell
ebvneg
lymphoma
cell
use
monoclon
antibodi
antigen
receiv
prof
sidorenko
apopt
cell
stain
hoechst
determin
fluoresc
microscopi
scheme
investig
cell
line
includ
follow
variant
studi
level
express
apoptosi
noninfect
cell
cultur
addit
apoptosisstimul
monoclon
antibodi
studi
level
apoptosi
express
cell
infect
ebv
studi
apoptosi
ebvinfect
cell
addit
mab
affect
drug
estim
calcul
surviv
index
id
use
mtt
method
shown
concentr
mgml
etoposid
well
doxorubicin
cell
line
caus
decreas
cell
prolifer
level
h
infect
cell
sensit
investig
drug
id
amount
mgml
drug
system
dg
ebv
addit
doxorubicin
concentr
mgml
result
apoptosi
cell
h
though
etoposideinduc
apoptosi
viruscel
system
took
place
cell
appear
apoptot
cell
took
place
within
mgml
dose
ad
drug
system
super
infect
cell
doxorubicin
reveal
apopt
cell
use
apoptot
test
set
consist
allow
determin
alreadi
h
cell
character
red
fluoresc
evid
start
apoptot
process
thu
investig
influenc
doxorubicin
etoposid
process
apoptosi
lymphoma
cell
infect
ebv
acknowledg
present
investig
partial
support
inta
grant
program
inta
grant
n
nadezhda
v
nesterova
nataliya
dyachenko
svetlana
zagorodnya
galina
v
baranova
inna
v
alexeeva
larisa
palchikovskaya
search
new
effect
prepar
capabl
inhibit
herpesvirus
reproduct
stipul
certain
resist
differ
group
chemic
prepar
biand
tricycl
nitrogencontainig
structur
non
nucleosid
proteas
inhibitor
wide
use
potenti
antivir
agent
use
retrovirus
herpesvirus
origin
cytidin
analogu
object
present
investig
studi
activ
epsteinbarr
viruslymphotrop
oncogen
viru
herpesvirida
famili
model
ebvinfect
vitro
use
line
lymphoblastoid
bcell
raji
infect
ebv
inhibit
reproduct
ebv
cell
cultur
determin
reduct
number
genomeequival
ebv
dna
cell
reveal
quantit
pcr
use
primer
reagent
r
russia
first
stage
investig
analysi
cytotox
cell
line
raji
studi
concentr
gml
concentr
inhibit
quantiti
aliv
cell
id
equal
substanc
gml
gml
minim
inhibit
concentr
mic
equal
gml
amount
genomeequival
dna
ebv
cell
reduc
mic
n
equal
gml
amount
genomeequival
reduc
henc
index
select
equal
accordingli
investig
influenc
apoptosi
raji
cell
infect
ebv
acknowledg
present
investig
partial
support
inta
grant
program
inta
grant
n
express
herpesviru
gene
lytic
cycl
fall
kinet
class
proceed
orderli
manner
order
defin
part
respons
variou
inhibitor
analys
mainli
perform
singl
gene
howev
precis
kinet
assign
number
gene
remain
unclear
present
comprehens
view
ebv
lytic
gene
express
affect
two
antivir
compound
quit
differ
mechan
action
akata
cell
latent
infect
epsteinbarr
viru
ebv
treat
antihuman
immunoglobulin
result
initi
lytic
viral
replic
cycl
acyclovir
acv
nucleosideanalog
ebv
dna
polymeras
inhibitor
maribavir
antivir
compound
inhibit
ebv
dna
polymeras
directli
use
studi
sidebysid
impact
drug
treatment
ebv
gene
express
identifi
viral
gene
requir
dna
replic
optim
express
ebv
gene
express
analyz
whole
genom
realtim
quantit
pcr
array
papin
j
vahrson
w
hinesboykin
r
dittmer
dp
method
mol
biol
analys
show
major
gene
fit
expect
profil
protein
involv
dna
replic
fall
earli
gene
group
inhibit
drug
structur
protein
fall
late
gene
group
inhibit
drug
treatment
howev
gene
show
discord
pattern
may
impli
addit
function
correspond
protein
result
independ
confirm
previou
observ
kinet
ebv
gene
express
provid
addit
insight
ebv
replic
strategi
action
drug
develop
effect
antivir
drug
requir
identif
specif
interact
activ
whose
disrupt
lethal
viru
rel
benign
host
sinc
virus
orthopoxvirus
oblig
intracellular
parasit
util
mani
host
cell
enzym
metabol
pathway
replic
task
prove
quit
difficult
fact
chiefli
respons
absenc
success
antivir
drug
use
smallpox
fortun
realiz
virus
use
proteolysi
catalyz
viralencod
proteinas
key
step
development
cycl
open
new
class
target
antivir
drug
develop
recent
work
identifi
poxviru
gene
encod
viral
core
protein
proteinas
vcpp
gene
highli
conserv
pathogen
poxvirus
predict
encod
cystein
proteinas
cleav
agx
site
produc
sever
major
core
compon
viral
particl
taken
advantag
attract
target
develop
effect
drug
block
orthopoxviru
replic
base
specif
mechanist
inhibit
vcpp
order
screen
compound
abil
inhibit
enzymat
activ
vitro
assay
develop
current
work
develop
biochem
assay
use
highthroughput
screen
result
develop
fluorescentquench
peptid
specif
assay
present
also
show
capabl
cleav
gene
product
orf
express
cellfre
transcript
translat
assay
mutat
inhibit
process
addit
specif
inhibitor
current
smallpox
vaccin
reactogen
human
standard
vaccin
percutan
scarif
plaqu
form
unit
pfu
live
vaccinia
viru
dryvax
result
lesion
take
day
resolv
treatment
would
hasten
resolut
lesion
without
affect
vaccin
efficaci
would
welcom
clinic
vaccin
presenc
antivir
would
limit
replic
viru
lead
smaller
rapidli
resolv
lesion
one
drawback
approach
would
reduct
strength
immun
respons
due
lower
mass
viral
antigen
test
hypothesi
use
cidofovir
cdv
alkoxyalkyl
cidofovir
analog
determin
antivir
treatment
affect
efficaci
vaccin
group
ancr
mice
vaccin
presenc
absenc
antivir
decreas
dose
dryvax
observ
similar
level
protect
presenc
absenc
cdv
dose
vaccin
well
reduct
lesion
size
resolut
time
next
evalu
whether
cdv
effect
protect
suboptim
amount
vaccin
employ
group
mice
vaccin
presenc
absenc
cdv
pfu
dryvax
dryvax
vaccin
dose
limit
would
expect
see
greater
effect
cdv
vaccin
efficaci
cdv
would
restrict
viral
replic
gener
threshold
antigen
mass
need
trigger
protect
immun
respons
suboptim
vaccin
test
increas
dose
aerosol
ectromelia
viru
statist
signific
differ
mortal
mean
time
death
mice
vaccin
presenc
absenc
cdv
extend
studi
examin
key
compon
primari
memori
immun
respons
follow
vaccin
presenc
absenc
antivir
taken
togeth
experi
support
hypothesi
presenc
cdv
vaccin
reduc
size
primari
lesion
without
affect
vaccin
efficaci
stephan
angeloff
institut
microbiolog
bulgarian
academi
scienc
sofia
bulgaria
intens
search
chemotherapeut
agent
activ
orthopoxvirus
actual
cours
view
potenti
menac
terror
attack
smallpox
viru
develop
effect
combin
antivir
consid
prospect
approach
respect
studi
combin
effect
cidofovir
idoxuridin
vaccinia
viru
vv
replic
cell
cultur
chick
embryo
fibroblast
cef
cidofovir
cdv
acycl
nucleosid
phosphon
manifest
therapeut
potenti
treatment
larg
scope
infect
caus
dna
virus
poxviru
includ
idoxuridin
iudr
pioneer
antivir
substanc
use
treatment
lethal
ortopoxviru
infect
system
administr
till
time
smallpox
erad
two
vv
strain
use
collect
institut
virolog
bratislava
institut
microbiolog
ba
sofia
experiment
design
combin
antivir
effect
cytotox
test
follow
prichard
shipman
threedimension
model
firstli
individu
ic
valu
compound
cpe
inhibit
test
monolay
cef
cultur
plate
determin
found
antivir
effect
strongli
depend
viral
inoculum
size
mark
suscept
cdv
iudr
two
vv
strain
establish
cytotox
compound
cef
cell
assay
monolay
maxim
toler
concentr
mtc
grow
cell
cultur
cell
growth
inhibitori
concentr
cgic
select
index
valu
individu
antivir
effect
cdv
iudr
versu
vv
found
close
evalu
mtcic
markedli
higher
cdv
cgic
ic
combin
effect
cdv
iudr
vv
replic
cef
cultur
character
markedli
synergist
one
previous
report
phosphonylmethoxi
propyl
adenin
hpmpa
activ
vitro
cowpox
viru
cv
vaccinia
viru
vv
oral
activ
howev
ether
lipid
ester
hpmpa
hexadecyloxypropyl
hpmpa
hdp
hpmpa
octadecyloxyethyl
hpmpa
ode
hpmpa
significantli
enhanc
activ
vitro
oral
bioavail
mice
studi
hdp
hpmpa
ode
hpmpa
prepar
water
administ
daili
oral
gavag
mice
use
mgkg
day
begin
h
inocul
cv
vv
hdp
hpmpa
ode
hpmpa
highli
effect
p
prevent
mortal
due
cv
mgkg
even
treatment
delay
h
post
infect
also
ode
hpmpa
hdp
hpmpa
highli
effect
p
prevent
mortal
mice
infect
vv
mgkg
treatment
delay
h
respect
ode
hpmpa
hdp
hpmpa
given
mgkg
begin
h
inocul
cv
replic
target
organ
liver
spleen
kidney
reduc
detect
level
howev
viru
titer
lung
significantli
alter
similar
studi
use
vv
hdp
hpmpa
also
reduc
viral
replic
liver
spleen
kidney
detect
level
oral
treatment
ode
hpmpa
reduc
replic
liver
spleen
kidney
also
lung
day
data
indic
hdp
hpmpa
ode
hpmpa
given
oral
activ
cv
vv
infect
mice
effect
cidofovir
result
suggest
compound
pursu
determin
potenti
treatment
human
orthopoxviru
infect
background
cidofovir
vitro
vivo
activ
poxvirus
use
drug
effect
prevent
treatment
peopl
expos
variola
major
viru
monkeypox
viru
correct
dose
schedul
administr
must
known
end
cidofovir
evalu
hollow
fiber
pharmacodynam
model
vaccinia
viru
infect
ascertain
doserespons
effect
pharmacodynam
variabl
close
link
inhibit
vaccinia
viru
replic
method
ec
valu
cidofovir
vaccinia
viru
grown
cell
determin
grow
viru
presenc
variou
concentr
drug
flask
dose
respons
effect
cidofovir
viru
replic
hollow
fiber
system
determin
grow
vaccinia
viru
cell
presenc
continu
infus
ec
concentr
cidofovir
determin
pharmacodynamicallylink
variabl
hollow
fiber
unit
contain
vaccinia
viru
infect
cell
either
continu
infus
drug
given
bolu
drug
equival
h
auc
follow
washout
simul
concentr
time
profil
cidofovir
report
man
case
efficaci
determin
fac
analysi
virusinfect
cell
treat
mab
specif
vaccinia
viru
drug
concentr
confirm
lcm
analysi
result
ec
valu
cidofovir
vaccinia
viru
grown
cell
hollow
fiber
model
continu
infus
cidofovir
reduc
number
virusinfect
cell
respect
dose
fraction
experi
cidofovir
given
either
continu
infus
bolu
follow
washout
effect
viru
replic
contrast
continu
infus
bolu
equival
auc
drug
follow
washout
inhibit
viru
replic
greater
conclus
data
suggest
auc
ec
ratio
pharmacodynam
link
variabl
best
correl
antivir
activ
cidofovir
vaccinia
virusinfect
cell
hollow
fiber
model
mark
n
prichard
angela
william
emma
harden
kathi
keith
earl
r
kern
univers
alabama
school
medicin
depart
pediatr
birmingham
al
usa
orthopoxvirus
herpesvirus
larg
dna
virus
dna
polymeras
contain
rather
conserv
activ
site
yet
viru
famili
exhibit
differ
suscept
nucleosid
analog
specul
observ
differ
due
larg
capac
virus
phosphoryl
compound
rather
substrat
specif
dna
polymeras
activ
select
antivir
drug
test
thymidin
kinas
posit
tk
tk
neg
strain
cowpox
viru
cv
herp
simplex
viru
type
use
cidofovir
serv
control
sinc
requir
phosphoryl
level
monophosph
degre
kinas
confer
activ
drug
determin
calcul
ratio
valu
tk
virus
compound
test
markedli
less
effect
strain
suggest
viral
kinas
requir
activ
drug
observ
drug
test
cv
halogen
uridin
deriv
shown
less
effect
strain
viru
rel
differ
ec
valu
compound
small
compar
differ
observ
infer
data
tk
encod
cv
narrow
substrat
specif
compar
tk
compound
substrat
enzym
phosphoryl
limit
extent
data
suggest
limit
activ
herpesviru
drug
orthopoxvirus
result
ineffici
activ
kinas
encod
famili
virus
addit
screen
nucleosid
analog
orthopoxvirus
requir
identifi
analog
effici
activ
viral
kinas
identifi
compound
high
degre
select
group
virus
g
andrei
p
fiten
e
de
clercq
g
opdenakk
r
snoeck
rega
institut
medic
research
ku
leuven
leuven
belgium
recent
describ
phenotyp
genotyp
character
sever
plaquepurifi
vv
lederl
strain
clone
isol
follow
select
cdv
differ
amino
acid
substitut
posit
observ
viral
dna
polymeras
sever
plaquepurifi
cdvr
clone
chang
posit
associ
gene
polymorph
suggest
comparison
dna
polymeras
sequenc
sever
orthopoxvirus
mutat
consid
associ
resist
cdv
hpmp
deriv
sinc
conserv
residu
among
orthopoxvirus
partial
total
homolog
correspond
amino
acid
herpesvirus
dna
polymeras
found
clone
isol
cycliccdv
ccdv
pressur
present
mutat
suggest
mutat
alon
confer
resist
hpmp
deriv
interestingli
dna
polymeras
sever
clone
isol
follow
plaqu
purif
lederl
strain
reveal
vaccin
strain
heterogen
popul
clone
name
lederl
amino
acid
delet
viral
dna
polymeras
sequenc
asndeletiongli
posit
correspond
sequenc
clone
name
nonlederl
alaasnv
type
clone
prove
equal
sensit
drug
test
cdvr
clone
select
nonlederl
popul
ccdvr
clone
origin
lederl
popul
evalu
pathogen
differ
clone
mice
g
inocul
intranas
differ
viral
dose
bodi
weight
record
daili
signific
differ
percentag
increas
bodi
weight
notic
strain
test
thu
day
postinocul
percentag
increas
bodi
weight
lederl
vaccin
strain
nonlederl
clone
lederl
clone
cdvr
nonclon
compar
uninfect
control
mice
anim
inocul
pfu
result
indic
cdvr
nonclon
much
less
pathogen
origin
vaccin
strain
vera
v
morozova
viktoria
v
voronina
maia
v
shveigert
eugeni
f
belanov
alexand
ilyichev
nina
v
tikunova
state
research
center
virolog
biotechnolog
vector
koltsovo
novosibirsk
russia
genu
orthopoxviru
includ
sever
speci
wellknown
pathogen
eg
variola
vaccinia
cowpox
monkeypox
virus
vaccinia
viru
vacv
use
past
effect
vaccin
smallpox
although
vacv
gener
safe
vaccin
dissemin
lifethreaten
infect
occur
infrequ
especi
individu
impair
immun
infect
treat
therapeut
administr
human
vacv
immun
globulin
vig
human
monoclon
antibodi
offer
obviou
altern
vig
fulli
human
mab
construct
use
specif
variabl
ig
domain
select
combinatori
phage
librari
collect
human
scfv
orthopoxvirus
obtain
combinatori
phage
scfv
librari
construct
variabl
domain
light
heavi
immunoglobulin
chain
deriv
popul
lymphocyt
obtain
donor
vaccin
vaccinia
viru
select
scfv
test
simultan
elisa
experi
bind
vaccinia
strain
elstre
cowpox
strain
grishak
ectromelia
strain
virus
select
scfv
react
virus
manner
six
scfv
found
groupspecif
bound
vaccinia
cowpox
virus
bound
vaccinia
ectromelia
virus
react
vaccinia
viru
standard
assay
viru
neutral
abil
antibodi
inhibit
viru
plaqu
format
eukaryot
cell
monolay
prnt
perform
virus
two
scfv
show
neutral
activ
test
virus
neutral
vaccinia
cowpox
viru
neutral
ectromelia
viru
combinatori
phage
display
librari
human
scfv
antibodi
gener
igg
heavi
light
chain
variabl
domain
gene
lymphocyt
four
vaccinia
viru
vacv
immun
donor
titer
antivacv
antibodi
sera
examin
elisa
donor
vaccin
popul
peripher
lymphocyt
educ
titer
peak
plateau
gene
encod
variabl
heavi
light
chain
domain
amplifi
rtpcr
use
primer
specif
conserv
region
gene
vh
vl
gene
randomli
combin
via
dna
linker
whose
structur
correspond
ser
sequenc
scfv
gene
clone
phagemid
vector
librari
construct
use
escherichia
coli
strain
construct
librari
contain
approxim
independ
clone
librari
enrich
use
biopan
procedur
two
antigen
use
pan
vaccinia
viru
elstre
variola
viru
recombin
protein
correspond
vacv
copengagen
individu
clone
enrich
popul
screen
vacv
antigen
simultan
posit
clone
select
select
scfv
assay
bind
vaccinia
variola
cowpox
ectromelia
virus
standard
assay
viru
neutral
abil
inhibit
plaqu
format
orthopoxvirus
prnt
perform
identifi
neutral
scfv
fulli
human
mab
orthopoxvirus
construct
human
vhand
vlfragment
constant
domain
human
vhand
vlfragment
gener
scfv
select
synthet
combinatori
phage
librari
human
scfv
antibodi
biopan
live
variola
viru
major
strain
variola
viru
butler
alastrim
strain
vaccinia
viru
elstre
construct
human
mab
produc
human
cell
antibodi
purifi
affin
chromatographi
bind
activ
antibodi
test
elisa
use
vaccinia
variola
virus
westernblot
analysi
use
identifi
target
protein
select
mab
standard
assay
viru
neutral
print
perform
estim
neutral
activ
mab
inhibitor
accumul
abnorm
proteaseresist
prion
protein
prpre
cell
cultur
sometim
prolong
surviv
scrapieinfect
rodent
transgen
mice
use
test
vivo
antiscrapi
activ
new
cell
cultureact
prpre
inhibitor
approv
drug
edibl
natur
product
could
consid
offlabel
usag
human
patient
transmiss
spongiform
encephalopathi
tse
inhibitor
amodiaquin
thioridazin
thiothixen
trifluoperazin
tetrandrin
tannic
acid
polyphenol
extract
tea
grape
seed
pine
bark
test
compound
administ
sever
week
begin
week
prior
week
intracerebr
intraperiton
k
scrapi
challeng
tannic
acid
also
test
direct
preincub
inoculum
none
compound
significantli
prolong
scrapi
incub
period
result
highlight
need
assess
tse
inhibitor
activ
cell
cultur
tse
infect
vivo
prior
test
compound
human
livestock
increas
import
human
adenovirus
immunocompromis
patient
urg
search
new
effect
antiadenoviru
compound
sinc
human
adenovirus
speciesspecif
anim
model
system
adenoviru
infect
reli
nonhuman
adenovirus
establish
mous
adenoviru
type
infect
scid
mice
model
evalu
antiadenoviru
agent
vitro
studi
mous
embryon
fibroblast
point
acycl
nucleosid
phosphon
analogu
cidofovir
phosphonomethoxi
propoxi
pyrimidin
hpmpodapi
dideoxythymidin
alovudin
activ
compound
scid
mice
infect
intranas
develop
fatal
dissemin
infect
day
character
inflamm
liver
duoden
hemorrhag
sever
techniqu
optim
monitor
viral
immunolog
patholog
aspect
infect
realtim
pcr
quantif
viral
dna
reveal
dissemin
sever
organ
includ
brain
lung
liver
spleen
gut
kidney
heart
immunohistochemistri
polyclon
antibodi
rais
earli
protein
show
viru
local
endotheli
cell
affect
organ
use
multiplex
rtpcr
assay
serum
level
inflammatori
cytokin
ie
shown
markedli
increas
studi
ongo
evalu
efficaci
antivir
cidofovir
model
previou
studi
sever
electrophil
agent
shown
potent
antivir
virucid
properti
arenavirus
report
describ
mode
action
disulfid
provid
nation
cancer
institut
usa
lymphocyt
choriomening
viru
lcmv
prototyp
speci
arenavirida
demonstr
z
protein
target
compound
z
kda
protein
conserv
ring
finger
domain
attract
antivir
target
treatment
lcmv
particl
induc
three
concomit
effect
viral
infect
destroy
ii
virion
render
unabl
synthes
viral
rna
upon
infect
new
host
cell
iii
electrophoret
profil
z
protein
alter
analyz
nonreduc
condit
wherea
pattern
main
virion
protein
remain
unaffect
interact
z
confirm
incub
purifi
recombin
lcmvz
protein
compound
nonreduc
condit
agent
induc
oligomer
z
high
molecular
weight
aggreg
due
intermolecular
disulfid
bond
cystein
residu
ring
finger
furthermor
report
lcmv
replic
affect
subcellular
local
prolinerich
homeodomain
prh
cellular
protein
human
hepatocyt
prh
physic
associ
z
protein
determin
whether
treatment
affect
zprh
interact
lcmvinfect
cell
treat
agent
stain
purifi
antibodi
monitor
prh
bodi
major
differ
prh
pattern
uninfect
cell
infectedtr
cell
observ
suggest
associ
prh
bodi
z
protein
ring
finger
block
compound
result
open
possibl
target
z
protein
new
antivir
strategi
hemorrhag
fever
arenavirus
rapid
sensit
screen
assay
establish
vitro
evalu
antivir
compound
bovin
viral
diarrhea
viru
bvdu
wide
use
surrog
hepat
c
viru
hcv
procedur
base
colorimetr
assess
viabil
virusinfect
cell
via
extracellular
leakag
lactat
dehydrogenas
ldh
optim
condit
ldh
level
correl
well
degre
viral
replic
use
system
evalu
sever
compound
antibvdv
activ
found
cyclooxygenas
cox
inhibitor
capabl
inhibit
bvdv
replic
nontox
concentr
among
activ
effect
concentr
ec
cytotox
concentr
cc
respect
refer
compound
ribavirin
threefold
activ
cytotox
thu
select
index
higher
ribavirin
addit
indomethacin
diclofenac
cox
inhibitor
wide
use
antiinflammatori
drug
clinic
also
display
select
inhibit
bvdv
replic
result
suggest
class
compound
pursu
mechan
action
vivo
efficaci
antivir
activ
flavivirida
famili
includ
hcv
gerhard
jan
paeshuys
robert
vrancken
frank
koenen
pierr
kerkhof
carin
letelli
erik
de
clercq
johan
neyt
bovin
viral
diarrhea
viru
bvdv
pestiviru
often
use
surrog
hepat
c
broad
screen
effort
found
exhibit
antibvdv
activ
ec
gml
cc
gml
refer
strain
nadl
bvdvtype
chosen
lead
compound
formal
remov
four
fluorin
result
analogu
improv
activityselect
ec
gml
cc
gml
second
step
substitu
introduc
onto
benzyl
ring
chloro
methyl
methoxi
etc
result
discoveri
bpip
analogu
highli
activ
select
inhibitor
bvdv
ec
gml
cc
gml
si
bpip
prove
also
activ
pestivirus
includ
sever
cpe
noncp
strain
bvdvtype
bvdvtype
well
classic
swine
fever
viru
ec
gml
border
diseas
viru
ec
gml
bpip
howev
inact
hepat
c
subgenom
replicon
system
use
recent
develop
plasmidbas
minigenom
rescu
system
crimeancongo
hemorrhag
fever
viru
riftvalley
fever
viru
uukuniemi
viru
screen
antivir
compound
base
morpholino
antisens
oligonucleotid
target
differ
region
minigenom
vrna
andor
crnamrna
antivir
effect
compound
apprais
basi
report
gene
activ
inhibitori
activ
compound
also
test
quantit
reduct
viru
titer
plaqu
assay
tcid
monitor
reduct
viru
antigen
use
indirect
immunofluorescencefac
procedur
base
result
plan
confirm
antivir
activ
promis
compound
suitabl
anim
model
andrea
e
zautner
birgit
jahn
peter
wutzler
michaela
schmidtk
institut
virologi
und
antiviral
therapi
friedrichschilleruniversiteit
jena
germani
email
andreaszautn
webd
recent
shown
coxsackieviru
variant
pd
pd
abl
enter
coxsackievirusadenoviru
receptor
car
lack
cell
use
heparan
sulfat
hs
addit
receptor
zautner
et
al
possibl
inhibit
pdinduc
cytopath
effect
growth
factor
bind
known
hs
sequenc
well
specif
desulf
heparin
examin
chines
hamster
ovari
cell
hepatocyt
growth
factor
hgf
bind
hs
sequenc
contain
n
compet
effect
pd
virion
cell
surfac
hs
contrast
basic
fibroblast
growth
factor
bfgf
bind
n
abl
hinder
pd
attach
furthermor
natur
heparin
heparin
inhibit
pdinduc
cytopath
effect
strong
decreas
antivir
activ
chemic
n
oand
heparin
polykation
compound
block
herpesviru
adsorpt
bind
heparan
sulfat
show
moder
antivir
activ
even
cpe
inhibit
use
gml
confirm
nsulfat
glcnac
hs
crucial
interact
pd
hs
point
heparin
specif
sulfat
pattern
use
block
viru
adsorpt
addit
lysosomotrop
agent
like
ammonium
chlorid
monensin
abl
reduc
pdinduc
cytopath
effect
hsposit
carneg
hslack
carexpress
cell
ralitsa
k
vassilevapencheva
angel
galabov
bulgarian
academi
scienc
institut
microbiolog
depart
virolog
sofia
bulgaria
oxoglaucin
aporfinoid
alkaloid
isol
glaucium
flavum
l
obtain
synthet
way
philipov
institut
organ
chemistri
bulgacadsci
result
widespectrum
vitro
antivir
screen
compound
select
investig
due
pronounc
inhibitori
effect
polioviru
replic
fl
cell
antivir
spectrum
includ
coxsacki
echo
virus
well
individu
effect
substanc
experiment
infect
newborn
mice
cox
cox
determin
appli
daili
dose
mgkg
sc
cox
compound
show
mark
protect
effect
express
lengthen
mean
surviv
time
decreas
mortal
rate
use
cox
oxoglaucin
show
lengthen
mean
surviv
time
combin
effect
substanc
enterovir
replic
inhibitor
disoxaril
guanidin
hydrochlorid
diphenylthiourea
deriv
test
experiment
model
order
increas
effect
compound
appli
sc
doubl
tripl
quadripl
combin
tripl
combin
oxoglaucin
disoxaril
manifest
highest
activ
dnb
previous
shown
exhibit
broadspectrum
antivir
activ
picornavirus
antimicrob
agent
chemoth
studi
potenti
scaffold
antivir
picornavirus
analogu
compound
prepar
effect
replic
coxsackieviru
b
cvb
determin
analysi
structureact
relationship
molecul
reveal
modif
substitut
pattern
left
phenyl
ring
lead
increas
antivir
activ
ii
introduct
bulki
substitu
right
side
result
dramat
decreas
activ
sever
analogu
small
hydrophob
substitu
posit
andor
show
similar
slightli
superior
activ
compar
lead
compound
dnb
antivir
activ
dnb
sever
analogu
assess
cytopath
effect
viru
yield
reduct
assay
ii
qrtpcr
iii
viral
antigen
express
detail
singl
cycl
timeofdrugaddit
studi
viral
replic
monitor
mean
qrtpcr
reveal
compound
inhibit
bind
penetr
host
cell
follow
passag
viru
cultur
presenc
increas
drug
concentr
dnbresist
viru
obtain
drugresist
viru
genotyp
enabl
identifi
antivir
target
molecular
level
sulfat
polysaccharid
known
present
broad
rang
biolog
activ
particular
repres
altern
search
antivir
substanc
envelop
virus
flavivirus
object
present
work
studi
antivir
activ
divers
polysaccharid
dengu
viru
type
human
cell
compar
monkey
vero
cell
refer
host
system
purpos
cell
human
hepatoma
cell
ph
cell
human
foreskin
fibroblast
use
sulfat
polysaccharid
divers
structur
type
assay
carrageenan
dextran
sulfat
heparin
dlgalactan
hybrid
cytotox
measur
mtt
method
determin
cytotox
concentr
cc
antivir
activ
evalu
viru
yield
inhibit
assay
determin
inhibitori
concentr
ic
cytotox
observ
assay
polysulf
concentr
gml
compound
effect
inhibitor
human
ph
cell
antivir
effect
similar
observ
vero
cell
show
ic
valu
rang
gml
select
index
cc
ic
rang
mode
action
polysaccharid
studi
cell
analyz
influenc
time
addit
compound
activ
infecti
center
assay
highest
inhibitori
effect
observ
compound
ad
cell
togeth
viru
inhibit
ad
immedi
adsorpt
h
pi
inhibit
signific
reduct
viru
plaqu
format
produc
later
time
also
inhibitori
action
polysaccharid
adsorpt
intern
studi
ph
vero
cell
signific
antivir
efficaci
attain
compound
present
either
adsorpt
intern
result
indic
initi
event
dengu
viru
entri
seem
main
target
compound
vitro
infect
human
cell
richard
kinney
clair
huang
becki
rose
andrew
kroeker
patrick
iversen
david
stein
cdc
ft
collin
co
usa
avi
biopharma
inc
corval
usa
five
antisens
phosphorodiamid
morpholino
oligom
pmo
design
hybrid
variou
region
viru
evalu
abil
inhibit
dengu
viral
titer
mammalian
cell
cultur
pmo
conjug
short
argininerich
peptid
order
facilit
entri
cell
cultur
vero
cell
incub
pmo
agent
inocul
dengu
viru
viral
titer
determin
plaqueassay
day
later
three
compound
target
aug
translat
startsit
cycliz
sequenc
terminu
show
littl
inhibitori
effect
viral
titer
two
compound
target
terminu
sl
pmo
cycliz
sequenc
cs
pmo
reduc
viral
titer
order
magnitud
compar
control
dosedepend
sequencespecif
manner
day
period
ten
micromolar
solut
sl
pmo
cs
pmo
reduc
viral
titer
four
dengu
serotyp
order
magnitud
case
detect
limit
two
highli
posit
compound
show
littl
nonspecif
cytopatholog
evidenc
lack
titer
reduct
relat
nonhomolog
west
nile
viru
grown
ident
cultur
condit
well
mtt
assay
data
indic
evalu
sl
pmo
cs
pmo
compound
potenti
dengu
therapeut
warrant
human
naiv
librari
singl
chain
fv
scfv
establish
variabl
domain
light
heavi
immunoglobulin
chain
deriv
popul
lymphocyt
six
healthi
human
donor
use
rtpcr
construct
librari
repertoir
light
heavi
immunoglobulin
domain
fuse
via
flexibl
linker
sequenc
insert
phagemid
vector
scfv
librari
express
use
escherichia
coli
strain
repertoir
scfv
librari
exce
independ
recombin
clone
confirm
antibodi
rang
bind
specif
isol
librari
subject
biopan
differ
antigen
includ
virus
recombin
protein
thu
scfv
surfac
epitop
hepat
b
viru
select
two
round
independ
pan
procedur
assay
elisa
western
blot
analysi
addit
scfv
librari
pan
inactiv
ebola
zair
viru
posit
clone
select
select
scfv
bound
inactiv
live
ebola
viru
western
blot
analysi
demonstr
seven
select
scfv
react
three
scfv
bound
np
ebola
viru
bind
characterist
antibodi
test
elisa
subsequ
dilut
ebola
viru
shown
scfv
select
naiv
librari
reveal
picogramm
live
ebola
viru
scfv
select
synthet
scfv
librari
earlier
reveal
nanogramm
viru
select
antiebola
scfv
construct
natur
vdomain
could
use
develop
fulli
human
mab
fact
scfv
bound
live
ebola
viru
obtain
naiv
librari
suggest
divers
variabl
domain
organ
could
resourc
antibodi
high
pathogen
organ
without
immun
librari
elena
v
zhirakovskaya
tatiana
batanova
aleksandr
chepurnov
nina
v
tikunova
ebola
viru
ebo
highli
pathogen
agent
human
primat
caus
hemorrhag
fever
high
level
mortal
guinea
pig
inocul
ebo
normal
develop
nonleth
febril
ill
serial
passag
initi
nonleth
ebola
viru
outbre
guinea
pig
result
select
variant
high
pathogen
guinea
pigadapt
variant
ebo
differ
wildtyp
virus
mutat
code
region
nucleoprotein
np
membraneassoci
virion
protein
rnadepend
rnapolymeras
l
gene
one
mutat
noncod
region
collect
human
scfv
antibodi
guinea
pigadapt
variant
ebola
zair
viru
obtain
combinatori
phage
librari
human
singlechain
antibodi
fragment
scfv
medic
research
council
center
cambridg
england
use
biopan
procedur
addit
sever
ten
human
scfv
wildtyp
ebola
zair
viru
select
crossreact
select
antibodi
assay
indirect
elisa
bind
reaction
wildtyp
ebola
zair
ebola
virus
specif
antibodi
assay
use
westernblot
analysi
nine
antibodi
bound
antibodi
bound
matrix
protein
fraction
electrophoresi
pcr
product
scfv
phage
antibodi
gelpurifi
sequenc
use
cyclesequenc
protocol
base
chain
termin
method
autom
dna
lubomira
nikolaevaglomb
irina
zhecheva
ani
nikolova
stephan
filipov
angel
galabov
enterovirus
respons
varieti
clinic
syndrom
diseas
rang
sever
mild
disord
lifethreaten
condit
enterovirus
etiolog
agent
nearli
case
viral
mening
case
enceph
caus
myocard
pericard
may
progress
dilat
cardiomyopathi
enterovirus
suspect
play
role
develop
juvenileonset
diabet
mellitu
also
caus
agent
summer
cold
herpangina
pleurodynia
hemorrhag
conjunct
enteroviru
specif
drug
avail
clinic
use
great
number
picornaviru
inhibitor
describ
far
shown
effect
vivo
none
approv
clinic
use
yet
etiolog
therapi
remain
elus
clear
need
continu
develop
new
inhibitor
enteroviru
replic
origin
synthes
aporphinoid
alkaloid
prove
select
inhibitori
effect
type
replic
preliminari
screen
test
agardiffus
procedur
object
present
studi
test
antivir
effect
oxoglaucin
replic
enterovirus
ie
coxsackievirus
endpoint
dilut
method
multicycl
cpe
inhibit
setup
fl
cell
use
determin
antivir
effect
oxoglaucin
reveal
mark
inhibitori
effect
test
virus
sensit
follow
concentr
reduc
viru
titer
log
rang
gml
gml
respect
maxim
toler
concentr
monolay
fl
cell
gml
concentr
reduc
growth
cell
gml
result
reveal
promis
antienterovir
spectrum
high
select
antivir
effect
oxoglaucin
degrad
japanes
enceph
viru
neutrophil
shailendra
k
saxena
sonilika
srivastava
nivedita
khanna
asha
mathur
japanes
enceph
viru
jev
arthropod
born
flaviviru
one
major
caus
acut
enceph
south
east
asia
australia
peripher
neutrophil
leucocytosi
infiltr
neutrophil
extraneur
tissu
report
human
experiment
anim
abil
neutrophil
degrad
phagocytos
japanes
enceph
je
virion
via
trigger
respiratori
burst
gener
toxic
radic
studi
jev
jevinduc
macrophag
deriv
factor
mdf
induc
increas
intracellular
oxid
signal
gener
superoxid
anion
via
activ
cytosol
nadph
subsequ
form
hydrogen
peroxid
maximum
activ
day
postinfect
respons
sensit
antimdf
antibodi
treatment
studi
reveal
rapid
degrad
phagocytos
je
viral
protein
nucleic
acid
viral
protein
degrad
partial
depend
gener
toxic
oxygen
speci
could
partial
abrog
pretreat
cell
staurosporin
data
indic
neutrophil
stimul
jev
mdf
gener
reactiv
oxygen
metabolit
help
degrad
phagocytos
viru
may
one
earli
defens
mechan
kill
viru
pramila
walpita
allison
groseth
heinz
feldmann
ramon
flick
nipah
viru
niv
one
sever
newli
emerg
virus
classifi
agent
categori
c
emerg
infecti
diseas
threat
pathogen
niaid
cdc
prioriti
pathogen
list
current
evid
suggest
viru
cross
speci
barrier
fruit
bat
infect
pig
human
respons
sever
ill
hundr
anim
human
outbreak
involv
human
mortal
rate
approxim
one
measur
need
control
cull
million
pig
two
recent
outbreak
bangladesh
involv
human
smaller
deadlier
case
fatal
mortal
rate
respect
moreov
mode
spread
break
suggest
humantohuman
transmiss
vaccin
effect
antivir
agent
current
avail
prevent
treatment
niv
diseas
process
apprais
gene
silenc
one
sever
approach
identifi
potenti
target
develop
ration
antivir
strategi
nipah
viru
facilit
studi
use
reston
ebola
viru
minigenom
rescu
system
well
infecti
clone
system
compar
three
small
hairpin
rna
shrna
deliveri
system
name
plasmidmedi
pol
pol
iiidriven
shrna
exogen
produc
shrna
abil
induc
gene
silenc
present
result
comparison
also
preliminari
result
evalu
shrna
target
niv
n
p
l
gene
mediat
gene
silenc
yale
univers
school
medicin
depart
pharmacolog
cedar
st
new
ct
usa
oligoadenyl
intermedi
interferon
activ
induc
interferon
treat
cell
although
discov
long
ago
role
cell
cytoplasm
establish
know
littl
action
cell
nuclei
found
amount
exceed
cell
cytoplasm
function
role
cell
nuclei
indic
oligoadenyl
test
sever
nuclear
enzym
enzym
dnapolymeras
dnapolymeras
dnapolymeras
inhibitori
activ
oligoadenyl
dnapolymeras
discov
activ
compound
nonphosphoryl
oligoadenyl
howev
phosphoryl
compound
also
inhibitori
although
lesser
degre
effect
inhibit
dnapolymeras
oligoadenyl
observ
nonphosphoryl
trimer
tetram
oligoadenyl
activ
dnapolymeras
also
strong
antipapillomaviru
activ
relat
oligoadenyl
structur
activ
dnapolymeras
antipapillomaviru
activ
present
depart
zoolog
tel
aviv
univers
tel
aviv
israel
find
treatment
viral
diseas
present
import
challeng
modern
research
much
effort
invest
seek
substanc
suppress
viral
activ
studi
sendai
viru
member
paramyxovirida
famili
use
model
aim
research
investig
fraction
cinnamon
extract
ce
novel
sourc
antivir
inhibitor
explor
commerci
potenti
abil
ce
neutral
viru
test
vitro
human
erythrocyt
vivo
mice
dose
gml
suffici
achiev
total
neutral
hau
viru
within
min
ce
long
shelflif
least
year
refriger
room
temperatur
still
retain
antivir
activ
dialysi
bag
cutoff
kda
heat
variou
temperatur
c
antivir
activ
also
stabl
wide
rang
ph
ce
also
prove
abil
inhibit
viru
vivo
viru
mix
ce
prior
infect
mice
mice
develop
diseas
lose
weight
die
moreov
result
obtain
mice
treat
ce
h
infect
viru
see
figur
furthermor
immun
mixtur
ce
viru
result
immun
mice
continu
gain
weight
wherea
nonimmun
control
group
lost
weight
significantli
infect
viru
conclus
ce
exhibit
effect
antivir
activ
sendai
viru
vitro
vivo
sinc
cinnamon
alreadi
includ
human
diet
investig
antivir
fraction
could
also
use
prophylact
treatment
antivir
nucleosid
requir
stepwis
phosphoryl
respect
triphosph
ddntp
order
exert
activ
ddntp
shown
better
chain
termin
drugresist
revers
transcriptas
recent
found
pyruv
kinas
pk
may
respons
last
step
phosphoryl
dideoxyand
acyclonucleosid
diphosph
ddndp
synthes
sever
ndp
investig
bind
affin
rabbit
muscl
pk
transitionst
analogu
complex
also
investig
bind
inhibitori
properti
ntp
pk
determin
possibl
toxic
deriv
quench
intrins
pk
tryptophan
fluoresc
upon
addit
modifi
ndp
use
determin
dissoci
constant
k
valu
enzymesubstr
complex
pkmg
ndpno
oxal
transitionst
analogu
complex
k
valu
pk
transitionst
analogu
complex
allow
better
differenti
affin
ndp
deriv
k
valu
direct
bind
ndp
enzym
modif
decreas
bind
affin
riboand
kcalmol
increas
bind
affin
analogu
signific
stereospecif
bind
rabbit
muscl
pk
rpand
spstereoisom
observ
publish
crystal
structur
data
comprehens
pictur
interact
pk
adp
transitionst
analogu
complex
deriv
fluoresc
quench
approach
allow
us
character
quantit
interact
determin
import
bind
affin
potenti
reemerg
smallpox
use
bioterrorist
weapon
underscor
need
new
agent
treatment
orthopoxviru
infect
although
cidofovir
approv
emerg
treatment
smallpox
complic
vaccin
gener
agreement
addit
drug
need
activ
given
oral
less
toxic
neyt
verbeken
de
clercq
report
deoxyuridin
idu
could
reduc
morbid
mortal
lethal
model
vaccinia
viru
infect
mice
increas
vivo
antipoxviru
efficaci
idu
provid
use
data
potenti
applic
optim
antiorthopoxviru
nucleosid
synthes
sever
idu
carboxylatebas
diester
iduderiv
ester
expect
display
substanti
varianc
biolog
halfliv
determin
experiment
hplc
cell
cultur
ascertain
cytopathogen
effect
plaqu
reduct
assay
sever
prodrug
show
signific
activ
vaccinia
cowpox
virus
notabl
dipropano
ester
idu
ec
valu
plaqu
reduct
assay
vaccinia
cowpox
viru
respect
hexadecyloxypropylcidofovir
hdpcdv
alkoxyalkylest
cidfovir
cdv
increas
antivir
activ
cdv
sever
log
studi
cellular
metabol
ccdv
cell
indic
intracellular
level
metabolit
cidofovir
monophosph
cdvp
substanti
lower
level
cdv
activ
metabolit
cidofovir
diphosph
cdvpp
suggest
convers
cdv
cdvp
may
ratelimit
believ
bypass
first
phosphoryl
step
cdv
might
increas
cellular
level
activ
metabolit
cdvpp
therefor
synthes
hexadecyloxypropylphosphocidofovir
hdppcdv
octadecyloxyethylphosphocidofovir
odepcdv
condens
protect
dimethoxytritylcidofovir
dmtrcdv
hdpphosphomorpholid
odephosphomorpholid
follow
deprotect
trifluoroacet
acid
alkoxyalkylphosph
ester
cidofovir
found
activ
cdv
compound
submicromolar
ec
mcmv
hcmv
least
sevenfold
activ
cdv
compound
particularli
activ
mcmv
vaccinia
cowpox
although
newli
synthes
alkoxyalkylphosph
adduct
cdv
somewhat
less
activ
hdpcdv
believ
compound
type
bypass
slow
first
phosphoryl
step
approach
may
especi
use
increas
activ
poorli
phosphoryl
nucleosid
phosphon
acycl
nucleosid
phosphon
anp
eg
cidofovir
adefovir
tenofovir
featur
acycl
side
chain
within
phosphon
group
phosphonomethoxi
group
effort
evalu
anp
novel
side
chain
design
synthes
test
new
seri
unsatur
acycl
nucleosid
phosphon
variou
virus
nucleosid
ppenn
synthes
start
protect
underw
onecarbon
homolog
hydroxymethyl
one
two
hydroxyl
group
convert
bromid
phosphon
acid
replac
variou
nucleobas
use
mitsunobu
reaction
ppenn
also
esterifi
longchain
alkoxyalkanol
modif
increas
intracellular
deliveri
anp
hexadecyloxypropyl
hdpppenn
octadecyloxyethyl
odeppenn
oleyloxyethyl
oleppenn
phosphonoest
phosphon
acid
prepar
unsatur
anp
evalu
variou
virus
includ
hcmv
vaccinia
cowpox
vzv
hbv
ebv
ppenn
exhibit
signific
antivir
activ
alkoxyalkyl
ester
show
moder
potent
broadspectrum
antivir
activ
hdpppena
effect
ebv
ec
hbv
ec
ec
hdpppeng
inhibit
vzv
ec
hcmv
ec
ec
hbv
ec
result
indic
sever
ppenn
alkoxyalkyl
ester
possess
signific
antivir
activ
investig
use
viral
infect
human
previou
studi
show
alkoxyalkyl
analog
acycl
nucleosid
phosphon
oral
bioavail
gener
low
level
drug
lung
key
earli
site
poxviru
replic
studi
examin
oral
bioavail
tissu
level
ester
ccidofovir
odbgcdv
mice
report
previous
odbgcdv
activ
cowpox
vaccinia
strain
ec
rang
pharmacokinet
studi
singl
dose
mgkg
odbg
c
cdv
administ
oral
intraperiton
ip
mice
anim
sacrif
plasma
variou
tissu
obtain
h
organ
weigh
treat
tissu
solubl
aliquot
plasma
tissu
count
drug
content
determin
oral
administr
peak
plasma
concentr
clabel
odbgcdv
metabolit
declin
h
follow
ip
administr
odbgcdv
peak
plasma
concentr
declin
h
rel
oral
bioavail
base
area
curv
auc
plasma
drug
metabolit
calcul
surprisingli
oral
odbgcdv
gave
peak
lung
level
nmolg
versu
nmolg
ip
odbgcdv
lung
auc
roughli
greater
follow
oral
administr
odbgcdv
versu
hdpcdv
spite
lower
oral
bioavail
former
compar
oral
hexadecyloxypropylcdv
odbgcdv
provid
much
higher
auc
drug
metabolit
lung
lower
auc
liver
conclus
esterif
cdv
provid
compound
given
oral
appear
target
lung
could
use
achiev
greater
therapeut
effect
viral
infect
lung
activ
alkoxyalkyl
alkyl
ester
deriv
cytosin
hpmpc
cidofovir
adenin
hpmpa
cyclic
cidofovir
orthopoxvirus
g
andrei
j
van
den
oord
ky
hostetl
jr
beadl
geypen
e
de
clercq
r
snoeck
cidofovir
cdv
cyclic
cidofovir
ccdv
shown
potent
inhibitor
poxviru
replic
vitro
sever
anim
model
howev
compound
activ
administ
oral
evalu
activ
sever
alkoxyalkyl
alkyl
ester
cdv
ccdv
hpmpa
includ
hexadecyloxypropyl
hdp
octadecyloxyethyl
ode
oleyloxyethyl
ole
oleyloxypropyl
olp
odgb
deriv
vaccinia
viru
vv
lederl
strain
cowpox
viru
cpv
brighton
strain
monolay
cultur
human
embryon
lung
hel
fibroblast
primari
human
keratinocyt
phk
deriv
also
test
organotyp
epitheli
raff
cultur
ex
vivo
model
repres
fulli
differenti
skin
analogu
test
activ
parent
compound
order
increas
activ
vv
cpv
hel
cell
odgbcdv
olpcdv
hdpcdv
olecdv
odecdv
increas
ec
valu
compar
parent
compound
phk
hdpcdv
olpcdv
odgbcdv
odecdv
olecdv
increas
ec
valu
compar
parent
compound
cell
type
oleccdv
hdphpmpa
odehpmpa
prove
activ
parent
compound
odehpmpa
activ
hdphpmpa
evalu
effect
compound
raft
cultur
two
seri
cultur
run
parallel
one
use
histolog
one
quantif
infecti
viru
olecdv
odecdv
hdpcdv
prove
activ
cdv
thu
concentr
gml
olecdv
odecdv
abl
inhibit
viral
product
log
concentr
log
log
reduct
observ
hdpcdv
cdv
respect
histolog
examin
raft
cultur
correl
quantif
viru
yield
bdcrb
potent
select
inhibitor
hcmv
lack
clinic
util
due
rapid
metabol
hypothes
bdcrb
prodrug
could
evad
bdcrbmetabol
enzym
bioevas
would
enhanc
vitro
efficaci
well
vivo
halflif
extent
bdcrb
system
exposur
end
thirteen
differ
amino
acid
prodrug
bdcrb
synthes
test
nglycosid
bond
stabil
ester
bond
stabil
cell
uptak
antivir
activ
cytotox
prodrug
exhibit
significantli
enhanc
nglycosid
bond
stabil
wide
rang
ester
bond
stabil
compound
rapidli
absorb
cell
except
charg
aspand
lysprodrug
phebdcrb
exhibit
select
inhibit
hcmv
replic
ic
cc
chosen
vivo
test
due
rapidli
cleav
ester
bond
aspbdcrb
chosen
assess
vivo
pharmacokinet
base
favor
stabil
profil
antivir
activ
well
separ
cytotox
addit
dilebdcrb
exhibit
rapid
cell
absorpt
well
stabl
ester
bond
nglycosid
bond
chosen
vivo
test
dilebdcrb
stabl
releas
suffici
bdcrb
blood
aspbdcrb
howev
exhibit
fivefold
increas
volum
distribut
roughli
equival
system
exposur
parent
drug
taken
togeth
fivefold
improv
halflif
aspbdcrb
clearli
exhibit
bioevas
suggest
bioevas
enhanc
drug
deliveri
acknowledg
research
support
nih
grant
train
grant
pll
cyclosalprodrug
introduc
intracellular
deliveri
system
therapeut
activ
nucleotid
due
synthesi
cyclosalphosph
triester
prodrug
isol
diastereomer
mixtur
case
possibl
separ
diastereom
semiprepar
hplc
chemic
hydrolysi
studi
show
differ
chemic
stabil
stereoisom
r
p
configur
stereoisom
found
antivir
potent
less
inhibitori
bche
pstereoisom
eg
shown
unfortun
possibl
separ
cyclosaltriest
diastereom
semiprepar
hplc
therefor
synthesi
lead
singl
isom
would
great
interest
present
synthet
rout
phosphoramid
base
pyrrolidin
moieti
high
diastereomer
excess
amid
may
convert
isomer
pure
phosphat
triester
present
second
gener
cyclos
pronucleotid
socal
lockin
modifi
cyclosalnmp
cyclosalconcept
alreadi
appli
success
sever
nucleosid
analogu
remark
advantag
prototyp
cyclosalnmp
pure
phinduc
deliveri
nucleotid
howev
due
lipophil
natur
cyclosaltriest
exclud
concentr
drug
equilibrium
form
cultur
medium
cell
content
therefor
intent
modifi
cyclosaltriest
order
trap
insid
cell
achiev
goal
phosphat
triester
bear
esterasecleav
site
cyclosalmoieti
synthes
modif
attach
cyclosalmoieti
via
alkyllink
ester
group
introduc
mask
unit
enzymat
cleavag
much
polar
cyclosalnmpcarboxyl
b
alcohol
could
releas
increas
polar
prevent
efflux
compound
enabl
lockin
previou
work
reveal
ester
cyclosalalcohol
enzymat
cleav
surprisingli
invert
ester
give
carboxyl
show
enzymat
cleavag
aim
increas
linker
length
improv
substrat
properti
synthesi
antihiv
activ
data
present
relat
result
drug
stabil
studi
chemic
media
cell
extract
cyclos
pronucleotid
effici
deliv
therapeut
activ
nucleosid
monophosph
cell
nucleosid
phosphon
pmea
pmpa
hpmpc
show
broad
antivir
activ
coupl
dnaand
retrovirus
interest
properti
nucleosid
phosphon
nucleotid
mimic
stabil
p
c
bond
lipophil
prodrug
pmea
base
cyclos
concept
synthes
compound
show
low
hydrolysi
stabil
lead
antivir
activ
slightli
better
nonmask
nucleosid
phosphon
lack
inhibit
human
bche
select
drug
deliveri
case
decid
design
stabil
nucleosid
phosphon
higher
stabil
achiev
substitut
phenol
oatom
less
electroneg
natom
synthesi
character
vitro
antivir
evalu
cycloamb
pmea
present
new
compound
show
ideal
stabil
inhibitori
bche
select
deliv
pmea
attempt
improv
therapeut
potenti
nucleosid
analog
variou
mononucleotid
prodrug
pronucleotid
report
last
decad
two
main
approach
develop
requir
either
structur
modif
introduct
transient
group
usual
group
constitut
two
compon
doubl
prodrug
concept
involv
decomposit
enzymemedi
process
work
topic
start
mononucleosid
symmetr
phosphotriest
bear
sate
group
biolabil
phosphat
protect
herein
present
new
seri
mononucleosid
mix
sate
phosphoest
involv
two
differ
enzymat
system
decomposit
process
abil
studi
mononucleosid
sate
aryl
phosphotriest
peyrott
et
al
sate
phosphoramid
diester
egron
et
al
sate
glucosyl
phosphorothiol
act
mononucleotid
prodrug
demonstr
cell
cultur
experi
egron
use
pronucleotid
appear
valuabl
strategi
overcom
cellular
limit
associ
first
phosphoryl
step
nucleosid
analogu
time
research
interest
focus
studi
mix
pronucleotid
carri
two
differ
biolabil
phosphat
protect
group
respect
design
seri
tbusat
aryl
phosphotriest
deriv
dideoxythymidin
azt
shown
kind
deriv
act
mononucleotid
prodrug
liber
correspond
monophosph
follow
two
success
enzymat
activ
due
esteras
phosphodiesteras
respect
schlienger
et
al
peyrott
et
al
herein
describ
synthet
approach
stabil
studi
tbusat
aryl
phosphotriest
deriv
azt
aryl
counterpart
dipeptidyl
residu
phosphoramid
technolog
conceiv
mean
improv
cellular
penetr
nucleotid
bypass
first
step
kinasemedi
activ
nucleosid
technolog
recent
appli
highli
potent
antivzv
bicycl
furopyrimidin
bcna
accord
new
seri
phosphoramid
plan
studi
made
chang
ester
moieti
use
sever
amino
acid
identifi
structureact
relationship
mechan
action
synthesi
involv
coupl
phenyl
dichloro
phosphat
esterif
amino
acid
salt
product
reaction
phosphochlorid
coupl
presenc
nmethylimidazol
give
desir
product
total
compound
synthes
evalu
antivir
activ
vzv
result
receiv
far
inconclus
sar
show
prodrug
activ
concentr
less
full
antivir
data
present
confer
ping
li
barbara
r
shaw
chemistri
depart
duke
univers
durham
nc
usa
nucleosid
boranophosph
nucleosid
amino
acid
phosphoramid
shown
potent
antivir
activ
potenti
act
nucleotid
prodrug
combin
two
type
compound
result
boranophosphoramid
linkag
nucleosid
amino
acid
new
class
potenti
prodrug
expect
possess
advantag
confer
type
parent
compound
develop
two
new
strategi
synthesi
nucleosid
boranophosphoramid
conjug
amino
acid
one
involv
hphosphon
chemistri
whose
applic
limit
due
low
yield
purif
difficulti
oxathiaphospholan
approach
prove
better
method
obtain
boranophosphoramid
base
adjac
type
mechan
tent
assign
configur
pdiastereom
carri
molecular
model
proton
spectra
result
accord
two
pdiastereom
nucleosid
amino
acid
boranophosphoramid
expect
differ
substrat
properti
toward
phosphoramidas
use
investig
role
phosphat
metal
ion
biolog
process
elucid
stereochem
metal
requir
enzymat
reaction
involv
phosphoramidas
moreov
due
presenc
boran
group
boranophosphoramid
expect
increas
lipophil
rel
parent
phosphoramid
compound
would
facilit
deliveri
prodrug
contain
antivir
nucleosid
advantag
combin
potenti
util
carrier
b
bnct
make
nucleosid
boranophosphoramid
conjug
amino
acid
use
compound
biochem
tool
antivir
drug
research
jerold
gordon
eric
romanowski
kathleen
yate
alison
mcdermott
univers
pittsburgh
charl
campbel
laboratori
pittsburgh
pa
usa
univers
houston
colleg
optometri
houston
tx
usa
antimicrobi
peptid
amp
essenti
part
innat
immun
evolv
live
organ
billion
year
combat
microbi
challeng
small
cation
peptid
multifunct
effector
innat
immun
skin
mucos
surfac
demonstr
direct
antimicrobi
activ
variou
virus
cmv
vsv
hiv
influenza
viru
adenoviru
vaccinia
viru
bacteria
fungi
parasit
laboratori
demonstr
direct
antivir
inhibitori
activ
vitro
human
alpha
beta
defensin
cathelicidin
variou
adenoviru
serotyp
gener
mechan
rapid
kill
amp
attribut
perturb
lipid
membran
blockag
viru
entri
cell
undefin
mechan
commerci
develop
engin
antimicrobi
peptid
system
topic
therapi
variou
diseas
progress
clinic
trial
summar
progress
date
well
critic
evalu
amp
clinic
promis
practic
limit
novel
antiinfect
drug
potenti
role
custom
antimicrobi
peptid
singl
therapeut
agent
adjunct
convent
antiviralsantibiot
immunostimul
natur
innat
immun
discuss
influenza
herp
virus
attract
attent
clinicist
research
around
world
initi
massiv
acut
chronic
diseas
accord
world
health
organ
data
almost
earth
human
popul
infect
herp
virus
diseas
caus
herp
viru
held
second
place
influenza
caus
viral
infect
lethal
elabor
method
mean
infect
treatment
actual
task
health
care
system
scope
present
work
studi
antivir
efficaci
sodium
dp
toward
influenza
b
strain
virus
herp
simplex
viru
hsv
studi
antivir
activ
said
prepar
newcastl
diseas
viru
ndv
studi
influenc
proteolyt
process
viru
membran
interact
dp
antivir
activ
dp
studi
vitro
model
influenza
viru
strain
ahong
ndv
strain
la
sota
replic
tissu
cultur
chicken
embryo
choryoallanto
membran
cam
antiherpet
activ
dp
vitro
studi
primarili
tripsin
cultur
chick
embryo
cell
cec
strain
us
antiinfluenza
activ
dp
vivo
evalu
ground
anim
lethal
reduct
day
infect
result
present
studi
allow
us
state
sodium
demonstr
suffici
antivir
activ
vitro
vivo
prepar
taken
dose
mkgml
inhibit
reproduct
influenza
b
virus
well
ndv
tissu
cultur
cam
dp
dose
mkgml
inhibit
reproduct
primarili
tripsin
cultur
cec
prophylact
therapeut
applic
dp
demonstr
consider
decreas
mortal
anim
infect
influenza
viru
prepar
inhibit
proteolysi
increas
take
place
virusmembran
interact
result
present
studi
allow
us
state
sodium
demonstr
signific
antivir
activ
could
recommend
clinic
trial
jonathan
j
lacass
ersilia
coccaro
mi
provench
lui
schang
univers
alberta
depart
biochemistri
edmonton
alta
canada
univers
alberta
depart
medic
microbiolog
immunolog
edmonton
alta
canada
antivir
drug
commonli
design
target
viral
protein
although
success
approach
certain
limit
exampl
drug
target
viral
protein
tend
activ
one
close
relat
virus
quickli
select
drugresist
strain
limit
cellular
protein
may
consid
potenti
target
novel
antivir
approach
especi
attract
mani
inhibitor
cellular
protein
develop
drug
cancer
metabol
diseas
cyclindepend
kinas
cdk
arguabl
cellular
protein
best
studi
potenti
target
antivir
drug
specif
pharmacolog
cdk
inhibitor
pci
develop
roscovitin
appear
well
toler
clinic
trial
cancer
sever
pci
roscovitin
flavopiridol
antivir
activ
vitro
wildtyp
drugresist
strain
hiv
hcmv
ebv
vzv
kshv
htlv
virus
pci
schedul
enter
clinic
trial
antivir
howev
antivir
mechan
differ
pci
remain
incomplet
character
pci
roscovitin
flavopiridol
differ
molecular
specif
shown
inhibit
differ
function
differ
virus
evalu
whether
pci
may
also
target
common
viral
function
analyz
antivir
activ
roscovitin
flavopiridol
structur
unrel
pci
preferenti
inhibit
differ
subset
cdk
herein
show
unrel
pci
prevent
initi
transcript
antivir
effect
requir
viral
protein
promot
specif
viral
genom
specif
pci
roscovitin
specif
viral
genom
result
show
pci
common
antivir
target
identifi
novel
function
target
antivir
drug
initi
transcript
viral
genom
drug
target
function
could
less
prone
select
drugresist
mutant
convent
antivir
drug
julien
gagneron
gill
gosselin
christoph
univers
montpelli
ii
umr
cnr
univers
montpelli
ii
montpelli
franc
sever
decad
larg
number
nucleosid
analogu
synthes
shown
present
potent
antivir
antitumor
activ
order
discov
new
nucleosid
deriv
endow
antivir
activ
modif
base
andor
sugar
moieti
natur
nucleosid
attempt
part
chose
introduc
modif
sugar
capabl
restrict
dynam
equilibrium
northerntyp
southerntyp
geometri
normal
character
sugar
moieti
standard
nucleosid
solut
respect
synthes
new
conform
lock
nucleosid
analogu
built
hexan
system
bear
pyrimidin
base
assum
conform
pucker
glycon
moieti
nucleosid
play
critic
role
modul
biolog
activ
new
conform
restrict
nucleosid
analogu
could
use
obtain
inform
regard
correl
sugar
ring
conform
biolog
activ
herein
report
synthesi
well
result
antivir
evalu
broad
rang
virus
karina
fincati
marta
trevisan
giulia
masi
francesca
sessa
francesca
favaretto
luisa
barzon
giorgio
pal
depart
histolog
microbiolog
medic
biotechnolog
univers
padua
itali
aim
studi
investig
effect
gene
express
profil
prolifer
human
hepatoma
cell
microarray
analysi
use
slide
contain
human
oligonucleotid
perform
human
hepatoma
cell
line
treat
uiml
h
analysi
cell
viabil
cell
cycl
perform
cell
treat
differ
dose
time
point
analysi
microarray
experi
demonstr
total
gene
induc
repress
cell
wherea
cell
gene
induc
total
gene
repress
cell
gene
overexpress
gene
underexpress
least
twofold
respect
untreat
cell
time
point
induc
gene
includ
gene
previous
implic
gene
eg
dck
stat
also
potassium
channel
eg
transcript
factor
eg
g
proteincoupl
receptor
eg
receptor
cofactor
eg
inhibit
gene
includ
mainli
involv
cell
metabol
eg
cell
prolifer
growth
factor
growth
factor
receptor
viral
infect
viru
receptor
viral
oncogen
cell
factor
interact
viral
protein
moreov
hierarch
cluster
analysi
identifi
gene
upregul
within
first
hour
treatment
h
shortterm
treatment
high
dose
inhibit
hepatoma
cell
prolifer
modifi
cell
cycl
demonstr
mtt
assay
flow
cytometri
conclus
character
gene
human
hepatoma
cell
line
demonstr
inhibit
express
gene
involv
viral
replic
cell
prolifer
thu
support
use
antivir
anticanc
agent
karen
watson
robert
w
buckheit
jr
imquest
bioscienc
inc
frederick
md
usa
topic
microbicid
prevent
sexual
transmiss
hiv
urgent
need
especi
develop
countri
effort
develop
topic
microbicid
receiv
increas
attent
recogn
unmet
need
safe
effect
easi
use
inexpens
mean
reduc
rate
hiv
transmiss
present
wide
varieti
therapeut
agent
evalu
topic
microbicid
especi
substanc
act
prevent
viru
attach
target
cell
addit
entri
inhibitor
highli
potent
nonnucleosid
rt
inhibitor
also
evalu
began
develop
pyrimidinedion
topic
microbicid
base
uniqu
dual
mechan
antihiv
action
includ
highli
potent
nnrti
activ
well
abil
inhibit
viru
entri
conform
target
form
upon
interact
viru
cell
seri
compound
thu
far
exemplifi
lead
molecul
inhibit
replic
test
clinic
strain
subnanomolar
concentr
fresh
human
pbmc
wide
varieti
congen
evalu
abil
inhibit
viru
attach
revers
transcript
compound
rank
base
activ
sever
highli
activ
entri
inhibitor
therapeut
indic
rang
million
identifi
evalu
potenti
topic
microbicid
variou
antihiv
assay
includ
activ
pbmc
cell
base
assay
combin
antihiv
activ
assay
assay
variou
moi
presenc
high
concentr
mucinpolysaccharid
compound
also
evalu
ex
vivo
cervic
epitheli
cell
base
tissu
assay
measur
inhibitori
activ
sj
compound
relev
tissu
base
assay
result
vitro
ex
vivo
assay
suggest
pyrimidinon
highli
effect
topic
microbicid
combin
abil
inhibit
viru
entri
revers
transcript
sar
evalu
defin
molecular
featur
respons
rel
potenc
molecul
inhibit
attach
rt
perform
present
intern
confer
antivir
research
preced
clinic
symposium
held
san
juan
puerto
rico
confer
begin
sunday
may
end
pm
thursday
may
scientif
session
held
carib
hilton
san
juan
purpos
intern
confer
antivir
research
provid
interdisciplinari
forum
investig
involv
basic
appli
clinic
research
worldwid
meet
review
recent
develop
area
antivir
research
specif
topic
cover
program
includ
synthesi
chemistri
biochemistri
mechan
action
molecular
biolog
drug
target
vitro
evalu
anim
model
pharmacokinet
toxicolog
clinic
trial
within
area
interest
invit
overview
speaker
oral
present
poster
present
san
juan
offer
excel
site
confer
offer
wonder
confer
facil
excel
atmospher
well
uniqu
tropic
island
find
local
exot
hideaway
mile
white
sandi
beach
mountain
valley
rain
forest
natur
wonder
within
reach
surround
warm
friendli
peopl
fortun
enough
time
confer
ideal
site
lover
outdoor
hike
el
yunqu
unbeliev
rain
forest
km
san
juan
provid
rare
wildlif
speci
flora
san
juan
provid
diver
paradis
scuba
snorkel
warm
water
temperatur
underwat
visibl
feet
allow
excel
view
rich
coral
reef
garden
altern
may
elect
spend
time
mile
beauti
beach
isla
verd
picturesqu
golf
cours
old
town
provid
great
local
color
museum
note
old
citi
invit
narrow
steep
street
pave
cobbl
adoquin
blue
stone
cast
furnac
slag
block
area
charm
centuri
spanish
coloni
build
mani
plaza
spectacular
attract
plenti
san
juan
includ
incred
el
morro
sixlevel
fortress
situat
feet
atlant
view
san
juan
bay
el
morro
breath
take
fort
open
public
daili
histor
intermingl
spaniard
african
italian
french
german
lebanes
cuban
produc
uniqu
divers
cultur
puerto
rico
food
puerto
rico
exot
blend
spanish
african
taino
american
influenc
local
call
cook
cocina
criolla
mean
creol
cook
similar
spanish
mexican
cuisin
puerto
rico
wine
produc
great
beer
cours
larg
varieti
nation
drink
rum
world
lead
rum
produc
date
back
sugar
cane
brought
columbu
invit
take
advantag
onceinalifetim
opportun
combin
import
learn
experi
magnific
travel
experi
join
us
san
juan
puerto
rico
intern
confer
antivir
research
